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ABSTRACT 
 
Aseptic loosening, the clinical end point of osteolysis, is the most common 
complication resulting in revision surgery of total hip arthroplasty (THA).  It is the result 
of focal peri-prosthetic inflammatory bone loss at the prosthesis-host interface, and is 
driven by particulate wear debris generated primarily at the articular bearing surface. 
There is variation between individuals in their inflammatory response to wear debris 
suggesting a genetic component.  Candidate gene studies have shown that 
susceptibility to osteolysis associates with polymorphic variation in genes encoding 
several inflammatory cytokines and bone regulatory molecules.  Better understanding 
of the genetic component is required to address the pathogenesis of aseptic loosening.  
Advances in high throughput genotyping and mapping of genomic variation has made 
it possible to examine common genetic variation or quantitative traits as possible risk 
factors of disease through genome wide association studies (GWAS). 
This thesis which forms my PhD candidature, describes several studies undertaken to 
understand the biological processes contributing to osteolysis.  We have followed the 
advances in genotyping and bioinformatics progressing from a candidate gene study 
to undertaking whole genome analysis. 
We describe the largest candidate gene study to date looking at tagging SNPs in 
genes thought to play important roles in bone turnover and inflammatory pathways.  
We have undertaken the first GWAS for osteolysis susceptibility and time to prosthesis 
failure following THA in over 3,700 patients.  During the recruitment process of the 
replication cohort from the Norwegian arthroplasty register we have proved the 
feasibility of using such registries for recruitment to answer research questions and 
establish linked biobanks for the study of musculoskeletal disease. 
Heterotopic ossification is also a common complication following THA and similarly its 
pathogenesis is poorly understood.  We also describe a GWAS looking for variants 
associated with the development of HO and its severity following THA.  
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Bp:  base pairs 
C  Cytosine 
CATK  Cathepsin K 
CEU:  Caucasian European in Utah 
CHR:  Chromosome 
CI:  Confidence interval 
CNV  Copy Number Variant 
CRP  C Reactive Protein 
CTX-1  C-telopeptides of type-I collagen 
DAMP: Danger associated molecular patterns 
dbSNP: SNP database 
DKK-1 Dickkopf 1 
DNA:  Deoxyribonucleic acid 
dsDNA: double stranded deoxyribonucleic acid 
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IL:  Interleukin 
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MMP  Matrix Metalloproteinase 
mRNA: messenger RNA 
MSC  Mesenchymal Stem Cell 
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MyD88: Myeloid differentiation primary response gene (88) 
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OPG:  Osteoprotegerin 
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PRR:  Pattern recognition receptor 
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RAP:  Regional association plot 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Overview 
 
Aseptic loosening following total hip arthroplasty (THA) describes mechanical failure 
of the prosthesis-host interface that arises as a result of periprosthetic inflammatory 
bone loss.  This inflammatory bone loss, termed osteolysis, is caused by the host 
response to wear debris generated from the prosthetic surfaces.   There is variation in 
individual’s response to wear debris and a number of environmental factors have been 
implicated.  Our group have previously shown that genetic variation contributes to the 
development of osteolysis and this work aims to explore this further.  In order to 
understand the content of this thesis this chapter outlines the impact of aseptic 
loosening following THA.  The pathophysiological manifestation of osteolysis will be 
described including the biological and molecular pathways responsible for normal and 
pathological bone turnover.  The genetic basis for osteolysis will also be discussed, 
outlining the justification for the methods in this study.  The secondary aim of this thesis 
is to investigate the genetic contribution to heterotopic ossification formation following 
THA.  The impact, pathogenesis and genetic basis will also be discussed. 
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1.2 Bone 
 
1.2.1 Function  
 
Bone is a highly active tissue which has both mechanical and metabolic functions.  It 
forms the skeleton which provides support, protects viscera and provides the 
framework required for body movement and locomotion.  As the principal reservoir of 
calcium in the body, bone plays a vital role in calcium homeostasis. Tight regulation of 
calcium metabolism relies on hormonal interaction with bone, kidneys and the small 
intestine.  Undifferentiated pluripotent stem cells in bone marrow are the precursors of 
all blood cell types with the exception of lymphocytes.  
 
1.2.2 Cells and Matrix 
 
The osteoblast 
 
Osteoblasts are highly active mononuclear cells which are derived from the 
mesenchymal cell lineage (Heino and Hentunen, 2008).  Differentiation of 
mesenchymal stem cells to preosteoblasts and subsequently mature osteoblasts 
relies on a number of transcription and growth factors (Ducy et al., 2000).  Mature 
osteoblasts acquire the ability to secrete non-mineralized extracellular matrix 
composed of type I collagen and known as osteoid, which they subsequently 
mineralize.  Osteoblasts respond to a number of hormones (fig 1.12).  The life span of 
the osteoblast has been estimated at three months, after which it has one of three 
fates.   It can either become embedded in its own matrix as an osteocyte, undergo 
apoptosis or become an inactive lining cell (Franz-Odendaal et al., 2006).  
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Figure 1.1 Hormonal control of osteoblast activity 
 
 
The osteocyte 
 
The osteocyte is the most abundant cell in bone accounting for 95% of all bone cells 
(Franz-Odendaal et al., 2006).  The differentiation of the osteocyte from the osteoblast 
takes 3 days and involves a decrease in cell size and  increase in size of cell processes 
(pseudopodia) (Knothe Tate et al., 2004).  This transforms the large round bodied 
osteoblast into a more stellate shaped cell.  The nascent osteocyte has thick 
elongating pseudopodia which radiate and are believed to be involved in the extrusion 
of the deposited matrix (Knothe Tate et al., 2004).  Mature osteocytes have much 
thinner and longer processes which connect to other osteocytes and osteoblasts via 
gap junctions.  These connections are important for intercellular communication. 
 
The osteocyte is thought to be the key regulator of adult bone remodelling, through 
RANKL and sclerostin signalling (Xiong, 2011) (Nakashima, 2011). The 
mechanosensory role of osteocytes is necessary for the maintenance of the bony 
matrix and will be discussed in a later section.  
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The osteoclast 
 
Osteoclasts are large multinucleated cells that resorb bone. They are derived from 
haemopoeitic stem cells and follow the same cell lineage as macrophages (Suda et 
al., 1992).    There are a number of processes adopted by osteoclasts which lead to 
the efficient resorption of bone mineral and matrix.  The area immediately surrounding 
the finger like projections of the ruffled border are known as Howship’s lacunae.  The 
plasma membrane of the osteoclast binds tightly to the bone matrix creating a sealing 
zone.  The underside of the plasma membrane forms the ruffled border which creates 
a large surface area for optimal bone resorption.  Secretion of hydrochloric acid 
through the ruffled border then dissolves the hydroxyapatite crystals.  The subsequent 
secretion of the proteolytic enzymes tartrate-resistant acid phosphatase (TRAP) and 
cathepsin K (CATK) lead to the degradation of the collagen matrices.  Degradation 
products are removed from the resorption lacunae through a vesicular transport 
system within the osteoclast (Vaananen et al., 2000). 
 
Figure 1.2 Osteoclast function (Adapted from Vaananen et al, 2000) 
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Bone extracellular matrix 
  
The extracellular matrix comprises organic and non- organic components.  The 
majority of the matrix is formed by bundles of type I collagen fibrils.  These fibrils run 
in parallel creating lamellae.  Between the fibrils are pores containing the inorganic 
components.   The inorganic constituent is mostly calcium hydroxyapatite with lesser 
amounts of carbonate, magnesium and phosphate (Clarke, 2008). A smaller 
proportion of the non- collagenous proteins including osteocalcin are also present and 
are involved in calcium binding, mineral stabilisation and bone regulation (Ducy et al., 
1996). 
 
Figure 1.3 Structure of extracellular matrix in lamellar bone (Adapted from Miller, 
Review of Orthopaedics, 4th edition, 2004) 
 
1.3 Bone modelling and remodelling 
 
Bone is a remarkable, specialised connective tissue.  By undergoing constant 
resorption and formation it is able to adapt to a host of physiological and environmental 
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circumstances.  Bone loss occurs during periods of prolonged immobility (Bauman et 
al., 1999) and also during long term microgravity (Vico et al., 2000).  In contrast, 
excessive loading of bone results in net bone formation (Souminen, 1993).  This 
functional adaption was first recognised by Wolff in 1892 (Wolff, 1892).  Almost a 
century later, Frost described two distinct mechanisms for bone adaption to 
mechanical loading (Frost, 1990a) (Frost, 1990b): 
 Modelling: involves osteoclast activation resulting bone resorption or 
osteoblast activation leading to bone formation, crucially, not at the same 
location.  An obvious example of this is skeletal growth and development during 
childhood.  In adulthood, this may occur in various disease states and in altered 
mechanical loading. 
 
Remodelling: involves coupled bone resorption and formation occurring at the 
same location in a defined temporal sequence of resorption followed by 
formation.  
 
Due to a large surface to volume ratio, 20% of cancellous bone is undergoing 
remodelling at any one time (Hill, 1998) compared to only 2 – 5% of cortical bone each 
year (Hadjidakis, 2006).  Bone remodelling is carried out by a team of cells known 
collectively as a “Basic Multicellular Unit” (BMU).  The leading region of the BMU 
contains around ten osteoclasts which create a resorption tunnel in the dominant 
loading direction (Petrtyl, 1996).  As the BMU moves across the surface of bone the 
thousands of osteoblasts residing in the tail deposit osteoid filling the tunnel (Parfitt, 
1994).   
33 
 
 
Figure 1.4 The basic molecular unit for bone.  Adapted from (Seeman and Delmas, 
2006) 
 
The resorption phase lasts around 3 weeks, whereas the osteoblastic refilling takes 
around 3 – 4 months (Martin TJ, 2008). The remodelling process always follows the 
same cyclic sequence of quiescence, activation, resorption, reversal and again 
returning to quiescence (Hill, 1998). 
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Figure 1.5 Bone remodelling cycle. Resorptive phase: activated osteoclasts resorb 
bone matrix.  Reversal phase: osteoblast precursors migrate to resorption lacuna.  
Formation phase: Osteoblasts lay down new matrix.  Resting phase: osteoblasts 
mature into lining cells and osteocytes.  Adapted from (Hill, 1998). 
  
 
 1.3.1 Molecular control of bone remodelling 
 
The cellular coupling involved in bone remodelling was first proposed by Frost in 1964 
(Frost, 1964).  Our understanding of the cellular and molecular aspects of bone 
remodelling has improved greatly over the last ten years with the discovery of RANKL 
and WnT signalling. 
 
Osteoclasts are derived from haematopoietic stem cells. Their differentiation into 
mature polykaryons relies on macrophage colony stimulating factor (M-CSF) and 
activation of receptor activator of nuclear factor κ B (RANK) by its ligand (RANKL), a 
member of the tumour-necrosis factor superfamily. (Figure 1.6). 
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Figure 1.6 Molecular control of osteoclast differentiation (adapted from Boyle W 
Nature 2003) 
 
The discovery of the importance of these mediators in osteoclastogenesis was due to 
a number of breakthroughs and provided a molecular mechanism for coupling.  Rodan 
and Martin first proposed that osteoblasts may play an important role in osteoclast 
regulations due to their reaction to the bone resorbing hormones PTH, vitamin D3 and 
prostaglandins (Rodan GA, 1981).  A study by Takahashi noted that a culture of both 
haemopoeitic and stromal cells lead to the production of osteoclasts, whereas these 
cells cultured separately did not (Takahashi et al., 1988).  The discovery of 
osteoprotegerin (OPG), a TNF receptor-related protein, was vital in our understanding 
(Simonet et al., 1997).  It was found to block osteoclast formation in vitro (Yasuda et 
al., 1998).  The relation of OPG to the TNFR family identified RANKL as the key 
cytokine regulating osteoclastogenesis.  The bone resorbing hormones induce RANKL 
expression in (Boyle WJ, 2003) osteoblasts which regulates adjacent osteoclasts in 
the BMU (Udagawa et al., 2000).  Recent evidence now suggests that osteocytes 
embedded in the bone matrix express a much higher amount of RANKL than 
osteoblasts implicating them as the leading source of RANKL contributing to bone 
remodelling (Nakashima, 2011) (Xiong, 2011). 
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The differentiation of osteoblasts relies on expression of Runx2, osterix (Osx) and the 
wingless (WnT) signalling pathway (Robling et al., 2006) (Figure1.18).  The WnTs are 
a family of glycoproteins now known to play a pivotal role in the regulation of bone 
formation, remodelling and development (Goldring and Goldring, 2007). WnT proteins 
exert their effects through two signalling pathways known as the canonical and non-
canonical pathways.  Canonical WnT signalling promotes osteoblast proliferation, 
mineralisation and inhibits apoptosis.  It also increases the OPG/RANKL ratio, thereby 
inhibiting osteoclastogenesis (Martin 2008 Ost Int).  In canonical signalling the binding 
of WnT ligands, such as WnT3a, to the LRP5/6:Frizzled coreceptor complex promotes 
the accumulation of cytoplasmic β catenin and its translocation to the nucleus 
enhancing transcription factors (Kobayashi et al., 2008). 
Figure 1.7 The WnT signalling pathway (Adapted from Martin Osteoporosis Int 2008) 
 
The understanding of the importance of WnT signalling in bone was greatly improved 
with the discovery of a mutation in the human low density lipoprotein receptor related 
protein 5 (LRP5) a WnT coreceptor.  The autosomal recessive disorder OPPG, where 
patients develop early osteoporosis, was found to be caused by loss of function in the 
LRP5 gene (Boyden et al., 2002). A genome wide association study has also linked 
LRP5 polymorphisms BMD and fracture risk (Richards et al., 2008).  In addition, a 
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mouse model blocking DKK-1 (a known inhibitor of WnT) was found to reduce 
osteoclast number and impair bone formation (Diarra et al., 2007). 
   
Non-canonical WnT signalling regulates bone homeostasis independently of β-
catenin.  The non-canonical WnT ligand WnT5a binds to the Ror2:frizzled co-receptor 
complex promoting osteoblast differentiation through Runx2 via JnkNK and PPARg 
signalling (Tu et al., 2007)  (Takada et al., 2007).  Maeda et al showed that osteoblast 
precursors also express WnT5a which increases RANK expression in osteoclasts, 
increasing their sensitivity to RANKL and thereby promoting osteoclastogenesis and 
bone resorption (Maeda et al 2012).  WnT5a has also been shown to activate the 
planar cell polarity pathway through RhoGTPase signalling (Kobayashi et al., 2008). 
 
GTPases of the Rho subfamily act as molecular switches which play a pivotal role in 
the regulation of actin cytoskeleton, membrane transport and transcription factor 
activity (Etienne-Manneville et al, 2002).  Of the 20 family members, the best studied 
are RhoA, Rac1 and Cdc42.  Rho GTPases are now known to be key downstream 
regulators of both canonical and noncanonical WnT signalling (Schlessinger et al, 
2009) (Zhu et al, 2013).  Activation of the small GTPase RhoA is required for WnT3a 
induced canonical osteoblastogenesis (Rossol-Allison et al, 2009). RhoA has also 
been shown to be important in the motility of osteoclasts and their ability to resorb 
bone (Chellaiah et al, 2000).  RhoGTPases have been shown to control a number of 
cellular responses in non-canonical WnT signalling acting as regulators downstream 
of Frizzled. (Schlessinger et al, 2009). 
 
1.3.2 Biomechanical control of bone remodelling   
As mentioned previously bone has the remarkable ability to adapt to loading.  The 
osteocytes are the principle cells involved in mechanotransduction control of 
modelling.  They exclusively express the SOST gene which encodes the protein 
sclerostin.  This protein inhibits the WnT signalling pathway by binding LRP5 resulting 
in the inhibition of bone formation. Linkage studies of families with the dysplastic bone 
disorders sclerosteosis and van Buchem disease, both characterised by an increase 
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amount of bone, and caused by loss of function mutations of SOST, lead to its 
discovery (Balemans et al., 2001).  Conversely, mechanical unloading of bone leads 
to sclerostin expression and consequently reduced bone mineral density (Lin et al., 
2009).   
 
 
Figure 1.8 Cellular and molecular coupling in bone remodelling (Adapted from 
Goldring, 2007). 
 
 
 
1.3.3 Bone loss after THA 
 
Bone loss following THA may be broadly categorised as occurring early or late.   
1. Early: The insertion of a prosthesis alters the local strain environment in the 
surrounding bone due to the difference in elastic modulus between the prosthesis 
and bone, and due to difference in the site of load transfer.  An example of this is 
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resorption of bone at the proximal femur that is well recognised and has been 
attributed to this process (Charnley and Cupic, 1973).    As the elastic modulus of 
metal is much greater than that of bone, load is transferred through the prosthesis 
distally.  Subsequently disuse osteoporosis occurs at the proximal end of the 
prosthesis (Oh and Harris, 1978).  A study by McCarthy found that 3 years after 
THA there was an average loss of 40% in bone mineral content inside the lesser 
trochanter and 28% average loss distally in the medial cortex of the femur 
(McCarthy et al., 1991).  A point of equilibrium does appear to be reached with 
resorption predominantly occurring in the first 2 years following arthroplasty 
(Bugbee et al., 1997). 
 
2. Late:  During use, wear particles are generated from the prosthesis bearing 
surfaces.  This triggers a foreign body chronic granulomatous inflammatory 
response resulting in osteoclast activation leading to periprosthetic bone resorption 
(Goldring SR, 1983).  This process is discussed in greater detail in the next section.  
 
Bone loss after THA also occurs as a result of normal ageing, at a rate of 
approximately 1-2% per year. This cause of periprosthetic bone loss will not be 
considered further in this thesis, but may contribute to prosthetic failure through 
periprosthetic fracture. 
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1.4 Osteolysis 
  
1.4.1  Impact of osteolysis 
 
Throughout this thesis the term osteolysis will be used to describe the bone loss that 
occurs as a result of the inflammatory process initiated by wear particulate debris; and 
the term aseptic loosening will be used to describe the mechanical failure of the 
prosthesis-bone construct that results from the osteolytic process. 
 
THA is one of the most successful orthopaedic procedures and has relieved pain and 
improved hip function in millions of patients worldwide.  Ninety percent of patients have 
either a good or excellent long-term outcome (Harris and Sledge, 1990).  It is an 
extremely cost effective procedure (Faulkner, 1998). The number of primary THA 
procedures is increasing every year with 98,211 carried out in England and Wales in 
the year ending 31st December 2015 (www.njrcentre.org.uk, 2016). 
 
Despite the success of modern prosthetic designs and bearing surfaces, around 10% 
of THA prostheses still fail within 10 years (Kurtz SM, 2007). Improvements in surgical 
technique and prosthesis design have decreased the incidence of deep sepsis, 
dislocation and fracture, however aseptic loosening, the clinical end point of osteolysis, 
remains the most frequent complication and in the UK accounts for 60% of all revision 
surgery (Table 1.1) (www.njrcentre.org.uk, 2016). Prosthesis loosening results in pain 
and disability, requiring revision surgery.  Revision THA is associated with a 3 to 8-
fold greater in-hospital mortality, poorer functional outcome, longer hospital stay, and 
higher cost than primary surgery (Kurtz SM, 2007, Mahomed NN, 2003, Doro C, 2006, 
Zhan C, 2007).  
 
Advances in materials, design and surgical technique has improved the wear 
performance of prostheses, which will decrease the future incidence of osteolysis.  
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However, an ageing population combined with younger more active patients now 
undergoing joint arthroplasty suggests that osteolysis and resulting prosthesis 
loosening will continue to be the major complication of THA.  
 
National Joint Registry Hip Annual Report Data 2016 
 Number % 
Revision procedures 88,822  
Indication for revision   
Aseptic Loosening 40,992 46% 
Osteolysis 12,988 14% 
Pain 18,407 20.7% 
Infection 11,189 12.5% 
Dislocation/ subluxation 12,117 13.6% 
 
Table 1.1 Summary of hip surgery data from 13th Annual Report National Joint 
Registry for England and Wales (www.njrcentre.org.uk, 2016) 
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Figure 1.9 Radiograph of hip replacement showing aseptic loosening 
 
1.4.2 Pathophysiology of Osteolysis 
 
The term aseptic loosening describes mechanical failure of the prosthesis-host 
interface, and arises primarily as the end result of focal periprosthetic inflammatory 
bone loss occurring at this interface. This pro-inflammatory microenvironment is driven 
by particulate wear debris, which is generated primarily at the articular bearing surface 
and at other non-articular prosthesis or cement surfaces (Goldring SR, 1983). Willert 
first proposed the involvement of prosthetic debris in the development of osteolysis.  
He identified a resultant foreign body reaction and granuloma formation which included 
macrophages and multinucleated giant cells (Willert HG, 1977).  This foreign body 
reaction has subsequently been reproduced in animal models (Goodman SB, 1990). 
Once particulate wear debris has been dispersed into the joint fluid it may initiate a 
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foreign body reaction at contact surfaces with the host tissues.  Schmalzried coined 
the term “effective joint space” to describe all areas where open communication with 
the joint pseudo-capsule may allow circulation of the joint fluid and particulate debris 
(Schmalzried TP, 1992). The effective joint space is thus dynamic and may advance 
along a tissue plane as osteolysis progresses. Variations in pressure in the joint space 
during activity may contribute to this circulation (Schmalzried TP, 1992). 
 
1.4.3 The Biology of Osteolysis 
 
The Fibrous membrane 
 
The process of aseptic loosening is characteristically accompanied with the 
development of a fibrous membrane at the bone-cement interface.  Histological 
analysis of this membrane has shown a synovial-like fibrovascular tissue containing 
cells including macrophages, fibroblasts and foreign body giant cells (Goldring SR, 
1983, Harris WH, 1976).  
 
Molecular signalling pathways involved in osteolysis 
 
The predominant cell types driving osteolysis, the macrophage and fibroblast, signal 
through various pro-inflammatory cytokines (including the interleukins, TNF alpha, and 
vascular endothelial growth factor VEGF) following either phagocytosis of the particles 
or through surface contact (Tuan RS, 2008).  
 
The biological process through which wear particles induce this inflammatory 
response is still not fully understood.  It has become clear that the innate immune 
system is involved in the initiation of the biological response. The innate immune 
system is the body’s first defence against foreign pathogens.  Its ability to recognize 
and eliminate pathogens relies on pattern recognition receptors (PRR). PRRs are 
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expressed by several cells in the monocyte cell lineage and include toll-like receptors 
(TLR) and the NOD-like receptors (NLR).  These subfamilies evoke an inflammatory 
response either directly through the activation of transcription factors upregulating pro-
inflammatory mediators or through the formation of inflammasomes.  
 
The inflammasome 
 
Caspases are cystein proteins which are important regulators of cell apoptosis and 
inflammation by cleaving interleukin precursors into their active forms.  A number of 
the NLRs have been shown to activate caspase-1 within multiprotein complexes 
known as inflammasomes (Martinon F, 2009).  One of the best characterised 
inflammasomes is the NLRP3 inflammasome. The complex consists of NLRP3, the 
adaptor molecule ASC and the cystein protease caspase-1 (Cassel et al., 2009). 
Activation of the NLRP3 inflammasome can occur as a result of (1) Danger associated 
molecular patterns (DAMPs) following cellular injury, (2) Pathogen associated 
molecular patterns (PAMPS) released from the cell walls of bacteria, (3) Particulate 
phagocytosis, (4) Reactive oxygen species (ROS) overproduction during cellular 
stress and infection. 
 
NLRP3 activation then allows caspase-1 to cleaveIL-1β to its mature and active form, 
IL-1β.   Although NLRP3 inflammasome activation is required for the maturation of IL-
1β it is not solely sufficient.  Pro-IL-1b must first be primed either through circulating 
toll like receptor activation by PAMPs and DAMPs and circulating IL-1β. 
 
The inflammasome in osteolysis 
 
There is now evidence that the NLRP3 inflammasome is involved in the inflammatory 
response to wear particles through IL-1β production.  The presence of PAMPs has 
been confirmed in the periprosthetic tissue of patients undergoing revision surgery for 
aseptic loosening (Nalepka JL, 2006).  Using RNA gene sequencing, the presence of 
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bacteria in the periprosthetic biofilm surrounding loose prostheses has also now been 
confirmed (Dempsey KE, 2007).   It has been shown both in vitro and in animal models 
that PAMPs adherent to particulate debris activate PRRs on macrophages, increasing 
the biological activity of wear particles (Greenfield EM, 2008). 
 
Caicedo et al demonstrated in vitro that metal implant debris stimulated an 
inflammatory response in macrophages through inflammasome signalling (Caicedo et 
al., 2009). Maitra et al found that in vitro UHMWPE wear particles are phagocytosed 
causing intracellular activation of NLRP3 through cathepsin B release.  In addition, 
alkane polymers generated by UHMWPE activate TLRs in cytokine release (Maitra R, 
2009). St Pierre et al showed in a mouse model that titanium particles induce an 
inflammatory response through the activation of the NLRP3 inflammasome (St Pierre 
CA, 2010). 
 
Osteoclast activation 
 
The indirect pathway 
The released pro-inflammatory cytokines, by macrophages, modulate the activation of 
other cell types in the periprosthetic environment, including osteoblasts.  Osteoblasts 
closely interact with osteoclasts in coupled bone remodelling, regulating bone 
resorption through the activation of osteoclasts (Rodan GA, 1981).  Activated 
osteoblasts stimulate the monocyte / macrophage cell lineage through activation of 
receptor activator of nuclear factor κ B (RANK) by its ligand (RANKL) and macrophage 
colony stimulating factor (M-CSF). Together these induce expression of genes 
required for the development and maturation of polykaryon osteoclasts and activation 
of their function of bone resorption (Boyle WJ, 2003).   This upregulation of 
periprosthetic bone resorption results in failure of the integrity of the prosthesis-host 
construct and loosening of the prosthesis. Activated macrophages also produce matrix 
metalloproteinases (MMPs) that directly degrade demineralised collagen matrix.  
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The direct pathway 
Fibroblasts are the most frequent cell type found in the loosening membrane, and also 
play a role in the pathogenesis of osteolysis. They produce the fibrous collagenous 
matrix which surrounds the prosthesis and in addition, secrete RANKL and IL-6, as a 
direct response to wear particles, which are both osteoclastogenic and stimulate the 
formation of multinucleated giant cells (Wei X, 2005, Sakai H, 2002).  In addition to 
upregulation of the osteoclastic response, particulate debris suppresses differentiation 
of mesenchymal stem cells (MSC) into mature functioning osteoblasts and reduces 
synthetic activity of mature osteoblasts further shifting turnover balance in favour of 
net bone loss (Wang ML, 2003). 
 
 
Figure 1.10 Summary of biological response to wear debris. Recruitment and 
activation of osteoclasts may occur directly through the production of RANKL by 
fibroblasts, or indirectly through the production of pro-inflammatory cytokines that 
stimulate the production of RANKL by the osteoblast. TNF may stimulate osteoclast 
differentiation and activation though both routes. 
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Other cells types may also be involved in the inflammatory response to wear 
particulate debris.  These include lymphocytes and mast cells. The presence of 
lymphocytes suggests involvement of the adaptive immune system.  It is suggested 
that particulate debris may undergo opsonisation which allows them to be targeted by 
B and T lymphocytes. Degranulated mast cells have been found in the periprosthetic 
tissue surrounding loose prostheses confirming their activation in the process of 
osteolysis (Solovieva SA, 1996) 
 
Variability in subject responses to wear debris 
 
Patients vary in their osteolytic response to particulate wear debris. Some show little 
bone resorption in the presence of marked prosthesis wear whereas others undergo 
marked osteolysis following a small amount of prosthesis wear (Figure 1.11) 
(Wilkinson JM, 2005). Macrophage responsiveness to in-vitro polyethylene and 
ceramic particulate debris stimulation has been shown to vary between individuals 
(Matthews JB, 2000) (Hatton, 2003). An in vitro study by Gordon et al found that 
monocytes (PBMCs) from patients with a susceptibility to osteolysis exhibited 
quantitatively greater inducible cytokine responses to particulate compared to patients 
without this susceptibility (Gordon, 2008) . It has therefore been suggested that patient 
variability in osteolytic response to particulate debris has a genetic basis. In support 
of this there is increasing evidence, through candidate gene studies, that genetic 
variants in cytokines and effector proteins involved in the pathogenesis of osteolysis 
are involved. 
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Figure 1.11 Patients exhibit variable osteolytic responses to wear debris. a) 
radiograph showing marked polyethylene wear, but no osteolytic response, b) 
radiograph showing mild wear but pronounced femoral and acetabular osteolysis with 
prosthesis loosening. 
 
1.5 Heterotopic ossification 
 
1.5.1 The clinical impact of heterotopic ossification 
 
Heterotopic ossification (HO) is the pathological formation of lamellar bone in extra-
skeletal tissues that do not normally ossify (figure 1.12).  HO can be differentiated 
histologically from calcification, by the presence of trabeculae (Balboni et al., 2006). It 
was first described by the German physician Reidel in 1883 and in 1918, Dejerne and 
Ceiller observed its formation in First World War soldiers who had sustained spinal 
cord injury (Dejerne and Ceiller, 1918). It is a common complication following THA with 
a variable reported incidence of between 5 and 90% (Charnley, 1972, Newman et al., 
2015, DeLee et al., 1976, Rosendahl et al., 1973).   HO has been shown to complicate 
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up to 25% of fractures, and occurs in up to 65% of blast injured amputees (Potter et 
al., 2007, Forsberg et al., 2009, Mitchell et al., 2010).  It’s incidence following spinal 
cord injury has been reported as 30% (Stover et al., 1991).  
 
There is an increased incidence of HO in males (DeLee et al., 1976, Pavlou et al., 
2012), those with a previous history of HO (Ritter and Vaughan, 1977), ankylosing 
spondylitis (Bisla et al., 1976), diffuse idiopathic skeletal hyperostosis (Blasingame et 
al., 1981) and hypertrophic osteoarthritis (Sawyer et al., 1991).  Rheumatoid arthritis 
has been shown to be protective against HO but it is unclear whether this is due to 
anti-inflammatory medication prescribed for this group of patients (Zhu et al., 2015).  It 
has been suggested that surgical technique plays a role in the incidence of HO 
formation.  This may be, in part, due to the amount of intraoperative tissue trauma 
evidenced by the increased rate of HO in revision surgery and longer operative 
procedures (Hierton et al., 1983).  There remains controversy whether surgical 
approach influences the formation of HO.  Bischoff et al and Ashton et al found lower 
rates of HO using a posterior approach versus an anterolateral approach (Bischoff et 
al., 1994, Ashton et al., 2000).  It has been suggested that less abductor retraction 
and subsequent ischaemia with a posterior approach may be responsible (Corrigan et 
al., 2015). Morrey et al found no difference between anterolateral, trans-trochanteric 
or posterior approaches (Morrey et al., 1984).   Similarly, Corrigan et al showed no 
difference in the HO incidence following hip hemiarthroplasty using anterior, 
anterolateral and posterior approaches (Corrigan et al., 2015).  Martin et al found no 
reduction in HO rate using a minimally invasive anterolateral approach compared to a 
direct lateral approach (Martin et al., 2011).  There is also debate whether use of 
cemented or cementless influences HO rate.  Pavlou et al found that fully cemented 
implant were more likely to form HO, and proposed that release of bone debris during 
reaming may be a contributing factor (Pavlou et al., 2012).  In contrast, a prospective 
randomised controlled trial found no difference between cemented or cementless THA 
(Nayak et al., 1997) 
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Figure 1.12 HO following cemented Charnley THA 
 
The majority of cases of HO following THA are asymptomatic and Charnley deemed 
its occurrence as a matter only of ”academic interest”(Charnley, 1972).  There are a 
number of reports, however, associating poorer post-operative functional outcome 
with increasing severity of HO (Nollen and Slooff, 1973, Pohl et al., 2005).  The 
incidence of clinically significant HO has been reported to be between 3 and 7% of 
THA cases (Board et al., 2007).  The most common symptom of HO is pain (Garland, 
1991).   In addition to pain, restriction of joint motion may occur, as well as neural or 
vascular compression (Garland, 1991, Hierton et al., 1983, Brooke et al., 1991).    
Other symptoms include localised warmth, swelling and erythema clinically mimicking 
infection (Orzel and Rudd, 1985).  Pyrexia may also occur (Macfarlane et al., 2008). 
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Early detection of HO is difficult.   It’s formation usually occurs within the first 2 
postoperative weeks with radiographic evidence appearing after 6 weeks.  Symptoms 
may not manifest until 12 weeks (Orzel and Rudd, 1985, Mavrogenis et al., 2011).   A 
number of studies have looked at biomarkers for early detection of HO.  Wilkinson et 
al found higher levels of N-terminal propeptide of type –I collagen (PINP), osteocalcin 
and C-telopeptides of type-I collagen (CTX-I) in patients who developed HO following 
THA compared with those who did not (Wilkinson et al., 2003).  Sell and Schleh 
reported significantly higher post-operative CRP levels in patients who developed HO 
(Sell and Schleh, 1999).  Three phase technetium 99m isotope bone scanning is the 
most sensitive method for early detection (Freed et al., 1982).  Its expense and the 
associated radiation exposure preclude it as a useful screening tool. 
 
Once HO has formed, a process that is usually complete by 12 months following 
surgery, treatment options are limited and usually consist of surgical resection.  This 
is further complicated by recurrence rates which have been reported to be as high as 
100% (Mavrogenis et al., 2011) 
 
1.5.2 Aetiopathogenesis of heterotopic ossification 
The exact aetiopathogenesis of HO is still not fully understood.  It can be broadly 
classified into traumatic, neurogenic or genetic in cause, with that following THA 
included in the traumatic group (Ekelund et al., 1991).  It has been proposed that 3 
prerequisites are required for the formation of HO: 1. Triggering event leading to 
release of osteogenic induction agents; 2. Osteogenic precursor cells; 3. An 
environment permissive of bone formation (Chalmers et al., 1975).  Although it 
remains unclear whether both the acquired and genetic forms share an exact 
pathogenesis, there do seem to be a number of common pathways (Winkler et al., 
2015).  Interplay between inflammatory, osteogenic, and neurogenic pathways has 
been suggested (Wang et al., 2015).   
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Figure 1.13 HO pathogenesis (adapted (Edwards and Clasper, 2015)) 
 
An established trigger for HO involves an initial inflammatory response (Sawyer et al., 
1991).  This inflammatory and hypoxic microenvironment has been shown to result in 
localised myocyte cell death (Shore and Kaplan, 2010).  This is then followed by 
angiogenesis and the differentiation of osteogenic precursor cells (Kaplan et al., 1993). 
The origin of these precursor cells is uncertain.  Lineage tracing studies have 
suggested that local myocyte osteoprogenitor cells contribute only minimally to the 
formation of HO (Lounev et al., 2009). Cortical bone derived stem cells and medullary 
mesenchymal stem cells are able to differentiate into osteoblasts and their release 
during fracture or during THA surgery may contribute to HO (Puzas et al., 1989, 
Winkler et al., 2015).  It has been shown that osteoprogenitor cells with an endothelial 
or endoneurial origin may migrate to the region of ectopic bone formation (Lounev et 
al., 2009, Lazard et al., 2015).    
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Urist discovered in 1965 that demineralised bone matrix induced heterotopic bone 
formation following trauma in a rabbit model (Urist, 1965).  He postulated that this 
osteogenesis was controlled by bone morphogenetic proteins (BMPs) (Urist and 
Strates, 1971). The role of BMPs signalling in the formation of HO is well established 
and their use as primary inducers forms the basis for many animal models used in the 
study of HO (Winkler et al., 2015).   BMP signalling has been shown to control 
osteoprogenitor migration and differentiation (Shore and Kaplan, 2010).   There is a 
contribution of a neuro-endocrine pathway in the formation of HO.  Neural 
inflammation induced by BMP2 results in the release of osteogenic precursors from 
peripheral sensory neurones (Salisbury et al., 2011).  The endoneurial derived 
progenitors migrate through newly formed endoneurial vessels to the site of bone 
formation (Lazard et al., 2015).  A number of cytokines/ chemokines capable of 
promoting osteogenesis have been propose and include platelet derived growth factor, 
fibroblast growth factor, transforming growth factor-β, insulin-like growth factor, 
epidermal growth factor, IL-6 and IL-10 (Edwards and Clasper, 2015).  The use of 
indomethacin in HO prophylaxis has led to the proposal that prostaglandin-E2 may be 
an important systemic factor (Ahrengart et al., 1988).  
 
The permissive environment required for ectopic bone formation is also not clear. 
Studies have shown that an environment with low oxygen tension induces chondrocyte 
differentiation leading to endochondral ossification (Schipani et al., 2001, Mobasheri 
et al., 2005).   Olmstead-Davies et al showed that BMP induced generation of brown 
adipocytes in the region of soft tissue injury leads to a low oxygen tension environment 
permissive of ectopic bone formation (Olmsted-Davis et al., 2007). 
 
1.5.3 Classification of HO following THA 
 
The two recognised patterns of HO following THA are found in the peri-femoral neck 
region and within the abductors. It most commonly occurs in the abductors (Board et 
al., 2007).  Brooker et al described a classification system for the ossification following 
THA on AP radiographs (figure 1.14) (Brooker et al., 1973): 
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Figure 1.14 The Brooker grading of HO around the hip: 
Class 1: a small island of bone 
Class 2: bone spurs from pelvis and proximal femur leaving at least 1cm between 
opposing surfaces  
Class 3: bone spurs from pelvis and proximal femur leaving gap less than 1cm 
Class 4: apparent ankylosis of the hip 
 
 
 
 
  
a 
Class I Class III Class II Class IV 
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1.6 The Genetic Basis of Disease 
 
The process of bone formation and resorption is governed by the interaction of a 
number of bone regulatory and inflammatory proteins.  The quantity and quality of 
each of these proteins is determined by the underlying genes which encodes them.  
Variation within the genetic code can lead to an alteration in the structure, function or 
expression of regulatory proteins and this section will therefore outline the basics of 
genetics and its variation.  
 
1.6.1 The structure of DNA 
The structure of DNA (deoxyribonucleic acid) was first recognised by Watson and 
Crick in 1953 (Watson JD and Crick FH, Nature 1953, 171: 737-738).  DNA consists 
of two helical chains of nucleotide bases covalently bound to a sugar-phosphate.  Two 
types of nucleotide bases exist: those derived from purine and those derived from 
pyrimidine.  The purine bases are adenine (A) and guanine (G).  The pyrimidine bases 
are cytosine (C) and thymine (T).  Purines always pair with pyrimidines, bound by 
hydrogen bonds in the following pairs: A-T or C-G (Passarge, Colour atlas of genetic, 
3rd edition, Thieme, 2006). 
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Figure 1.15 Structure of DNA 
 
The sequence of base pairs confers the genetic information.  Each triplet of bases 
(known as a codon) code for a specific amino acid.  A total of 64 triplets are possible.  
As there are only 20 amino acids much of the DNA strand is non-coding.  Coding 
regions are known as exons and non-coding regions are known as introns.  Although 
introns were once thought to be redundant, it is now understood that they may contain 
promoter regions involved in gene expression (Williams Optometry 2001).  The 
transcribing RNA is spliced, removing the introns, and forms mature mRNA ready for 
translation (Passarge, Colour atlas of genetics).  
 
Replication of DNA occurs with the breakage of the hydrogen bonds joining each base 
pair.  Each strand acts as a template to generate a new strand.  A complimentary 
strand of RNA transcribes the sequence.  The transcribing RNA is then spliced, 
removing the introns, and forms mature mRNA ready for translation (Passarge, Colour 
atlas of genetics).  
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1.6.2 Genetic variation 
 
The Human genome project successfully sequenced the human genome by 2004 
(IHGSC, 2004).  It consists of 3.3 billion base pairs with only 3% representing coding 
regions (Burton et al., 2005).  Within a given ethnic population, the sequence of DNA 
between individuals is 99.9% identical (Feuk et al., 2006).  The relatively small 
proportion of variation within the code confers the phenotypic heterogeneity within a 
population.  These variants occur at approximately every 1000 nucleotide base pairs 
of the code; thus the human genome differs by about 20 to 30 million bases pairs 
between individuals (Jorde and Wooding, 2004). Genetic variation is not only 
responsible for evolutionary advantage; it is also a potential cause of disease.  The 
individual specific risk of common diseases is thought to be influenced by the sum of 
many genetic variations, each potentially causing small changes in biological function 
and consequently subtle changes in phenotype (Misch EA, 2008). 
 
There are two main sources of genetic variation: mutation and recombination.  
Mutations can occur as a result of environmental mutagens including a number of 
chemicals and ionising radiation or, less commonly, may occur spontaneously.  
Recombination is the exchange of genetic material between two chromosomes. When 
a chromosomal pair is lined up during meiosis there may be crossing over resulting in 
the exchange.  This is known as homologous recombination and is an important 
evolutionary process. It allows the restructuring of genetic material increasing 
variability and helps to eliminate unfavourable mutations (Passarge, 2007).  Double 
strand breaks in DNA can be repaired by homologous recombination where a 
homologous chromosome is used as an accurate template.  DNA end joining (non-
homologous recombination) is a process that ligates the DNA ends without homology.  
It is therefore more susceptible to result in mutation. 
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Types of variation 
 
Human genetic sub microscopic variants can be divided into 2 nucleotide composition 
classes (Frazer et al., 2009): 
 
1. Single nucleotide variants 
A Single nucleotide polymorphism (SNP) is a single base change in a nucleotide 
sequence.  Two copies of each chromosome are inherited (one maternal and one 
paternal).  This creates a possible 2 alleles at any given locus.  An individual can be 
either heterozygous or homozygous for the allele.  The minor allele frequency (MAF) 
denotes the frequency of the less common allele in a population.  It has been estimated 
that the human genome contains 11 million SNPs.  Around 7 million of these occur 
with a MAF of over 5% and the remainder of at least 1% with which they are defined 
(Frazer et al., 2009). 
 
2. Structural variants 
Structural variants are all variants that larger than 1 kb.  It is believed they account for 
20% of all genetic variation and underlie over 70% of the variant bases (Frazer et al., 
2009).  They include insertion or deletion variants, block substitutions, inversions and 
copy number variants (CNV). CNVs occur when segments of identical sequences are 
repeated in some chromosomes but not others.  Recent evidence suggests that they 
may account for 13% of the human genome (Stankiewicz and Lupski, 2010). 
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Implications of genetic variation 
 
Synonymous variation 
Not all variations confer a change in phenotype.  If the variation does not alter the 
polypeptide product of a gene a synonymous (or silent) variation occurs.  Thus, as 
long as a change in the DNA sequence creates a codon which codes for the same 
amino acid, a structural but not functional change will occur. 
 
Missense variation 
A missense variation occurs when a sequence variation results in a change of the 
encoded polypeptide.  This change in amino acid may alter the function of a protein 
leading to a reduction or even loss of its biological activity.   
 
Promoter variation 
Each cell differs in its expression of certain genes and polypeptide product.  This 
control of transcription is regulated by the promoter region which is responsible for the 
activation of RNA polymerase.  The promoter region is typically within 200bp upstream 
of its corresponding gene (Meuller, 2003), but may extend further or be on a non-
contiguous DNA section.  Any variation in this region can alter the binding of 
transcription factors which in turn can alter gene expression.  
 
Nonsense variation 
If a substitution leads to the introduction of a stop codon there may be a premature 
termination of translation of a peptide.  The resulting protein is unlikely to retain normal 
function. 
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Frame-shift variation 
These variations occur as a result of insertion or deletion.  This alters the codon 
reading frame and greatly changes the translated protein which is unlikely to retain 
normal functional. 
 
Genetic variation has the potential to alter phenotype through the gain or loss of 
function.  Alterations in transcription and translation of DNA result in changes in protein 
expression and structure respectively.  Variation within coding regions has an obvious 
effect on gene structure but variation in non-coding regions also has the potential to 
alter phenotype through changes in gene regulation.  
 
Epigenetics 
In addition to allelic variation, gene expression can be influenced without a change in 
genotype.  The study of heritable changes in phenotype without an underlying change 
in nucleotide sequence is termed epigenetics. Epigenetic modification occurs as a 
result of environmental influence.  There are three methods in which epigenetic 
modification can occur:  DNA methylation, histone modification and RNA associated 
silencing (Egger et al, 2004).   
 
DNA methylation is a process whereby methyl groups bind to the C5 position of 
cytosine bases.  This normally occurs where there is an adjacent guanine base; known 
as a CpG (5’-C-phosphate-G-3’) site.  5-Methylcytosine in a promoter CpG site binds 
methylated CpG binding proteins which leads to inhibition of transcription initiation by 
preventing the binding of transcription factors (Jones et al, 2001).   
 
DNA is packaged around intracellular histone octamers forming a complex known as 
chromatin.   Histones can be epigenetically modified by acetylation and methylation, 
consequently altering the formation and function of chromatin.  Histone methylation 
has been shown to regulate transcription and influence stem cell differentiation (Varini 
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et al, 2013).  In contrast to histone methylation, which has been associated with both 
promotion and suppression of transcription, histone acetylation has been shown to 
activate transcription.  Acetylation leads to altered chromatin folding which allows 
promoters to be more accessible to RNA polymerases thereby promoting gene 
expression (Eberharter et al, 2001). 
 
Non-coding RNAs, such as siRNAs (small inhibitory RNAs) and miRNAS 
(microRNAs), are now thought to play an important role in the regulation of epigenetic 
mechanisms of gene expression.   These small non-coding RNAs act by promoting 
mRNA degradation and inhibiting translation (Phillips, 2008).  More recently, non-
coding RNAs have been shown to regulate cytosine methylation and histone 
modifications (Piletic et al, 2016). 
 
1.6.3 Genetic epidemiology 
 
Genetic epidemiology is the “science which deals with the aetiology, distribution, and 
control of disease in groups of relatives and with inherited causes of disease in 
populations” (Morton, 1982).  The study of genetic variation was undertaken even 
before the discovery of DNA through the use of Mendel’s laws of inheritance (Stern C, 
1966) (Fisher, 1918).  Advances in technology and understanding of molecular biology 
led to the evolution of the epidemiological evaluation of the genetic basis of disease.  
All genetic epidemiological studies ask the same questions: Is there a genetic 
component to the disorder and what are the genes responsible for this disorder?   
 
The framework for genetic epidemiology 
The first step in the approach to identifying whether a disease has a genetic 
component is through the study of families.  This is usually in the form of observational 
studies on sibling/twin concordance or parent-offspring concordance.  Segregation 
analysis is then used to determine the mode of inheritance within the family.  Linkage 
analysis then allows us to localise a chromosomal area containing shared genetic 
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markers which are linked to the causative variant.  Association analyses are then used 
to investigate specific alleles within this region under the linkage signal 
 
 
Figure 1.16 Traditional framework for identification of causative genetic variants 
(adapted from Burton PR, Lancet 2005). 
 
Families have traditionally been used to study traits as it is difficult to obtain large 
representative cohorts from the general population with the desired expressed 
phenotype of study.  Family studies were useful and very successful in the 
determination of various Mendelian inherited disorders (Beaudet et al., 1989), (Gusella 
et al., 1983).  The large effect size of single variations in disease causing alleles made 
these relatively straight forward to identify through the principle of genetic linkage.  
Common complex diseases, however, have polygenic inheritance with each causative 
allele contributing a small effect to the expressed phenotype.  Linkage analysis in 
families has been used to study complex diseases, however, has had limited success, 
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due to inadequate power (Risch and Merikangas, 1996).  This has led to the use of 
large population association analyses.     
 
 
 
Figure 1.17 Genetic architecture of variants.  Adapted from (Manolio et al., 2009) 
 
 
1.6.4 Linkage analysis studies 
 
Linkage analysis follows the passage of genetic markers within haplotypes through 
the generations (Williams et al., 2011).  If a marker consistently accompanies the 
phenotype of interest, this suggests a gene that is in close to proximity to that marker 
may confer causation (Burton et al., 2005).  In practice, haplotypes cannot be traced 
further than a few generations and affected siblings are therefore commonly used to 
compare haplotypes.  An important factor in linkage analysis is the rate of 
recombination segregating two loci.  This is known as the recombination fraction (Ɵ) 
and describes how far apart genetic loci are by quantifying the probability of 
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recombination between them (Williams et al., 2011).   Loci that are close to each other 
on the same chromosome are more likely to be segregated together than loci on 
separate chromosomes (Teare, 2005).  If Ɵ is ≥50% then the loci are just as likely to 
recombine as not as they are far apart or on different chromosomes (Williams et al., 
2011) Ɵ is used to calculate the logarithm of the odds (LOD) score which is the 
likelihood of linkage between two loci.  The higher the LOD, the greater the evidence 
that two loci co-segregate and are linked (Teare, 2005).  Using this method, linkage 
analysis can narrow down a genomic location containing the gene of interest (Williams 
et al., 2011), (Teare, 2005). 
 
1.6.5 Association analysis studies 
 
Genetic association studies look for association between genetic variants and a 
phenotype in a study population of unrelated individuals.  They compare the frequency 
of alleles between affected individuals and a control group of unaffected individuals.  
They are therefore usually case-control studies.  Association analysis has greater 
power than linkage studies to detect variants with small effects and are therefore 
popularly used to study common complex diseases (Cordell, 2005).  Identified variants 
can either be causative loci (directly associated) or markers in linkage disequilibrium 
(LD) with the causative loci (indirectly associated).  Two loci are deemed to be in LD 
if, they are present together on a haplotype more frequently than would be expected 
when tested across many individuals (Jorde, 2000).  As it is likely that a number of the 
causative variants will be in non-coding regions it is difficult to select candidates for 
association analysis.  Therefore, indirect association analyses are most commonly 
used despite being weaker than direct analyses. (Palmer, 2005).  In order to reduce 
the risk of false negatives in indirect association studies we need adequate mapping 
of variants and their LD markers.  This genetic mapping is being carried out by the 
International HapMap Project.  The International HapMap (haplotype mapping) project 
established in 2002 provides an online open source database which catalogues SNP 
frequencies, genotypes and haplotypes data for 4 genetically diverse populations 
(Yoruba in Ibadan, Nigeria (YRI), Han Chinese in Beijing, China (CHB), Japanese 
individuals from Tokyo, Japan (JPT) and European ancestry living in Utah from the 
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Centre d’Etude du Polymorphisme Human database (CEU)) (International HapMap 
Consortium, 2005).  The website contains a genome browser which allows the user to 
find SNPs in any region of interest and can be used to determine tag SNPs for use in 
association studies. The advancement of SNP mapping and LD patterns together with 
technological advances allows investigators to now select a set of genetic markers 
that efficiently assays most common genetic variations (Skol et al., 2006).  The 1000 
genome project was an international collaboration which was established in 2008 with 
the aim of creating a comprehensive description of common human genetic variation.  
The final phase of the project, published in 2015, characterised over 84 million SNPs 
in 2,504 individuals from 26 populations around the world and provides one 
benchmark for studies of human genetic variation (Auton et al., 2015).  
 
1.6.6 Genome wide association studies (GWAS) 
 
The reduced cost of genotyping, advancements in genomic, increasing SNP 
databases and LD pattern mapping has allowed us to carry out association analyses 
across the whole genome. GWAS can be undertaken across large populations using 
a hypothesis-free approach. It therefore allows us to identify susceptibility loci without 
first having to undertake a linkage scan.  The scanning of loci across the whole 
genome aims to identify clusters of SNPs in association with a particular phenotype. 
Clustering would imply that markers are in LD with other and therefore close to the 
susceptibility locus (Williams et al., 2011).  Many early studies are often said to be 
underpowered and robust study design including population stratification, adequate 
genotyping and analysis is paramount (Hattersley, 2005).  In order to reduce the risk 
of false positive results and increase the power of these studies, replication and meta-
analyses should be undertaken. 
 
1.6.7 The genetic association with osteolysis 
 
A number of candidate gene studies have shown that genetic variation in genes 
encoding various inflammatory cytokines is associated with osteolysis. Wilkinson et al 
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showed an association between variability within the DNA encoding the tumour 
necrosis factor (TNF) promoter region (dbSNP rs361525) and risk of osteolysis 
following THA (Wilkinson, 2003).  Subjects with osteolysis were approximately 1.7 
times as likely to carry the variant DNA code as those subjects with no osteolysis. This 
association has been replicated in an independent population by Ambruzova et al 
(Ambruzova Z, 2006).  Gordon et al have reported genetic variation within the genes 
encoding Interleukin-1 receptor antagonist (IL-1RN) and IL-6 is also associated with 
osteolysis (Gordon A et al., 2008). Similar associations have also been identified in 
other populations (Kolundzic, 2006, Gallo, 2009, Malik, 2007).   
 
Variation within genes that regulate bone turnover also associate with osteolysis. 
Gordon et al showed that carriage of the dbSNP rs288326 variant in the FRZB gene 
encoding secreted frizzled-related protein-3 (Frp3), a regulatory glycoprotein within 
the osteogenic Wnt signalling pathway that modulates mesenchymal stem cell 
differentiation of osteoblasts (Martin TJ, 2008), associated with susceptibility to 
osteolysis following THA (Gordon A et al., 2007). Its carriage also associated with the 
development of heterotopic ossification following THA.  Malik et al have also shown 
associations between aseptic loosening and other candidate loci within the genes 
encoding matrix metalloproteinase 1 and the vitamin D receptor (Malik, 2007), 
mannose-binding lectin (Malik MH et al., 2007), and the RANK/OPG pathway (Malik 
MH et al., 2006).  
 
Recent studies using beadchip assays have shown that many genes are differentially 
expressed in wear debris-induced cells and tissues (Garrigues GE, 2005, Shanbhag 
AS, 2007, Koulouvaris P, 2008), and have highlighted our limited understanding of the 
spectrum of biological mediators involved in the pathogenesis of osteolysis. The 
identification of further risk loci is required to further understanding of the pathogenesis 
of aseptic loosening.  This would potentially allow for the development of screening 
tools, and provide investigational targets for prophylaxis or treatment with the aim of 
reducing the need for revision surgery, and its associated morbidity. 
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The reducing cost of genotyping, advances in genomic technology, and increasing 
SNP mapping now allows us to carry out cost-efficient association analyses across 
the whole genome in large populations, and is the next step that will allow a more 
complete understanding of the contribution of genetic factors to osteolysis. 
 
 
1.6.8 The genetic association with HO 
 
The increased incidence of HO in bone forming disorders and the heterogeneity in HO 
manifestation in patients with similar injury patterns suggests a genetic predisposition.  
To date, the majority of genetic research has looked at the rare heritable causes of 
HO and few screening studies have been carried out in other populations.   
 
The rare genetic forms of HO, fibrous dysplasia ossificans progressiva (FOP) and 
progressive osseous heteroplasia (POH), are characterised by progressive extra-
skeletal bone formation following minor trauma (Kaplan and Shore, 2000).  FOP is 
caused by an autosomal dominant mutation in the ACVR1 gene.  ACVR1 encodes the 
bone morphogenetic protein (BMP) type I receptor activating-like kinase2 (ALK2) 
(Shore et al., 2006).  This gain of function mutation has been shown in the knock-in 
mouse model to promote the spontaneous and injury induced formation of HO (Kaplan 
et al., 2012).  Bone formation typically starts in the neck and thoracic spine but 
progresses over time eventually bridging the joints of the axial and appendicular 
skeleton (Shore and Kaplan, 2010).  This leads to complete immobilisation of the body 
and has led to the colloquial term “stone man syndrome.”  Like FOP, POH leads to 
extensive ectopic ossification but is differentiated by a number of clinical differences.  
The heterotopic ossification originates in the dermis and progresses into the deeper 
soft tissues (Kaplan et al., 1994).  POH is caused by an inactivating mutation in GNAS, 
which encodes the stimulatory G-protein alpha subunit that activates adenylyl cyclases 
and is involved in bone formation (Shore et al., 2002).   
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Larson et al found that patients with HLA-B27 were more likely to develop HO following 
traumatic spinal cord injury (Larson et al., 1981).  The absence of HLA-B27, however, 
does not preclude the development of HO.  Candidate gene studies have associated 
variants in genes encoding the β2adrenergic receptor, toll-like receptor (TLR) 4, 
complement factor H, and secreted frizzled related protein 3 (sFRP3) with 
susceptibility to HO (Gordon A et al., 2007, Mitchell et al., 2010).  As with osteolysis, 
no genome wide analyses for HO have been carried out to date.  This hypothesis free 
approach has the potential to identify variants in genes which have never before been 
implicated in its pathogenesis.  This will further our understanding of the biological 
pathways involved which currently elude us. 
 
1.7 Study Hypotheses 
 
1. We hypothesise that genetic variation contributes to osteolysis susceptibility 
and time to prosthesis failure following THA. 
2. We hypothesise that genetic variation contributes to heterotopic ossification 
susceptibility and severity following THA. 
3. We hypothesise that national joint registries can be utilised for large scale 
recruitment and postal collection of saliva samples provides adequate DNA 
yield to establish a DNA biobank for high throughput genotyping. 
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1.8 Study Aims 
 
1.8.1 Primary Aims 
 
1. To conduct a candidate gene study to determine whether variants in genes 
involved in bone turnover and inflammatory pathways contribute to osteolysis 
susceptibility and time to prosthesis failure following THA. 
2. To conduct a GWAS to identify susceptibility loci for osteolysis and time to 
prosthesis failure following THA. 
 
1.8.2 Secondary Aims 
 
1. To conduct a replication study of osteolysis GWAS results and meta-analysis 
of both stages. 
2. To conduct a single stage GWAS to identify susceptibility loci for heterotopic 
ossification (HO) after THA. 
3. To conduct a single stage GWAS for severity of HO after THA.  
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CHAPTER 2 
METHODS 
 
2.1 Overview 
 
This chapter outlines the various methodological approaches, their principles and 
application as used in the thesis. Specific methods, as they apply to individual studies 
are outlined briefly within each results chapter, as the applications differ for each 
experiment.   
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2.2 Phenotype Definition 
 
2.2.1 Osteolysis case definition  
 
Available radiographs were examined to identify presence of aseptic loosening.  The 
criteria of Harris and McGann were used to define loosening of the femoral prosthesis 
(Harris and McGann, 1986): 
Definition of loosening Radiographic morphology 
Definitely loose 1. Migration of cement 
2. Fracture of cement 
3. Lucent line at the cement stem interface 
Probably loose Continuous (100%) line at the cement bone 
interface without prosthesis migration 
Possibly Loose Incomplete lucent line (50 - 90%) at the cement 
bone interface 
 
 
The criteria of Harris and Penenberg were used to define loosening of the acetabular 
cup prosthesis (Harris and Penenberg, 1987):  
Definition of loosening Radiographic morphology 
Definitely loose 1. Migration of the acetabular cup 
2. Fracture of cement 
Impending loosening Continuous (100%) line at the cement bone 
interface that is nowhere less than 2mm wide 
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Femoral gradings: definitely loose and probably loose and acetabular gradings: 
definitely loose and impending loosening were included in this study as cases.  
Possibly loose grades were excluded from the study. 
 
 
2.2.2 Prosthesis survival time 
 
Prosthesis survival time was measured in the cases as the time between the date of 
primary surgery to the date of radiographic diagnosis of osteolysis (or date of revision 
surgery if the date of diagnosis was not known).  In the controls, it was determined as 
the time between the date of primary surgery and the date of the most recent 
radiograph.   
 
2.2.3 HO Identification and grading 
 
Presence of HO was assessed on AP plain radiographs of not less than 1-year post 
THA.  Cases comprised subjects with radiographic evidence of post-operative HO and 
were graded (0-4) using the Brooker classification as described earlier in this thesis. 
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2.3 Ein Bild Roentgen Analyse (EBRA) measurement of wear 
 
2.3.1 Principles of EBRA 
 
Polyethylene wear rate is an important predictor of osteolysis. It is therefore important 
to have reliable methods for measuring polyethylene wear radiographically.  Good 
correlation between radiographic measurements of wear and measurements made on 
retrieved cups has been shown (Livermore et al., 1990).  The EBRA method, 
developed at the University of Innsbruck, Austria, was originally used to assess 
acetabular cup and femoral stem migration (Wilkinson et al., 2002).  The software was 
later modified allowing wear measurements to be made (Ilchmann et al., 1995).  A grid 
of transverse and longitudinal tangents is drawn between prominent pelvic structures 
determining the position of the pelvis (Figure 2.1).   
 
Figure 2.1 Reference lines of EBRA. 
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Following this, the software allows the size and position of the femoral head and the 
acetabular cup contrast wire to be measured.  The software then measures the 
distance between the centre of the femoral head and the centre of the cup on the x 
and y axes, thereby calculating a vector of linear wear of the polyethylene cup by the 
femoral head.    
 
Figure 2.2 Schematic representation of the wear vector as measured by EBRA.  It is 
calculated by measuring the distance on the x and y axis of the centre of the femoral 
head to the centre of the acetabular cup. 
 
EBRA has good accuracy when compared to other plain radiographic measurement 
methods (Ilchmann et al., 1995).     
 
2.3.2 Discovery cohort wear measurements 
 
EBRA software was used to calculate wear measurements for patients with available 
and appropriate radiographs. For the osteolysis group, measurements were obtained 
from radiographs obtained immediately prior to revision surgery.  The control group 
measurements were taken from the most recently available radiographs.  Wear 
vectors were used as a covariate in the osteolysis susceptibility and time to failure 
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quantitative trait analyses.  Subjects without radiographs were allocated interpolated 
wear rates calculated by the mean of wear rates in their group (cases or controls).  As 
EBRA had been used to measure linear wear for subjects previously recruited in the 
Sheffield genetic hip study, this method was continued for our newly recruited 
subjects.  Although we accept of lack of volumetric wear measurement using EBRA, 
we deemed linear wear an acceptable measure as the largest femoral head diameter 
was 29mm.  
 
2.4 DNA Sampling 
 
2.4.1 Sources of DNA 
 
Genomic DNA can be extracted from a number of human sources where nucleated 
cells are present.  Blood is the most commonly used source of DNA for genetic testing 
and it yields large amounts of high quality DNA.  Its collection does, however, require 
study subjects to attend for an invasive procedure, and collection needs to be carried 
out by trained phlebotomists   Large scale genetic epidemiological studies require 
large numbers of study subjects and therefore require more convenient methods of 
DNA sample collection.  Saliva has been shown in various studies to be a viable 
alternative source of genomic DNA to whole blood for genetic epidemiological studies 
and whole genome scanning (Ng, 2005), (Rogers et al., 2007), (Nishista, 2009) 
(Rylander-Rudqvist et al., 2006).   Both blood and saliva were used in this study.  All 
DNA samples from extant subjects were extracted from whole blood and have been 
stored at -80oC.  Prospectively recruited patients have been recruited through postal 
invites and therefore all DNA samples have been extracted from saliva samples 
received through this route. 
 
2.4.2 DNA collection  
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All saliva samples were collected using the Oragene OG-500DNA self-saliva collection 
kit (DNA Genotek, Inc., Ottawa, Ontario, Canada).  This is an all in one system for the 
collection, stabilisation, transportation and purification of saliva.  Each kit contains (1) 
Collection tube: The lid of which contains 2mls of DNA stabiliser and purifier (to prevent 
bacterial growth and degradation of DNA), (2) Sealing cap, (3) Instructions for use.
   
    
2.4.3 Sample collection 
 
The instructions for saliva donation, as recommended by DNA Genotek, are: 
 
Figure 2.3 Collection instructions 
1. Spit into the collection tube until the level of saliva has reached the fill line after 
the bubbles have settled. 
2. Close the lid pushing hard until a click is heard, thus breaking the seal releasing 
the DNA stabiliser and purifier. 
3. Unscrew the funnelled lid from the collection bottle as it does not have a 
satisfactory seal for storage and transportation. 
4. Tightly screw small cap provided onto the collection tube for transportation and 
storage.  
It is important not to eat, drink, smoke or chew gum for 30 minutes before providing a 
saliva sample. 
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2.4.4 DNA extraction 
 
Equipment and reagents required: 
 
1. Water bath at 50oC 
2. Centrifuge that accommodates 15 mL tubes and capable of 4500 rpm. 
3. Micro-centrifuge that accommodates 2 mL Eppendorf tubes and capable of 
12,000 rpm 
4. 15 mL conical Falcon tubes 
5. 2 mL micro-centrifuge tubes 
6. 100% ethanol at room temperature 
7. 70% ethanol at room temperature 
8. TE DNA storage buffer (10 mM TrisHCl, 1 mM EDTA)  
9. prepITTM·L2P DNA purifier reagent 
10. 3 mL sterile pastette pipettes 
 
DNA extraction procedure (CIGMR SOP and Oragene DNA laboratory protocol) 
 
1. Mix saliva sample in collection tube by gently shaking to ensure sample is 
properly mixed with Oragene DNA solution. 
2. Incubate sample at 50oC in a water bath for at least 1 hour to maximize DNA 
yield and ensure nucleases are permanently inactivated. 
3. Transfer the entire sample (4 mL) into the 15 mL Falcon tube noting the 
sample volume and colour. 
4. Add 160 µL of prepIT DNA purifier reagent and mix by vortexing for a few 
seconds.  The sample should become turbid as impurities are precipitated. 
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Figure 2.4 Turbid impurities 
 
5. Incubate in -20 oC freezer for 5 minutes, remove, shake and place back in 
freezer for another 5 minutes to assist impurity removal. 
6. Centrifuge at room temperature at 4500 rpm for 15 minutes.  Following this 
step a pellet of impurities will be seen at the bottom of the tube.  The 
supernatant should be clear and will contain DNA in solution 
 
 
Figure 2.5 Impurity pellet 
 
7.  Remove the supernatant with a 3 mL pastette pipette carefully avoiding 
disturbance of the pellet.  If any disturbance of the pellet occurs the sample 
must be re-centrifuged. 
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8.  Add 4 mL of 100% ethanol at room temperature and gently mix by inverting 
tube 10 times.  The precipitated DNA should now become visible in the tube 
as a string or clot of white fibres. 
 
Figure 2.6 Visible DNA 
 
9. The sample should be left to stand at room temperature allowing full 
precipitation of DNA. 
10. Centrifuge the sample at room temperature at 4500 rpm for 15 minutes.  
Following this step a pellet of DNA should be seen at the bottom of the tube.  
11. Pour out the 100% ethanol (the DNA pellet should be stable at the bottom 
of the tube). 
12. Add wash of 1 mL of 70% ethanol to ensure any residual inhibitors are 
removed. 
13. Carefully removed the DNA pellet with the 70% ethanol and place into a 2 
mL micro-centrifuge tube. 
14. Centrifuge at 12000 rpm for 15 minutes 
15. Pour out ethanol (again DNA pellet should be stable at bottom of tube) and 
leave tube to stand at room temperature for 20 minutes allowing remaining 
ethanol to evaporate and pellet to fully dehydrate. 
16. Rehydrate pellet by adding 1 mL of TE buffer and vortex sample for 30 
seconds.  The sample should be placed on orbital plate shaker overnight to 
ensure complete rehydration of DNA.   
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2.4.5 Sample storage 
 
Appropriate storage of DNA samples is important to ensure optimum yield and quality.  
The storage factors that can potentially affect DNA are storage tube material, storage 
temperature, and freeze thaw cycles (Lee, 2010).     
TE buffer is used in the rehydration and storage of extracted DNA.  Cell lysis during 
DNA extraction can alter the pH of the solution.  Tris buffers the solution keeping the 
pH to near neutral and protecting the pH sensitive DNA.  EDTA helps inactivate 
nucleases by chelating the cations required for their normal function. 
Isolated DNA may be stored at 4oC for several weeks, -20oC for several months and -
80oC for years (Holland et al., 2003). An EU workshop for Biobanks has recommended 
that DNA samples are frozen to prevent bacterial growth and reduce risk of sample 
loss through evaporation (EU_Workshop, 2003). The UK Biobank recommends 
storing samples at -20oC to inhibit nucleases (UK Biobank 2004).   A study by Smith 
et al comparing optimal storage conditions found that the highest quantity of DNA 
remained in the samples stored at -80oC (Smith and Morin, 2005).  Freeze-thawing 
causes double strand breakages of DNA (Grecz et al., 1980).   DNA Genotek claim 
that Oragene DNA samples can be freeze-thawed 3 times without evidence of DNA 
degradation (www.dnagenotek.com). 
The majority of our samples were stored initially at room temperature until DNA was 
extracted following manufacturer’s recommendations. A small number of samples 
were stored at -20oC prior to extraction.  All samples were stored at -20oC following 
extraction.  Long term storage following processing was at -80oC. 
2.5 DNA quality control measures 
 
2.5.1 Summary of control process 
 
DNA samples included in the candidate gene study had previously undergone quality 
control measures using picogreen quantification and gel electrophoresis analysis.  The 
81 
 
quality control process before whole genome scanning included visual inspection, 
volume measurement, Sequenom MassARRAY iPLEX assay quality control (QC), 
picogreen quantification and gel analysis.   
 
Figure 2.7 Quality control process used in these studies 
 
2.5.2 Visual inspection 
 
Each sample plate is inspected to ensure no damage had occurred on transportation 
and that no samples were of uncharacteristic colour.    
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2.5.3 Sequenom MassARRAY iPLEX assay quality control 
 
The Sequenom MassARRAY iPLEX assay QC plex contains 30 autosomal SNPs and 
5 gender SNPs.  It allows the identification of plate rotations and ensures that the 
gender information in the accompanying manifest is reflected in the physical plate. 
 
2.5.4 Visualisation by electrophoresis on an agarose gel 
 
Principles of DNA gel electrophoresis 
 
Electrophoresis is a method used to separate DNA strands based on their rate of 
movement while under the influence of an electric field (Sharp et al., 1973).  Agarose 
is a natural polysaccharide purified from seaweed.  The agarose gel used is porous 
and permits passage of the DNA strands.  The negatively charged phosphate ions 
forming the DNA backbone are attracted to the positive electrode at one end of the gel 
tray initiating movement of the DNA strands.  The rate of movement of a DNA fragment 
is directly proportional its size (Southern, 1979).   
 
Equipment required: 
1. Agarose powder 
2. Microwave 
3. 500µg/mL ethidium bromide  
4. Gel casting tray and comb well divider 
5. 1X TE buffer 
6. Power supply 
7. Distilled water 
8. Xylene cyanol loading dye 
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Agarose gel electrophoresis method: 
 
Ethidium bromide is mutagenic and should be handled with extreme caution. 
1. Make a 1% agarose gel by mixing 1g of agarose powder in 100ml of 1X TE 
buffer.  Place in the microwave for 2 minutes until all powder crystals have 
dissolved. Add 2µL of ethidium bromide and swirl.  Pour in to a gel casting tray 
with well divider in place and leave for at least an hour to cool. 
2. Once cooled, transfer the solidified gel into a distilled water basin and pull out 
well divider to reveal wells. 
3. Put 4µL of the DNA ladder standard into well number 1. 
4. Mix 2µL xylene cyanol loading dye with 8µLof of each DNA sample to be tested.  
The xylene loading dye gives colour to the samples and also renders them 
denser that the buffer causing them to sink in the wells.  Like DNA, it is 
negatively charged, and moves towards the positive electrode.  It can therefore 
be used is used to assess how fast the gel is running.  
5. Pipette each 10 µL DNA sample into each well. 
6. Slide the top on the water basin and run gel for 30 minutes. 
7. Place gel into UV reader 
 
Electrophoresis for DNA extraction technique validation 
 
Fourteen test samples of volunteer DNA were extracted from 2ml saliva samples. Test 
samples were run on an electrophoresis agarose gel in conjunction with a 1Kb DNA 
standard ladder in order to validate the extraction method, (figure 2.8).  All samples 
showed high molecular weight DNA (greater than 10Kbp), with no evidence of 
degradation. 
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Figure 2.8 Agarose electrophoretic gel of 14 test samples of showing extracted high 
molecular weight DNA. 
 
 
Electrophoresis as part of Sanger quality control measures: 
300ng of each sample was separated via gel electrophoresis on a 2% gel.  DNA 
fragments were identified using ethidium bromide.  Degraded samples, identified as 
missing or very faint bands, were excluded from the study.   
 
2.5.5 DNA Quantitation 
 
Determining DNA concentration extracted from human tissue samples is an important 
quality control step for the success of genotyping assays.  Commonly practiced 
methods include spectrophotometry (nanodrop) and fluorometry (picogreen/ Qubit 
fluorometry). 
 
85 
 
 
Principles of PicoGreen quantitation 
 
The main disadvantage of spectrophotometry is the inability to distinguish between 
double stranded DNA (dsDNA), single stranded DNA (ssDNA) and RNA.  In addition, 
the presence of proteins and phenols in the sample can alter the UV readings (Blotta 
et al., 2005).  Spectrophotometry tends, therefore, to over-estimate the concentration 
of double stranded DNA in a sample.  
 
The introduction of cyanine dyes improved the specificity of nucleic acid quantitation.  
PicoGreen is a sensitive fluorochrome that selectively binds dsDNA.  When bound to 
dsDNA, fluorescence enhancement is very high and due to its specificity, presence of 
ssDNA and RNA has little effect on the quantitation result (Ahn S. Nucleic acids 
research 1996).  The concentration of dsDNA in a test sample can be measured by 
plotting fluorescence on a linear range determined by known standard DNA 
concentration. 
 
Picogreen quantitation as part of Sanger quality control measures 
 
Picogreen quantitation was carried out by the genotyping team at the Wellcome Trust 
Sanger Institute (WTSI), Cambridge.  Double stranded DNA (dsDNA) concentration 
was measured using the Invitrogen Quant-iT PicoGreen dsDNA assay.  Samples with 
a concentration of less than 35 µL were excluded from the GWAS study. 
 
Principles of Qubit Fluorometry 
 
In addition to picogreen quantitation carried out at the WTSI, we undertook prior 
quantitation of suspended DNA samples using Qubit™ dsDNA BR Assay Kits and the 
Qubit™ 2.0 Fluorometer (Invitrogen Ltd, Paisley, UK).  Qubit fluorometry uses the 
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same principles as picogreen.  The dyes used selectively bind dsDNA.  This binding 
alters the fluorescence of the dye increasing its fluorescence by several orders of 
magnitude.  The manufacturers have shown that the QubitdsDNA assays have 
comparable accuracy to Invitrogen Quant-iT PicoGreen dsDNA assay. 
 
Qubit™ 2.0 Flourometric Quantitation method: 
 
 
1. Pre-label the 0.5ml PCR Tubes (Axygen PCR-05-C tubes, Part No. 
10011-830, VWR) with the Patient ID of the samples you in intend to 
quantitate. Label 2 additional tubes for the DNA standards 1 and 2.  
Note: The Sample tubes should always be kept in the same linear order 
as your spreadsheet; this will help with re-entering the values into the 
spreadsheet later on. 
 
2. Prepare the Working Solution by mixing the Qubit dsDNA BR Reagent 
with the Qubit dsDNA BR Buffer in a 1:200 ratio. Invert 10 times to mix. 
The exact amounts needed to make up the working solution can be 
calculated using the following formulae. 
 
• 200 x n = t 
• t - n = b 
Where n = the number of samples to be quantitated + 2. 
   Also,  n = the amount of Qubit dsDNA BR Reagent needed (µl) 
b = the amount of Qubit dsDNA BR Buffer needed (µl) 
              t = the total volume of the working solution 
 
3. Load 190µl of the Qubit working solution into each of the two standards 
tubes and load 10µl of the corresponding standard into each tube. 
 
4. Load 198µl of the Qubit working solution into each of the tubes 
intended for the samples. Try to avoid creating bubbles. If processing a 
large number of samples in one run (>100), it is recommended that you 
load the working solution in batches of 50 at a time, this reduces the 
risk of contamination and evaporation from the assay tubes.  Note: 
When using the Fluorometer you can load anything between 1µl and 
20µl of sample into each tube as long as the final assay tube volume is 
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made up to 200µl, therefore the amount of Qubit Working solution 
needed in each tube depends on the amount of sample you want to 
use. However, when quantitating following DNA extraction using 
Oragene -500 DNA Self Collection Kits and ethanol precipitation, the 
optimal amount of sample needed is 2µl, as this way you are less likely 
to find that the concentration of DNA in your assay tube is too high or 
too low for the fluorimeter to read.  
 
5. Load 2µl of each sample into its corresponding tube, vortexing the 
stock tube briefly prior to each load. Try to avoid creating bubbles. 
Pipetting accuracy is very important. 
 
6. Once all of the assay tubes have been made up to 200 µl with the 
working solution and the DNA sample, shake the samples to mix and 
remove any bubbles. 
 
7. Allow the Assay tubes to incubate at room temperature for 2 minutes.  
Note: After this incubation period, the fluorescence signal is stable for 3 
hours only at room temperature. 
 
8. Turn on the Qubit 2.0 Fluorometer and select DNA, then dsDNA Broad 
Range 
 
9. The fluorimeter will prompt you to read new standards, follow the 
instructions for reading these standards. New standards should be set 
every time you perform a batch of quantitations. Always check the 
standards with the ‘Check Stds.’ Tab, one should be low concentration 
with a value of approximately 100, and the other should be high 
concentration at around 10,000. 
 
10. Quantitate the first sample as prompted by the fluorimeter, this involves 
placing the sample into the well, closing the lid, then pressing ‘read’. 
You should always remove any bubbles prior to reading by gently 
flicking the assay tube. Try not to hold the tubes in your hand for too 
long as raising the temperature will affect the reading. 
 
11. After the first sample has been read, press ‘Calculate Stock Conc.’. 
Select the appropriate Sample volume from the wheel (in our case 2 µl) 
and this will calculate the concentration of the sample in your stock 
tube. Choose the units ‘ng/µl’. This will help with entering the data into 
your spreadsheet. 
88 
 
 
12. Proceed to read all of the samples. It is very important that the order is 
kept the same and sample readings aren’t missed or duplicated as the 
order that the samples are read are the only way of matching them 
back to their corresponding patient ID numbers. 
 
13. Once all read, double check that you have the correct number of 
readings, then save the data to a memory card. 
 
14. The total DNA yield for each sample was calculated with the following 
formula: v (c x d) where v = stock volume, c = concentration of DNA in 
assay tube, d = dilution factor.   
  
2.6 DNA Genotyping 
 
2.6.1 Candidate gene approach 
 
SNP Tagging 
 
Tagging SNP selection was performed using Hapmap Gene Browser (release #24, 
phase 1 and 2 – full dataset, www.hapmap.ncbi.nlm.nih.gov) and Haploview software 
(v4.2, www.broadinstitute.org/haploview/haploview) using a pairwise tagging 
approach (r2=0.8). Common variants (MAF≥0.05) within the gene of interest, and 
extending 5Kb upstream and 2Kb downstream to include variants within the adjacent 
regulatory flanking sequences, were tagged using this approach. 
 
FASTA file configuration 
 
Once tagging SNPs were identified using the HapMap Gene Browser (release #24, 
phase 1 and 2 – full dataset, www.hapmap.ncbi.nlm.nih.gov) was used to generate a 
FASTA file for genotyping.  A FASTA file consists of the variant of interest and its 
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flanking sequence which is used on the probe design to allow hybridisation and 
identification of the variant in question. 
 
Principles of KASPar assay genotyping 
 
Genotyping for the candidate gene study described in chapter 4 was outsourced to 
KBioscience Ltd (Hoddeston, Herts, UK) using competitive allele specific PCR 
(KASP).  KASPar is run initially as a standard polymerase chain reaction (PCR).  The 
primer mix consists of 2 allele specific oligonucleotide forward primers and a common 
reverse primer.  During the first round of PCR the allele-specific primer binds to the 
region directly upstream of the SNP of interest while the 3' end of the primer binds to 
its complementary base on the SNP.  Simultaneously the reverse primer binds the 
complementary strand.  The KASP Taq DNA polymerase extends each strand thereby 
copying the region of DNA containing the SNP of interest.  There are two 
oligonucleotides in the assay mix which are fluorescently labelled at their 5' ends.  
These sequences are identical to the tail sequence of the allele specific primers and 
are labelled with either FAM or VIC.  During the annealing stage the fluorescently 
labelled oligonucleotides binds to its complementary tail sequence and is further 
extended by the KASP Taq.  Further PCR amplification produces more fluorescently 
labelled templates.  The fluorescent signal generated allows differentiation of 
heterozygosity or homozygosity for an allele. 
 
2.6.2 Principles of high throughput genotyping 
 
A DNA microarray is a solid slide which is “arrayed” with multiple microscopic spots, 
known as features.  Each spot contains picomoles of oligonucleotides of specific DNA 
sequences known as probes (Manoj Kumar, 2009).  These probes are attached to the 
solid surface by a covalent bond.  Each probe is used to hybridize a complimentary 
DNA strand allowing a specific locus (allele) to be examined through fluorescence 
based detection (Schena et al., 1995).   
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A genotyping array must have the ability to interrogate loci associated with the 
phenotype of interest.  This may be either directly, by including genetic variants 
responsible or indirectly, by including SNPs in sufficient linkage disequilibrium with the 
causative variants (Carlson et al., 2003).  Data from the international hap map project 
allows the indirect approach to be implemented and forms the basis for SNP selection 
of genotyping arrays.    
 
Figure 2.9 Principle of microarrays 
 
2.6.3 Microarray chip selection 
 
There are a number of commercially available microarray chips, each providing better 
coverage in some genomic regions than others (Saccone).  Ideally one would choose 
the chip that best matches the study population.  The most popular criterion for this is 
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global coverage, defined as the fraction of common SNPs tagged by the SNPs on the 
chip (Li et al., 2008). 
 
2.6.4 Discovery cohort GWAS genotyping Illumina Human610-Quad BeadChip:  
 
Genotyping for the discovery cohorts described in chapters 5 and 7 was carried out 
using the Illumina Human610-Quad Beadchip. It uses tag SNPs to the coverage of 
624,000 randomly selected SNPs.  It provides 89% coverage of the Caucasian 
European (CEU) HapMap loci (MAF>5%, LD r2>0.8) using tags based on the 
Caucasian HapMap population (Illumina DNA analysis, www.illumina.com). 
 
 2.6.5 Replication cohort GWAS genotyping Sequenom MassARRAY iPLEX assay 
MassARRAY iPLEX platform: 
 
The replication cohort genotyping was performed using the Sequenom MassARRAY 
iPLEX assay Sequenom MassARRAY iPLEX assay MassARRAY iPLEX assay and 
the MassARRAY® System (Agena Bioscience Inc, Hamburg, Germany).  Sequenom 
MassARRAY iPLEX assay’s MassARRAY software designs extension primers for 
SNPs of interest.  It is able to perform high throughput genotyping using a multiplexed 
PCR approach using a single extension primer and is capable of >100,000 genotypes 
per day (Gabriel et al., 2009). 
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2.7  Genome data analysis 
 
2.7.1 PLINK  
 
PLINK (version 1.07) is an open-source whole genome association analysis toolset 
which can be download from the psychiatric and neurodevelopmental genetic unit 
website affiliated with the Harvard Medical School 
(www.pngu.mgh.harvard.edu/~purcell/plink). It was developed by Shaun Purcell at the 
Centre for Human Genetic Research (CHGR), Massachusetts General Hospital and 
the Broad Institute of Harvard (Purcell et al., 2007).  It was designed to deal with the 
many challenges of whole genome study analysis.  It has the ability to manage with 
large GWAS datasets. It can deal with confounding caused by population stratification 
and non-random genotype failure.  It has the ability to perform a number of association 
analyses allowing for covariates.  It can also utilise common SNP panels to examine 
chromosomal regions in order to identify unexpected relatedness as a cause for 
multiple rare variants. It can be run on an MS-DOS platform as a command line 
program.  It focuses purely on the analysis of genotype/ phenotype data in the form of 
PED and MAP files. 
 
PED Files 
 
The PED file is a white space delimited file and contains phenotypic and genotypic 
data.  The first 6 columns are mandatory and contain: Family ID, Individual ID, Paternal 
ID, Maternal ID, Sex, Phenotype.  
No blanks can be left in the file. If any data is unknown (such as sex or paternal/ 
maternal ID) they are recorded as 0.  Phenotypic data must be entered as either a 
binary or continuous (quantitative trait) value.  PLINK automatically recognises which.  
The following columns contain the allele data at each locus for each individual. 
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MAP Files 
 
The MAP file is also a white space delimited file.  It contains the genetic information.  
Each line describes a single marker and contains 4 columns:  Chromosome, 
Reference SNP (rs) number, Genetic distance (morgans), Base pair position (bp 
units). 
Each marker must represent those in each genotypic column on the PED file.  The 
minimum data required on a MAP file for an analysis to be carried out is the rs number.  
Data for each rs number is available on the HapMap website 
(www.hapmap.ncbi.nlm.nih.gov). 
  
PLINK quality control measures 
 
Prior to association analyses sample and SNP quality controls measures were 
undertaken.   
 
Missingness 
The missingness command identifies missing data from the MAP and PED files.  
Individuals or SNPs with missing data are excluded from analyses. 
 
Minor allele frequency (MAF) 
A list of minor allele frequencies can be generated for each SNP.  A MAF threshold 
can be selected during association analyses.  Variants with MAF <0.05 were not 
included in analyses. 
 
Hardy-Weinberg Equilibrium   
 The Hardy-Weinberg principle states that for a population, the allele and genotype 
frequencies remain constant unless less there is non-random mating, mutations, 
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evolutionary selection, limited population size, migration (Hardy, 1908).  Deviation 
from this equilibrium may potentiate bias in allele frequencies in a population and 
checking Hardy-Weinberg equilibrium is now common practice in association studies 
(Wigginton, 2005).    
The Hardy Weinberg equation can be used to estimate the frequency of alleles in a 
population. 
For a population in genetic equilibrium:     p2 + 2pq +q2 = 1  
Where p = frequency of the dominant allele and q = frequency of the recessive allele. 
A list of genotype counts and Hardy-Weinberg test statistics can be generated for each 
SNP using PLINK. A p value threshold is calculated as per Bonferroni (0.05/ number 
of markers).  Any marker with a p value below 0.0001 was excluded from analyses. 
 
Association analyses 
 
Standard case/control association analysis can be carried out using χ2 test.  In order 
to adjust for covariates a linear regression model is used.  The minor allele frequency 
threshold of >0.05 and confidence interval of 95% was adjusted and implemented in 
each analysis. For continuous phenotypic data a linear regression model analysis for 
quantitative trait loci was carried out.  Again, covariates were adjusted for.  
 
2.7.2 GWAS Power calculation 
 
The power calculation for our GWAS was made using Quanto v1.2 (Gauderman and 
Morrison, 2006). Our discovery analysis had ≥80% power to detect a variant with risk 
allele frequency 0.35 with an allelic OR of 1.65.  The replication analysis had ≥80% 
power to detect a variant with risk allele frequency of 0.45 and allelic OR of 1.45.  We 
attempted to reduce the impact of modest power by looking only at common variants 
(MAF ≥0.05) but consequently we are unable to predict the importance rarer variants 
may have on osteolysis.   
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2.7.3 SNPTEST whole genome association analyses 
 
SNPTEST 
 
SNPTEST is an open-source program for single SNP association in genome wide 
analyses.  The software is part of the Oxford University genome-wide analysis 
software suite (OGWASS) and can be downloaded from 
https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.  To use SNPTEST 
all commands were created using the UNIX common operating system.  A knowledge 
of the appropriate UNIX command lines was required to run this software and create 
the shell scripts required for analyses. Due to the large volume of data and statistical 
tests run in GWAS all analyses were run using the Sanger Institutes platform load 
sharing facility (LSF) known as “The Farm.”  This workload management platform uses 
multiple LSF clusters to efficiently run association analyses and other data-intensive 
processes.   
 
Sample and SNP Quality Control 
 
We undertook post quality control checks at sample and SNP level. Samples were 
excluded if they failed gender check, had a call rate <95%, or had excess 
homozygosity or heterozygosity out with 3 SD of the mean (using autosomal SNPs) 
Genome-wide pair-wise identity by descent (IBD) for each sample was used to identify 
duplicates and related samples. We removed any sample with a π^ >0.2.  Ancestry 
was validated by multidimensional scaling (MDS) and principle component analysis 
(PCA) using Goldsurfer (Pettersson et al., 2008) after autosomal data from the 
discovery cohort was merged with HapMap 3 data 
(The_International_HapMap_Consortium, 2007).  Samples identified by genotype to 
be from individuals of non-UK European ancestry were excluded from association 
analyses. SNP QC was carried out on autosomal SNPs.  SNPs were excluded if they 
had a minor allele frequency (MAF) ≥5% and a call rate <95%, or a MAF <5% and call 
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rate <99%.  Monomorphic SNPs were excluded.  SNPs with an exact Hardy Weinberg 
Equilibrium (HWE) p<0.0001 were excluded.  
 
1000 Genome Imputation 
 
Genotype imputation is the process of predicting genotypes which haven’t been 
directly assayed.  This is an in silico process which uses data from a reference panel 
to infer missing genotype data into a study dataset.  This increases the number of 
SNPs that can be tested for association thereby increasing power (Spencer et al., 
2009).  It also has the potential of improving fine mapping of an associated region 
(Marchini and Howie, 2010).  We imputed the GWAS dataset using the European 
reference panel from the 1000 Genomes Project (Dec 2010 phase I interim release) 
(1000 Genomes consortium et al, 2010), and using IMPUTE2 (Marchini et al., 2007).  
  
SNP Association Analysis Plan 
 
1. Create a folder for association analyses which includes the following files: i) 
Sample file (needs to be a space delimited text file), ii) Gen file (separate file 
for each chromosome, iii) snptest program. 
2. Create shell script to run snptest association analysis. 
3. The analysis will generate 3 output files per chromosome (text, log, and error).  
Check that all error files are empty and check in log files that correct number of 
samples and covariates has been included in analysis. 
4. Create a new folder named “snptest output” and copy all text output files into 
folder 
5. Use the merge perl script to merge all files into a single output file. 
6. Use the filter perl script to filter merge output file (change MAF and info scores 
to desired threshold on script before running). 
7. Using R scripts, create Manhattan and QQ plots for the filtered output file 
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8. In order to identify low p value snps, run the perl filter script again but this time 
include a p value threshold of  9 x 10-5.  
9. Open new file in excel spreadsheet and sort in p value order (smallest to 
largest). 
10. Sort by chromosome order and add sorting level for chromosomal position 
(smallest to largest). 
11. Add new column and name “signal.” 
12. Looking at the chromosomal positions group snps into signals within 300Kb of 
each other. 
13. Now resort by signal and add sorting level for p value.  The lowest p value snp 
in each signal is the index snp. 
14. Using Locuszoom software, create regional association plots for each signal. 
 
Whole genome association analyses 
 
Osteolysis susceptibility case-control analysis and a quantitative trait locus (QTL) 
association analysis for time to prosthesis failure was undertaken on >10 million 
variants under the additive model using method score implemented in SNPTESTv2.   
Phenotype data was normalised where required and we performed a linear regression 
to adjust for age, gender, fixation method, osteolysis-free survival time. Residuals 
were then transformed to z-scores.  Association analyses were undertaken with and 
without and polyethylene wear as a covariate. 
An HO susceptibility case-control analysis and an evaluation of disease severity using 
a binomial analysis of Brooker grades 1 and 2 vs grades 3 and 4 in the cases was 
undertaken under the additive model using the score test in SNPTEST v2.3.0 
(University of Oxford, Oxford, UK).  Association analyses were adjusted for age and 
gender as these have previously been described as known risk factors for HO (DeLee 
et al., 1976, Hierton et al., 1983).  SNPTEST output files were further filtered to exclude 
SNPs with a frequentist info score <0.4 and a minor allele frequency (MAF) <0.05. 
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2.7.4 Osteolysis replication analyses 
 
Index SNPs from signals with p<9x10-5 were prioritised for replication.  Genotype-
calling intensity plots were examined and SNPs with poorly clustering plots were not 
taken forward. Only associating SNPs with an imputation information score >0.4 and 
a minor allele frequency (MAF) >0.05 were progressed for the replication association 
analyses. 
 
Samples failing gender check or with call rate <80% were excluded.  SNPs were 
removed if their call rate was <80% or with HWE p <10-4. Association analyses were 
undertaken using logistic regression in PLINK v1.07. Z-standardised residuals were 
generated on phenotype data requiring normalisation and regressed on age, gender, 
implant type, fixation method and osteolysis-free survival time.   
 
2.7.5 Meta-analysis 
 
Genome Wide Association Meta-Analysis (GWAMA) 
 
GWAMA is an open source software developed by the Wellcome Trust Centre for 
Human Genetics, University of Oxford, which was designed to perform meta-analysis 
for GWAS (Magi and Morris, 2010). The software along with source files and sample 
data can be downloaded at http://www.well.ox.ac.uk/GWAMA.  The following 
information is required for each SNP to be meta-analysed: (i) the marker identifier; (ii) 
the allelic effect estimate and corresponding standard error (or an allelic odds ratio 
and 95% confidence interval in the case of a dichotomous trait); and (iii) the allele for 
which the effect has been estimated and the complimentary non-reference allele.  
GWAMA aligns all studies to the same reference allele at each SNP and meta-analysis 
is performed for each SNP by combining allelic effects weighted by the inverse of their 
variance.  
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Summary statistics from both the osteolysis discovery and replication analyses were 
combined and meta-analysed using the fixed-effects model implemented in GWAMA 
v2.1 (Magi and Morris, 2010). 
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CHAPTER 3 
STUDY POPULATIONS 
3.1 Overview 
 
This chapter outlines the subject recruitment strategies, inclusion criteria, and 
population demographics for the UK populations studied in this thesis.  The subject 
recruitment and population demographics for the Norwegian replication population are 
described separately in chapter 6. 
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3.2 Discovery Population  
 
3.2.1 Inclusion criteria 
 
All subjects recruited in the GWAS discovery cohort comprised unrelated men and 
women recruited in the United Kingdom and of North European ancestry who had 
previously undergone primary cemented or hybrid (cemented femur) THA for 
idiopathic osteoarthritis. All subjects have received a prosthesis using a metal-on-
conventional polyethylene bearing couple. 
 
3.2.2 Exclusion criteria 
 
Any subject not of North European ancestry was excluded to prevent genetic 
admixture.  Patients with alternative bearing couples such as metal on metal, ceramic 
on polyethylene, or ceramic on ceramic were also excluded. This ensured that the 
particulate exposure hazard was similar in all cases. Fully cementless implants were 
also excluded.  This was because subjects already recruited through the Sheffield 
genetic hip study had all undergone fully cemented or hybrid THA and we wanted to 
reduce the number of variables in our complete cohort. Any subject who had 
undergone THA for a diagnosis other than primary osteoarthritis, such as inflammatory 
arthropathy or neck of femur fracture, was excluded.  This exclusion included subjects 
with an indication of osteoarthritis secondary to another pathology such as avascular 
necrosis, developmental hip dysplasia or Perthes’ disease.  
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3.2.3 Case definition 
 
Osteolysis 
 
The cases comprised subjects with radiographic evidence of aseptic loosening or 
osteolysis affecting either the acetabular or femoral prosthetic component, as defined 
in the previous chapter, whether the prosthesis had been revised or not.  Revisions 
for indications such as dislocation, or infection were excluded; as were revisions of 
fully cementless implants and revisions for liner wear in the absence of aseptic 
loosening or osteolysis. 
 
Heterotopic ossification 
 
Cases comprised subjects with radiographic evidence of post-operative HO following 
THA and were graded (0-4) using the Brooker classification (see Figure 1.14). 
 
3.2.4 Control definition 
 
Osteolysis 
 
The controls comprised subjects who had primary THA for idiopathic osteoarthritis ≥7 
years previously, were asymptomatic from the replaced hip, and free from documented 
complications relating to osteolysis or aseptic loosening following primary surgery and 
with radiographic evidence of being osteolysis-free. 
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Heterotopic ossification 
 
Controls comprised subjects who had no evidence of HO on plain AP radiographs of 
the pelvis taken not less than 1 year following primary THA.   
 
 
3.2.5 Subject recruitment 
 
All UK subjects were recruited as part of 2 research protocols approved by a research 
ethics committee:   
1. Samples recruited under the ethics approval of the Sheffield Musculoskeletal 
Biobank (Oxfordshire Research Ethics Committee, REC reference number 
10/H0606/20, 28th May 2010; approval letter in appendix A). This approval was 
renewed on 24th April 2015, REC reference number 15/SC/0132; approval letter 
in appendix B) 
2. Samples recruited under the ethics approval of the arcOGEN study 
(Oxfordshire Research Ethics Committee, REC reference number 
07/H0606/150, 3rd January 2008; approval letter in appendix C). 
 
Each subject provided written consent for DNA samples to be collected for research 
purposes. 
 
Sheffield Musculoskeletal Biobank Samples 
 
Subjects under Biobank ethics approval comprise 2 extant cohorts, and one 
prospective collection: 
1. Sheffield Genetic Hip study cohort 
2. Wrightington Genetic hip study cohort 
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3. Newly recruited patients from Sheffield Teaching Hospital NHS Foundation 
Trust, Sheffield  
 
Sheffield Genetic Hip Study Cohort 
 
A total of 684 patients were recruited between April 2000 and April 2006 as part of a 
series of case-control candidate gene studies looking at the association between 
osteolysis and genetic variants.   All subjects were unrelated Caucasian men and 
women of North European origin having previously undergone primary cemented THA 
with a metal-on-conventional polyethylene bearing couple for idiopathic osteoarthritis.   
 
631 patients from this cohort with available DNA were included in the case-control 
candidate gene study discussed in chapter 4. 
 
A total of 602 subjects with available DNA from this cohort were included in the GWAS 
study.  Three hundred and seventy-five subjects from this cohort have already 
undergone GWAS genotyping as part of the arcOGEN study (discussed below).  A 
further 226 DNA samples extracted from whole blood from subjects in this cohort, and 
stored in the Sheffield Musculoskeletal Biobank, were forwarded for GWAS 
genotyping.  Two hundred and ten (93%) passed quality control.  Following pre-
genotyping QC, it was noted that one of these patients had already undergone 
genotyping as part of arcOGEN.  The remaining 209 were genotyped.  Of those who 
failed QC, 2 had too low a concentration, 9 were degraded samples unsuitable for 
genotyping and 5 had a gender fail. 
 
Wrightington Genetic Hip Study Cohort 
 
312 patients were recruited from Wrightington Hospital between August 2002 and 
August 2006 for a series of case-control candidate gene studies looking at the 
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association between osteolysis and genetic variants.  All subjects were of European 
Caucasian origin and had undergone total hip arthroplasty with a Charnley monoblock 
femoral stem and either a Charnley or Ogee flanged conventional polyethylene 
acetabular cup.  Only patients with a primary diagnosis of osteoarthritis were included.   
One hundred and thirty patients from this cohort were suitable for inclusion in this study 
having met the inclusion criteria and having available DNA samples.  All included 
subjects had extracted DNA samples from whole blood stored at the Sheffield 
Musculoskeletal Biobank.   
One hundred and twenty-five (96%) passed quality control and underwent genotyping.    
Five failed on gender quality control.  Of those who passed QC, 49 were male and 40 
had either undergone revision surgery for aseptic loosening or had radiographic 
evidence of osteolysis.    
 
Newly recruited Subjects 
 
Patient arthroplasty databases from Sheffield Teaching Hospitals NHS Foundation 
Trust were examined using the above inclusion and exclusion criteria.  Subjects were 
then cross referenced with the Patient Focused Information (PFI) database to check 
they were still alive and had available contact details.  Four hundred and eighty-three 
patients were identified and invited to participate in the study.  Three hundred and 
thirteen patients replied to the invitation (response rate of 65%). One hundred and 
sixty-three (34%) did not respond after a reminder letter.  Of those who replied, 265 
(55%) agreed to donate a saliva sample to the Biobank.  All responders who agreed 
to participate in the study were sent a consent form, a questionnaire (appendix D) and 
an Oragene OG-500 saliva collection kit with a return mailer kit. Two hundred and 
twenty subjects returned the saliva kit with a donated sample (completer rate of 45%).  
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Figure 3.1 Response rates of Sheffield recruitment 
 
Figure 3.2 Bar chart outlining response rates (%) for each age group 
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No statistically significant difference was found between age and response rate 
(ANOVA with a post hoc Sheffe comparison, p >0.05).  No statistically significant 
difference was found between gender and response rate (ANOVA with a post hoc 
Sheffe comparison, p >0.05).  One of the saliva samples from the completers leaked 
in transit and was not suitable for further processing.  The remaining 219 saliva 
samples from completers were processed and DNA extracted.   The mean volume of 
samples was 1.76ml (SD 0.43, range 0.5 – 3ml).  Overall mean yield of DNA from 
extracted saliva samples was 159.1µg (range 0.03 to 1220.8µg, SD 231.6) using 
picogreen.  In 8 samples the DNA content was below the detection limit.   No 
correlation was found between volume of saliva donated and yield of DNA (Spearman 
ranks correlation rs = 0.03, P>0.05).  No correlation was found between age and DNA 
concentration (Spearman ranks correlation rs = -0.09, P>0.05). 
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Figure 3.3 Scatter plot comparing saliva volume with DNA yield 
 
Electrophoretic analysis of DNA samples showed degradation in two (0.9%) samples.  
Seventy (32%) samples were found on picogreen assay to have a concentration below 
the threshold of 35ng/µL required for GWAS genotyping. One sample failed on 
Sequenom MassARRAY iPLEX assay gender QC.  
 
Ten subjects were subsequently found to have incorrect data entered onto the 
arthroplasty database and did not meet the inclusion criteria giving a current total of 
131 subjects (60 male) suitable for genotyping.  Sixty-three of these patients had either 
undergone revision surgery for aseptic loosening or had radiographic evidence of 
osteolysis. 
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3.2.6 arcOGEN study population 
 
The arcOGEN study was a 2 stage genome wide association study of 7,410 subjects 
with hip and/or knee OA recruited from 9 UK centres (Sheffield, Nottingham, Oxford, 
London, Edinburgh, Newcastle, Southampton, Worcester and Wansbeck).  Inclusion 
criteria were radiographic OA with Kellgren Lawrence grade ≥2 or OA sufficiently 
symptomatic to require total joint arthroplasty.  
 
Sheffield 
 
All extant Sheffield genetic hip study subjects were donated to the arcOGEN project.  
375 of these samples passed QC and underwent GWAS genotyping. Of these, 172 
were male and 151 had either undergone revision surgery for aseptic loosening or had 
radiographic evidence of osteolysis.   All subjects were suitable for inclusion in this 
study.  
 
Other centres 
 
121 (46 male) subjects from London, Edinburgh, Newcastle and Oxford meeting our 
inclusion criteria were identified from the arcOGEN database.  All subjects had already 
undergone genotyping as part of the arcOGEN study.  Twenty-nine had radiographic 
evidence of osteolysis. 
 
3.2.7 Total recruitment for discovery cohort 
 
1071 subjects from the above cohorts met the inclusion criteria for this study and had 
available DNA samples which were sent to the WTSI.   
961 (433 male) subjects were genotyped having passed Sanger pre-genotyping QC.  
Of these, 357 were osteolysis cases.  Subjects in the osteolysis group were younger 
and a greater proportion were male versus subjects in the control group (Table 3.1).  
110 
 
 
Table 3.1  Characteristics of discovery study subjects 
a Student’s t-test 
b χ2 test 
 
 
Figure 3.4 Discovery cohort recruitment summary flowchart 
 
Characteristic Control Group 
(n= 604) 
Osteolysis group 
(n= 357) 
p value 
Age at primary THA 
(years)a 
66±9 61±9 < 0.001 
Sex (male/female)b 242/362 191/166 <0.001 
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3.2.8 Post genotyping sample QC exclusions 
 
Further sample QC was carried out as described earlier in section 2.8.3.  Of the 961 
samples passing pre-genotyping QC a further 67 were excluded:  5 for gender fail, 1 
for % heterozygosity, 6 for ethnicity,12 for relatedness.  14 were further found to be 
duplicates, and 29 were found to have incorrect data entered onto the phenotype 
database.  The total number of subjects passing all QC steps and with both complete 
phenotype and genotype data suitable for whole genome association analyses was 
894 (402 were male and 317 were osteolysis cases). 
 
3.2.9  Discussion 
 
The discovery cohort comprised a combination of prospective recruitment with the 
collation of extant cohorts.  There was subject overlap between the Sheffield cohorts 
and careful database cross referencing and multiple quality control steps were carried 
out to prevent duplication of subjects.   
 
The study population reflected known epidemiological risk factors for osteolysis with a 
higher number of male subjects and subjects of younger age seen in the osteolysis 
group (Eskelinen et al., 2006) (Furnes et al., 2001) (Roder et al., 2003) (Bordini et al., 
2007). 
 
A previous study using postal collection of saliva samples found the lowest response 
rates in the most elderly patients (Rylander-Rudqvist et al., 2006). Our results did not 
reflect this.  The trend suggested that the youngest group had the lowest response 
rates however this did not reach statistical significance in our population size.  The 
one saliva sample that leaked during postage occurred because the saliva collection 
instructions had not been followed properly.  All other samples survived transit having 
been collected and packaged as per manufacturer’s instructions. 
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We found that the DNA concentration varied greatly between saliva samples, ranging 
from 0.3ng/µL to 1220.8ng/µL.  The mean yield of 150µg from our samples fell within 
the expected range outlined by the manufacturers. It is higher than that achieved by 
other epidemiological studies (Rylander-Rudqvist et al., 2006, Ng, 2005) and similar 
to the median yield achieved by (Rogers et al., 2007).  32% of samples yielded a 
concentration of less than the 35ng/µL required for GWAS genotyping.  This is a 
similar percentage found by Rylander–Rudqvist (Rylander-Rudqvist et al., 2006).   
Nishista et al found that a larger saliva volume correlated with a larger DNA yield (Ng 
et al, 2005).   We did not find a statistically significant correlation between saliva 
volume and DNA yield. 
 
We found that postal recruitment of subjects identified using hospital datasets 
achieves reasonable response rates.  Postal collection of saliva samples was an 
effective, non-invasive and convenient method of obtaining DNA samples.  Although 
DNA extracted from saliva can be used for whole genome analysis, the large variation 
between saliva samples in our study suggests that some samples may require 
concentrating before GWAS genotyping.  This should be considered when planning 
recruitment in any epidemiological study using saliva as a source of DNA. 
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CHAPTER 4 
GENETIC VARIATION IN INFLAMMATORY AND BONE TURNOVER 
PATHWAYS AND RISK OF OSTEOLYTIC RESPONSE TO 
PROSTHETIC MATERIALS 
 
 
4.1 Overview 
 
This chapter describes a 2-stage case-control association study using a candidate 
gene approach.  Previous candidate SNP and candidate gene studies looking at 
variation within genes encoding inflammatory cytokines and protein involved in the 
regulation of bone turnover and their association with osteolysis formed the basis for 
this study.  Here, we examined two cohorts, comprising 758 (347 male) Caucasian 
subjects who had undergone THA with a metal on polyethylene bearing couple; 315 
of whom had developed osteolysis. Key genes within inflammatory, bone resorption, 
and bone formation pathways were screened for common variants by pairwise-SNP 
tagging. In the discovery cohort four SNPs within RANK, and one each within 
KREMEN2, OPG, SFRP1, and TIRAP (p < 0.05) were associated with osteolysis 
susceptibility. Two SNPs within LRP6, and one each within LRP5, NOD2, SOST, 
SQSTM1, TIRAP, and TRAM associated with time to implant failure (p < 0.05). Five 
SNPs showed the same effect direction in the replication analyses but none reached 
statistical significance.  Meta-analysis of the two cohorts identified four SNPs within 
RANK, and one each within KREMEN2, OPG, SFRP1, and TIRAP associated with 
osteolysis susceptibility (p < 0.05). Our results suggest that variation within 
inflammatory signalling and bone turnover pathways may play a role in susceptibility 
to osteolysis 
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4.2 Introduction 
 
Several investigators have shown that particulate debris from prosthetic materials 
initiate inflammatory signalling through pattern recognition receptors (PRR).  
Furthermore, these PRRs are expressed in osteolytic membrane taken from patients 
with failing prostheses (Takagi et al., 2007, Tamaki et al., 2009).  Bone turnover is 
closely regulated by the interplay between the Wnt and RANK signalling pathways 
(Boyle WJ, 2003, Goldring and Goldring, 2007).  Candidate gene studies also show 
that variants within several pro-inflammatory cytokines associate with osteolysis 
susceptibility (Wilkinson, 2003, Ambruzova Z, 2006, Gordon A et al., 2008, Kolundzic, 
2006, Gallo, 2009, Malik, 2007).  Similarly, variations within several genes involved in 
the regulation of bone turnover associate with osteolysis susceptibility (Malik, 2007, 
Gordon A et al., 2007, Malik MH et al., 2007, Malik MH et al., 2006).  These studies 
have focused on specific candidate variants within genes that are known to regulate 
inflammatory responses or bone turnover, and thus have not explored other potential 
variants within or adjacent to candidate genes. 
Here we used a 2-stage case-control association study design to identify susceptibility 
loci for osteolysis and quantitative trait loci (QTL) for time to prosthesis failure within 
pivotal genes that modulate inflammatory signalling and bone turnover. We applied a 
SNP-tagging approach to systematically and economically screen for common 
variants both within and in the flanking regulatory regions of the genes studied. 
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4.3 Methods 
 
Subject recruitment for this study is described in chapter 3.  Subjects recruited for the 
Sheffield genetic hip study and the Wrightington genetic hip study were included in 
this candidate gene study.   
 
4.3.1 Discovery Cohort 
 
The discovery cohort included the Sheffield recruitment population recruited from 
Northern England between April 2000 and April 2006. The definitions of cases and 
controls, inclusion and exclusion criteria are described in Chapter 2   Briefly, cases 
comprised patients undergoing revision surgery for osteolysis or aseptic loosening, 
and controls were patients who had undergone THA greater than 7 years previously 
and had no current radiographic evidence of osteolysis or prosthesis loosening. 
Polyethylene wear in both patient groups was quantitated as previously described in 
Chapter 2 (Wilkinson et al., 2005, Wilkinson et al., 2002) and used as an analysis 
covariate. 
 
4.3.2 Replication Cohort 
 
The ‘replication' population comprised the Wrightington cohort, recruited from the 
North West of England between 2002 and 2004. The definitions of cases and controls, 
inclusion and exclusion criteria are described in Chapter 2 and elsewhere (Malik, 
2007).  Briefly, cases comprised patients undergoing revision surgery for osteolysis or 
aseptic loosening within six years of implantation, and controls were patients who had 
undergone THA at least 10 years previously and were currently asymptomatic, and 
had no radiographic evidence of osteolysis or aseptic loosening. 
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4.3.3 Genotyping 
 
DNA was extracted from peripheral whole blood using methods previously described.  
Genotyping was carried out by competitive allele specific PCR (KASP), (LGC 
Genomics, Hoddesdon, UK), as described in Chapter 2. Tagging SNP selection was 
performed using Hapmap Gene Browser (release #24, phase 1 and 2–full dataset, 
www.hapmap.ncbi.nlm.nih.gov) and Haploview software (v4.2, 
www.broadinstitute.org/haploview/haploview) using a pairwise tagging approach 
(r2 = 0.8). Common variants (MAF ≥ 0.05) within the gene of interest, and extending 
5 Kb upstream and 2 Kb downstream to include variants within the adjacent regulatory 
flanking sequences, were tagged using this approach. The following genes were 
selected for genotyping: MD2, MSK1, MSK2, MyD88, NOD1, NOD2, P2Y1, P2Y6, 
P2 × 7, SQSTM1, TLR1, TLR2, TLR4, TLR5, TLR6, TLR9, TRAM, TIRAP, TRIF 
(inflammatory signalling); DKK1, KREMEN2, LRP5, LRP6, SFRP1, SOST, Wnt3A 
(bone formation); TNFRSF11A (encoding RANK), TNFRSF11B (encoding OPG), and 
TNFSF11 (encoding RANK) (bone resorption). A total of 318 SNPs were directly 
genotyped using this approach (full tagging SNP details given in Supplementary Table 
4.1). 
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Candidate 
gene 
Gene 
ID 
Tag SNP 
RANK 
  
  
TNFRS
F11A 
  
  
 rs10469252, rs12165104, rs12158117, rs12956925, rs12970081, 
rs17069901,  rs17069902, rs17069904, rs17720953, rs4303637, 
rs4426449, rs4429388, rs4485469, rs4524033, rs4524035, rs4941125, 
rs65672721, rs6567276, rs7226991, rs7236060, rs7237982, 
rs7239667, rs8083511, rs8089829, rs8094884, rs8099222, rs9646629, 
rs9951012, rs9960450, rs17069845, rs8086340 
OPG TNFRS
F11B 
 rs3134067, rs11573847, rs11573905,, rs7463176, rs7464496, 
rs3102735, rs3134056, rs6469783, rs1994276, rs7820642, rs3134058, 
rs2875845, rs11573869, rs1485286, rs3134063, rs11573901, 
rs3134053, rs1032129, rs11573871, rs53102724, rs1095591,  
RANKL TNFS11  rs4942143, rs346574, rs1054016, rs2148072, rs875625, rs4338693,, 
rs9562414, rs931273 
Sequestosome 
1 
SQSTM
1 
 rs10277,rs7711505,rs513235,rs502729, 
rs4797,rs2241349,rs155788,rs3734007,rs515110,rs513165 
MD2 LY96 rs11783456, rs4738414, rs7839393, rs10808798, rs10504554, 
rs17226566, rs1905045, rs1991262 
CD14 CD14 rs2569193, rs2569190, rs4914 
NOD1 NOD1 rs4272257, rs2709803, rs2907749, rs2256023, rs6949758, 
rs11536450, rs17770244, rs1558068, rs4720004, rs3823773, 
rs7789045 
NOD2 NOD2 rs3135499, rs17313265, rs13339578, rs5743291, rs8056611, 
rs574328 
TLR1 TLR1 rs5743565, rs5743611, rs574359 
TLR2 TLR2 rs1816702, rs5743708, rs11938228, rs1898830, rs5743704, 
rs7656411, rs3804100, rs3804099 
TLR4 TLR4 rs2149356, rs5030728, rs7044464, rs10759932, rs12377632, 
rs1927906, rs1554973, rs11536857, rs11536897, rs11536889, 
rs11536869 
TLR5 TLR5 rs2241097, rs851139, rs2241096, rs2353476  
TLR6 TLR6 rs3775073, rs6531668, rs5743810, rs5743794 
TLR9 TLR9 rs187084, rs352143, rs352140 
TRAM TICAM2 rs256997, rs9326969, rs10079000, rs2288384, rs17473484, rs419939, 
rs11957931, rs256946,  
TRIF TICAM1 rs8120, rs1046673, rs4807650, rs4807651, rs7255265  
TIRAP TIRAP rs7932766, rs8177382, rs8177375, rs4937114, rs1786704, rs591163, 
rs8177352, rs6853, rs7744 
P2Y1R P2RY1 rs701265, rs17451266, rs12497578 
PRY2R 
 
P2RY2 rs1790081, rs1783596, rs4944831, rs12364461, rs949141, rs508859, 
rs17244555, rs557451 
P2y6r P2y6 rs12276627, rs3741152, rs11235714, rs12798517, rs3741153, 
rs7925649, rs1806516, rs2027765, rs12803970, rs1790063 
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P2X7R P2RX7 rs2567989, rs2686369, rs17434809, rs654856, rs12821688, rs500930, 
rs208292, rs2230911, rs17434640, rs12314721, rs17434647, 
rs1653609, rs208294, rs208302, rs11065464, rs6489794, rs1718134, 
rs503720, rs2857585, rs7137837, rs208296, rs12829218, rs1186055, 
rs2230912, rs7958311, rs504677, rs1718125, rs3751143, rs35933842, 
rs28360457, rs1653624 
DKK1 DKK1 rs1528877, rs1896367, rs2241529, rs2288335 
KREMEN2 KREMEN
2 
rs4238844, rs2285829, rs731721, rs7184777, rs4786361 
LRP5 LRP5 rs314750, rs312779, rs3781590, rs1784235, rs3781586, rs312024, 
rs545382, rs606989, rs312781, rs676318, rs314779, rs3781596, 
rs3781600, rs312023, rs11228202, rs638051, rs4988327, rs11826287, 
rs312009, rs314756, rs12417014, rs901824, rs2242340, rs312014, 
rs3781579, rs4930573, rs4988331, rs624947 
LRP6 LRP6 rs7957531, rs2417086, rs718403, rs2075241, rs1012672, rs11054738, 
rs7980903, rs7966410, rs10772542, rs7304561, rs12310020, 
rs2284396, rs17302049, rs11054704, rs12833575, rs10845493, 
rs12309338, rs10743980 
Myd88 Myd88 rs4988457, rs6767684, rs7744, rs6796045 
Sfrp1 Sfrp1 rs11786592, rs9693456, rs7833518, rs4736964, rs10106678, 
rs7832767, rs968428, rs4736959, rs6651363, rs3242, rs921142, 
rs9694405, rs17574424 
Sclerostin SOST rs1234612, rs865429, rs851062, rs851056 
MSK1 RPS6K
A5 
rs4904742, rs1018548, rs1286098, rs10150820, rs1286112, 
rs3783834, rs8013649, rs11848326, rs11159989, rs1286264, 
rs2401952, rs1286092, rs11620665, rs12590018, rs17261092, 
rs7151354, rs1957386, rs1286060, rs6575165, rs9944098, rs1286148, 
rs7151724, rs1286127, rs10150585, rs17722981, rs1152431, 
rs10134356 
MSK2 RPS6K
A4 
rs10897487, rs612448, rs3782101 
 
Table 4.1. Tagging SNPs used to screen each gene, including 5Kb upstream and 2Kb 
downstream. Tags were generated using Hapmap Genome Browser (release #24, 
phase 1 and 2 – full dataset, www.hapmap.ncbi.nlm.nih.gov) and Haploview software 
(v4.2, www.broadinstitute.org/haploview/haploview) 
 
4.3.4 Association Analysis 
 
Quality control (QC) and association analyses were carried out using PLINK v1.07 
(www.pngu.mgh.harvard.edu/∼purcell/plink). Two genotype-phenotype association 
analyses were performed: A case-control association analysis for susceptibility loci for 
osteolysis, and a quantitative trait analysis (QTL) for time to prosthesis failure (cases 
only and defined as the time from insertion to osteolysis diagnosis) using linear 
regression. Signals reaching a statistical significance threshold of p < 0.05 in the 
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discovery cohort after adjustment for age, sex, time since surgery, and annual 
prosthesis wear rate were taken forward for analysis in the replication cohort. Finally, 
case-control and time-to-failure meta-analyses of signals genotyped in both cohorts 
were performed using GWAMA v1.4 (WTSI). 
 
4.4 Results 
 
Seven hundred and fifty-eight subjects were included in the analyses, of whom 315 
formed the osteolysis group. The discovery cohort comprised 631 patients (275 
osteolysis cases). The replication cohort comprised 127 patients (40 osteolysis cases). 
130 subjects, as described in section 3.2.5, were initially included but 3 were later 
excluded due to gender fail at quality control.  Subjects in the osteolysis group were 
younger, a greater proportion were male and they had higher annual polyethylene 
wear rate versus the control subjects (Table 4.1, p < 0.05). These findings are 
consistent with known risk factors for osteolysis and were included as covariates in 
the association analysis. 
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Subject characteristics Control 
Group 
Osteolysis 
Group 
P value 
Discovery cohort n=356 n=275  
Age at THA (years +SD)a 65+8 59+9 <0.001 
Sex (male/female)b 147/209 148/127 0.002 
Osteolysis free survival (years+SD)c 12+4 10+5 <0.001 
Polyethylene wear (mm) 0.77(0.49 to 
1.23) 
1.18 (0.75 to 
1.91) 
<0.001 
Replication cohort n=87 n=40  
Age at THA (years+SD)a 72+8 69+7 0.03 
Sex (male/female)b 29/58 23/17 <0.001 
Osteolysis free survival (years+SD)c 18+6 4+1 <0.001 
 
Table 4.2. Characteristics of study subjects. Analysis is cases versus controls within 
each cohort by aStudent’s t-test, bChi-squared test, or cMann-Whitney U test, as 
appropriate. 
 
4.4.1 Osteolysis Susceptibility 
 
In the discovery case-control association analysis 4 SNPs within TNFRSF11A, 
including rs4524033, rs9960450, rs7226991, and rs4485469, and one each within 
KREMEN2 (rs4786361), SFRP1 (rs921142), TIRAP (rs8177375), and TNFRSF11B 
(rs11573847), met the significance threshold of p < 0.05 for carriage forward into the 
replication analysis (Table 4.2). At replication, four of these SNPs showed an 
association in the same direction as for the discovery cohort (rs4524033, rs7226991, 
and rs4485469, all in TNFRSF11A; and rs921142 in SFRP1), but none reached 
statistical significance. Meta-analysis of the two cohorts identified eight SNPs which 
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were associated with susceptibility to osteolysis (Fig. 4.1, p < 0.05). Four of these 
signals lay within TNFRSF11A, and 1 each within TNFRSF11B, SFRP1, KREMEN2, 
and TIRAP. 
 
 
 
Table 4.3.  Discovery cohort osteolysis susceptibility loci meeting the replication 
threshold (P<0.05). Analysis is cases (n=275) versus controls (n=356) using PLINK 
(version 1.07).  
 
 
Gene Chromosome SNP Minor 
allele 
OR OR 
95%L 
OR 
95%U 
P value 
TNFRSF11A 18 rs4524033 A 1.693 1.241 2.309 0.0009 
SFRP1 8 rs921142 G 1.323 1.036 1.691 0.025 
TNFRSF11A 18 rs9960450 C 0.500 0.273 0.918 0.025 
TNFRSF11B 8 rs11573847 G 1.668 1.061 2.621 0.027 
KREMEN2 16 rs4786361 A 0.745 0.574 0.969 0.028 
TNFRSF11A 18 rs7226991 A 0.733 0.552 0.972 0.031 
TIRAP 11 rs8177375 G 0.646 0.426 0.980 0.040 
TNFRSF11A 18 rs4485469 G 0.765 0.588 0.995 0.046 
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Figure 4.1.  Meta-analysis discovery and replication cohorts of susceptibility loci for 
development of osteolysis. Analysis is cases (n=315) verses controls (443) across 
discovery and replication cohorts and made using GWAMA software (version 1.4). The 
effect column indicates the effect direction of the given allele in the stage 1 and stage 
2 cohorts. 
 
4.4.2 Time to Failure 
 
Two SNPs within LRP6 (rs10743980 and rs2417086), and one each within LRP5 
(rs606989) NOD2 (rs5743289), SOST (rs851056), SQSTM1 (rs155788), TIRAP 
(rs1786704), and TRAM (rs10079000) associated with time to implant failure in cases 
at p < 0.05, and were carried forward (Table 4.3). At replication one SNP in TIRAP 
(rs1786704) showed the same direction of association with the discovery cohort, but 
none reached statistical significance, and no SNPs were associated with time to failure 
following meta-analysis of the two cohorts (Fig. 4.2, p > 0.05). 
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Table 4.4.  Discovery cohort quantitative trait loci associated with time to prosthesis 
failure in cases (n=275) meeting replication threshold (P<0.05). Analysis made by 
linear regression using PLINK (version 1.07). 
 
 
 
 
Gene Chromosome SNP 
Minor 
allele BETA 
BETA 
95%L 
BETA 
95%U P 
LRP6 12 rs10743980 T -0.913 -1.687 -0.139 0.022 
SOST 17 rs851056 G -0.865 -1.620 -0.109 0.026 
TRAM 5 rs10079000 A -0.912 -1.726 -0.099 0.029 
SQSTM1 5 rs155788 C -0.907 -1.716 -0.098 0.029 
NOD2 16 rs5743289 T 1.034 0.104 1.965 0.030 
LRP6 12 rs2417086 G -0.836 -1.601 -0.071 0.033 
TIRAP 11 rs1786704 C -0.952 -1.851 -0.052 0.039 
LRP5 11 rs606989 T 1.601 0.073 3.129 0.041 
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Figure 4.2.  Meta-analysis discovery and replication cohorts of quantitative trait loci 
associated with time to prosthesis failure.  Analysis is within cases only (n=315) across 
discovery and replication cohorts and made using GWAMA software (version 1.4). The 
effect column indicates the effect direction of the given allele in the stage 1 and stage 
2 cohorts. 
 
4.5 Discussion 
 
We conducted a 2-stage case-controlled association study to identify common genetic 
variants that associate with susceptibility to osteolysis, and with time to diagnosis in 
cases. At meta-analysis of the two stages we identified eight SNPs that were weakly 
associated with osteolysis susceptibility. Seven of these lay within bone resorption (six 
signals) or bone formation (two signals) pathways, and one within genes that regulate 
inflammatory signalling (TIRAP). 
 
Variants within TNFRSF11A (encoding RANK) and TNFRSF11B (encoding OPG) 
showed the strongest association with susceptibility to osteolysis, and are consistent 
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with the function of these genes in regulating osteoclast differentiation and activation. 
The functional role of these variants is uncertain, as all lie in non-coding regions of the 
gene. However, they may act as markers for coding SNPs or regulate transcription 
and translation through effects on mRNA stability, splicing, or binding of miRNAs. 
 
Variation within bone formation pathways was associated with osteolysis, and 
previously showed variation within SFRP3 was associated with both osteolysis and 
heterotopic ossification susceptibility (Gordon A et al., 2007). SFRP1 is also a Wnt 
antagonist.  SFRP1-/- mice have high trabecular bone mass, (Bodine et al., 2004) and 
inhibition of SFRP1 activity associates with increased bone formation (Gaur et al., 
2009).  The rs921142 variant within SFRP1 lies in the 5'UTR region and may thus 
affect stability of the RNA transcript Kremen2 is a transmembrane protein that blocks 
the LRP6 receptor inhibiting Wnt signalling, and Kremen2 deficient mice have 
increased bone formation (Schulze et al., 2010).  Our finding of an association 
between osteolysis and variation within Kremen-2 is previously unreported. 
 
We found fewer than anticipated associations within the inflammatory signalling 
pathways, given their reported importance to osteolysis. The only consistent 
association found was between the TIRAP rs8177375 variant and susceptibility to 
implant failure. This variant also showed a trend toward association with time to 
prosthesis failure in the osteolysis cases (β—1.12, p = 0.08), but failed to meet the 
threshold for genotyping in the replication cohort. TIRAP is an adaptor protein that 
modulates many inflammatory pathways, including inflammatory signalling through 
TLR-4, and also transduces signals from TLR2 (Greenfield et al., 2010).  This TIRAP 
variant is located in the 3' UTR and associates with risk of sepsis-induced lung injury 
(Song et al., 2010). 
 
We used knowledge of the haplotype architecture of candidate genes to conduct a 
screen for common variants across the whole of each gene, including its regulatory 
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flanking sequences. We used a 2-stage design to reduce the likelihood of false positive 
associations, carrying forward to replication only those signals reaching a significance 
threshold of p < 0.05 in the discovery cohort. This approach also has several 
limitations. Although the presented sample size combines the two largest cohort 
studies of the genetics of osteolysis reported to date, (Gordon A et al., 2008, Malik, 
2007) it remains small in genetic association study terms. We aimed to address the 
issue of multiple testing and false positive associations through a 2-stage analysis 
process, followed by meta-analysis of the datasets for signals undergoing replication 
analysis. Our study only had power to detect common variants with relatively large 
effects sizes and with modest p-values. For example this design had 80% power (at 
p < 0.0005, joint analysis, multiplicative model, CaTS), (Skol et al., 2006) to detect a 
variant with an OR of 1.5 with a MAF of 0.35, but only 7% power to detect a variant 
with similar effect size and a MAF of 0.05. Although our design aimed to reduce the 
number of candidate SNPs genotyped without loss of sensitivity for identifying disease 
loci by using Hapmap data on their haplotype structure, candidate pathways and 
genes were selected based on a-priori knowledge of their importance to the 
pathogenesis of osteolysis. 
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CHAPTER 5 
A WHOLE GENOME ASSOCIATION STUDY OF SUSCEPTIBILITY TO 
HETEROTOPIC OSSIFICATION FOLLOWING TOTAL HIP 
ARTHROPLASTY 
 
5.1 Overview 
 
This chapter describes a discovery-stage genome wide association study of 
heterotopic ossification susceptibility and severity following THA. A replication cohort 
for this phenotype is currently being collected.  The aetiopathogenesis of HO is still 
not fully understood and the majority of genetic research has looked at the rare 
heritable causes of HO. Only a few screening studies have been carried out in other 
populations.  In this study we aimed to identify genetic risk loci by conducting a 
genome-wide association study comprising 891 Caucasian European patients (410 
HO cases). All had undergone THA for primary osteoarthritis and were recruited from 
the United Kingdom. Genotyping was undertaken using the Illumina 610 beadchip 
followed by imputation using the European reference panel from the 1000 Genome 
Project.  An HO susceptibility case-control analysis and an evaluation of disease 
severity in those with HO was undertaken using SNPTEST v2.3.0.  8 signals were 
associated with HO susceptibility and 11 with HO severity at p<9.9x10-6.in this 
discovery set.   The most significant signal that was associated with HO susceptibility 
lay in flanking region of ARHGAP18 (index SNP rs59084763, p=2.48x10-8) and 
reached genome wide significance.  Two other signals approaching genome wide 
significance lay in the flanking region of BMP-2 (index SNP rs11699612, p=9.3x10-8) 
and within LGI1 (index SNP rs10882328, p=3.8x10-7). The most significant signal that 
was associated with HO severity lay within KIF26B that encodes the kinesin like 
protein KIF26B (rs35338958, p=1.65x10-6). Signal replication in an independent cohort 
will be required to confirm these associations.   
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5.2 Introduction 
 
Heterotopic ossification (HO) is a common complication following total hip arthroplasty 
(THA) with a reported incidence of up to 61% (Newman et al., 2015).  In addition to 
restriction of joint motion HO can lead to pain, as well as neural or vascular 
compression (Garland, 1991, Hierton et al., 1983, Brooke et al., 1991).  The exact 
pathogenesis of HO remains unknown and investigators in recent years have 
attempted to identify the osteoprogenitor cell origin and signalling pathways involved 
both in the acquired and hereditary forms. 
 
The increased risk of HO in patients with ankylosing spondylitis (Bisla et al., 1976), 
diffuse idiopathic skeletal hyperostosis (Blasingame et al., 1981) and hypertrophic 
osteoarthritis (Sawyer et al., 1991) together with the heterogeneity in HO manifestation 
in patients with similar injury patterns suggests a significant genetic predisposition.  To 
date, the majority of genetic research has looked at the rare heritable causes of HO 
(FOP and POH) and few screening studies have been carried out in other populations.  
Candidate gene studies have associated variants in genes encoding the β2adrenergic 
receptor, toll-like receptor (TLR) 4, complement factor H, and secreted frizzled related 
protein 3 (sFRP3) with susceptibility to HO (Gordon A et al., 2007, Mitchell et al., 
2010).  Here we aimed to identify genetic risk loci associated with the formation of HO 
following THA by conducting a genome-wide association study. 
 
5.3 Subjects and Methods 
 
5.3.1 Subject Recruitment and Phenotype Characterisation 
 
The cohort examined in this study consisted of the recruited GWAS discovery 
population. Controls comprised subjects who had no evidence of HO on plain AP 
radiographs of the pelvis taken not less than 1 year following primary THA.  Cases 
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comprised subjects with radiographic evidence of post-operative HO and were graded 
(0-4) using the Brooker classification. As described in section 1.5.3 (Brooker et al., 
1973). 
 
5.3.2 Genotyping and Association Analysis 
 
Genomic DNA was extracted from either whole blood or saliva and genotyped using 
the Illumina 610k beadchip (Illumina, San Diego, CA).  We imputed the GWAS data 
using the European reference panel from the 1000 Genome Project.  We undertook 
post genotyping quality control checks as described in section 2.8.3.   
 
An HO susceptibility case-control analysis and an evaluation of disease severity.  We 
were unable to normalise the HO grade data and therefore undertook a binomial 
analysis comparing grades 1 and 2 versus grades 3 and 4 in the cases under the 
additive model using the score test in SNPTEST v2.3.0 (University of Oxford, Oxford, 
UK).  Association analyses were adjusted for age and gender as these have previously 
been described as known risk factors for HO (DeLee et al., 1976, Hierton et al., 1983).  
SNPTEST output files were further filtered to exclude SNPs with a frequentist info 
score <0.4 and a minor allele frequency (MAF) <0.05. 
 
5.4 Results 
 
5.4.1 Patient characteristics 
 
Eight hundred and ninety-one subjects were analysed (401 males). Of these, 410 
subjects formed the HO group.  The mean age of subjects was 63.5 (SD 8.9) and no 
difference in mean age was found between the groups (63.65+8.9 vs 63.42+8.9, 
p=0.7).  There was a higher proportion of males in the HO group versus the control 
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group (p<0.0001).  The Brooker grading of HO in the cases was as follows: grade 1 
n=207, grade 2 n=133, grade 3 n=69, grade 4 n= 1.  
 
5.4.2 HO Susceptibility Analysis 
 
We identified 8 independent signals with index SNPs at p<9.9x10-6 that were 
associated with HO susceptibility (table 5.1).  The most significant signal lies 1Kb 
downstream of ARHGAP18 and reached genome wide significance (rs59084763, 
effect allele T, effect allele frequency (EAF) 0.194, odds ratio OR 1.87, 95% CI 1.48 
to 2.38, p=2.48x10-8) (figure 5.1).    Two signals approached genome-wide 
significance: variant rs11699612 (effect allele T, EAF 0.25, OR 1.74, 95% CI 1.4 to 
2.16, p=9.3x10-8) lies 300Kb upstream of BMP2 (figure 5.2).  Variant rs10882328, 
(effect allele A, EAF 0.287, OR 0.57, 95% CI 0.47 to 0.71, p=3.8x10-7) lies within an 
intronic region of LGI1 (figure 5.3). 
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Table 5.1. Results of the HO susceptibility analysis.  This table includes all 
independent SNPs with p<9.9x10-6.  Chr = chromosome, EA = affect allele, NEA = non 
affect allele; OR = odds ratio, OR_95L/95U = lower and upper margins of 95% CI. 
 
 
 
 
 
 
 
 
 
 
Index SNP Chr EA NEA EAF OR OR 95L OR 95U P value Gene 
rs59084763 6 T C 0.194 1.872 1.475 2.375 2.48E-08 Downstream of 
ARHGAP18 
rs11699612 20 T C 0.246 1.735 1.395 2.157 9.39E-08 Upstream of BMP2 
rs10882328 10 A G 0.287 0.577 0.468 0.713 3.87E-07 LGI1 
rs1059129 7 G A 0.152 1.904 1.463 2.477 2.60E-06 PMS2P1 
rs35946190 9 G A 0.182 0.573 0.446 0.736 3.93E-06 ASTN2 
rs3768863 2 G A 0.550 0.661 0.548 0.798 6.82E-06 BIN1 
rs6463103 7 G T 0.773 0.622 0.498 0.778 9.15E-06 Upstream of 
LOC105375249 
6-137128553 6 A C 0.061 2.239 1.495 3.354 9.32E-06 Upstream of PEX7 
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Figure 5.1.  Regional association plot for rs59084763 (that lies downstream of 
ARHGAP18) from the HO susceptibility analysis.  The index SNP is denoted by the 
purple marker.  The colour reflects the pairwise r2 with index SNP.  The region extends 
500kb upstream and downstream of the index SNP. 
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Figure 5.2.  Regional association plot for rs11699612 (that lies upstream of BMP2) 
from the HO susceptibility analysis.  The index SNP is denoted by the purple marker.  
The colour reflects the pairwise r2 with index SNP.  The region extends 500kb 
upstream and downstream of the index SNP. 
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Figure 5.3.  Regional association plot for rs10882328 (that lies within LGI1) from the 
HO susceptibility analysis.  The index SNP is denoted by the purple marker.  The 
colour reflects the pairwise r2 with index SNP.  The region extends 500kb upstream 
and downstream of the index SNP. 
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5.4.3 HO Severity Analysis 
 
Eleven signals were associated with HO severity with index SNPs at p<9.9x10-6 (table 
5.2).  No signals in the severity association analysis reached genome wide 
significance.  The most significant signal lay within an intronic region of KIF26B.  The 
index SNP within this signal was rs35338958 (OR 3.0, EAF 0.099, 95% CI 1.85 to 
5.01) at p=1.65x10-6 (figure 5.4).   
 
Index SNP Chr EA NEA EAF OR OR 95L OR 95U P value Gene 
rs35338958 1 T C 0.099 3.044 1.850 5.008 1.65E-06 KIF26B 
rs13109480 4 C T 0.071 2.896 1.634 5.135 1.88E-06 Upstream of 
HSP90AB2P 
rs11953126 5 G A 0.474 0.426 0.289 0.629 2.42E-06 LOC105374705 
rs2300936 9 G A 0.087 3.355 1.994 5.642 3.86E-06 C5 
rs491425 18 G A 0.663 2.632 1.667 4.158 5.02E-06 FHOD3 
rs1367425 2 T C 0.218 0.437 0.301 0.636 5.07E-06 no nearby genes 
rs11880610 19 C G 0.098 2.788 1.684 4.617 5.98E-06 ZNF331 
rs4612038 5 A G 0.300 2.351 1.621 3.411 6.00E-06 EDIL3 
rs34242676 9 C T 0.288 2.220 1.525 3.232 6.15E-06 Downstream of 
GRIN3A 
rs13235561 7 A C 0.333 2.148 1.485 3.110 6.19E-06 LOC105375122 
rs10058296 5 T C 0.087 2.373 1.489 3.783 6.59E-06 Upstream of 
HTR1A 
 
Table 5.2. Results of the HO severity analysis.  This table includes all independent 
SNPs with p<9.9x10-6.  Chr = chromosome, EA = affect allele, NEA = non affect allele; 
OR = odds ratio, OR_95L/95U = lower and upper margins of 95% CI. 
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Figure 5.4.  Regional association plot for rs35338958 (that lies within KIF26B) from 
the HO severity analysis.  The index SNP is denoted by the purple marker.  The colour 
reflects the pairwise r2 with index SNP.  The region extends 500kb upstream and 
downstream of the index SNP. 
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5.5 Discussion 
 
We have undertaken the first GWAS examining HO susceptibility and severity 
following THA. We have identified a number of possible association signals within or 
in the flanking regions of ARHGAP18, BMP2, LGI1 and KIF26B that warrant further 
investigation by replication in suitable cohorts. 
 
The variant rs59084763 associated with susceptibility to HO and lies 1Kb downstream 
of ARHGAP18. Although this signal is not within ARHGAP18, downstream flanking 
regions may contain downstream promoter elements (DPE) which regulate the 
initiation of transcription. Variation within such a region has the capacity to alter the 
level of RNA transcription and subsequent gene activity.  The ARHGAP gene family, 
encodes the RhoGAP proteins, which activate GTPase, modulating cell signalling.  
The Rho family of GTPases play an important role in cell differentiation, proliferation 
and migration (Symons, 1996). ARHGAP18 has been suggested as one of the crucial 
factors for the regulation of RhoA for the control of cell spreading, and migration 
(Maeda et al., 2011).   Our identification of SNP associations in the flanking region of 
ARHGAP18 may prove promising in light of recent evidence suggesting the progenitor 
cells for HO likely migrate to the site of bone formation (Lazard et al., 2015).  RhoA 
has been shown to influence mesenchymal stem cells into an osteogenic lineage 
(Arnsdorf et al., 2009, Chen et al., 2011).  ARHGAP18 may therefore be important in 
both the migration and osteogenic lineage of HO progenitor cells and is a plausible 
associated candidate for replication and follow on functional studies. 
 
The intergenic variant rs11699612 associated with HO susceptibility lies 300Kb 
upstream of BMP2. Upstream regions contain promoter and enhancer regions that 
regulate transcriptional activity of the gene.  Variants within these regions have the 
potential to influence RNA transcriptional regulation by altering the binding of RNA 
polymerase and other transcription factors.  The bone morphogenetic proteins belong 
to the transforming growth factor beta (TGFβ) superfamily, a group of growth factors 
involved in embryogenesis and tissue healing (Termaat et al., 2005).  The role of BMPs 
in heterotopic ossification is well established.  Their discovery by Urist in the 1960s 
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was through the induction of bone in the skeletal muscle of rabbits (Urist and Strates, 
1971).  Overexpression of BMPs have been linked to HO development (Kaplan et al., 
2004).  Evans et al found greater transcript levels and expression of BMP2 in war 
wounds which developed HO (Evans et al., 2014).  BMP2 is now commonly used as 
an inducer in many rodent models of HO (Engstrand et al., 2008).  The osteoinductive 
properties of BMP-2 has led to its use as an adjunct in spinal fusion (Burkus et al., 
2016).  Like ARHGAP18, BMP2 has been shown to influence the activation of RhoA 
in early osteogenesis.  Wang et al identified two polymorphisms, Ser87Ser 
(rs1049007) and Ser37Ala (rs2273073), in BMP2 that associated with susceptibility to 
ossification of the posterior longitudinal ligament (Wang et al., 2008).  As well as direct 
osteoinduction in HO, BMP-2 signalling has been linked to both neural and 
inflammatory pathways.  MacDonald et al showed that the administration of BMP-2 
can induce inflammation (MacDonald et al., 2010).  BMP2 and BMP3 (osteogenin) 
have also been shown to be chemoattractants for monocytes (Convente et al., 2015).  
Interestingly, Kaplan et al showed that reduction of the immune response using 
transgenic mice did not prevent the formation of HO (Kaplan et al., 2007).  This 
suggests that in addition to the immune system, other mechanisms such as neuronal 
pathways are involved.  Salisbury et al showed that BMP-2 causes peripheral nerves 
to express osterix (Salisbury et al., 2011).  Osterix is a zinc finger containing 
transcription factor which plays an important role in osteoblast differentiation 
(Nakashima et al., 2002).  BMP-2 also induces substance P release from neurones 
which leads to recruitment and degranulation of mast cells leading to HO and further 
links the neuronal and inflammatory pathways (Salisbury et al., 2011).  Lazard et al 
demonstrated that BMP-2 causes neural derived progenitor cells (likely neural crest 
stem cells) to undergo osteogenic differentiation and migrate to the site of HO (Lazard 
et al., 2015).  The evidence for the involvement of BMP-2 in the formation of HO 
suggests it is a plays a key role in the interplay of various contributing pathways. 
 
The intronic variant rs10882328 associating with HO susceptibility was found within 
LGI1.  LGI1 was originally discovered in gliomas but has also been linked to an 
autosomal dominant form of epilepsy (Chernova et al., 1998, Poza et al., 1999).  This 
gene encodes the Leucine-rich, glioma inactivated 1 (LGI1) protein.  The LGI1 protein 
is thought to regulate the strength of synaptic transmission by bridging between the 
139 
 
disintegrin and metalloprotease 22 and 23 (ADAM22 and ADAM23) transmembrane 
proteins (Fukata et al., 2010).  Yu et al found that absence of LGI1 causes an increase 
in synaptic transmission (Yu et al., 2010). The association of LGI1 with HO is novel 
and its function in neuronal signalling is still not fully understood.  It may provide a link 
for the neuronal involvement in the development of HO. 
 
The signal that was most strongly associated with HO severity lay within KIF26B.  The 
Kinesin Superfamily Proteins (KIFs) are molecular motors responsible for intracellular 
transport of proteins and signal transduction (Hirokawa et al., 2009).  KIF26B which 
grouped with KIF26A form the Kinesin-11 family and are important in limb 
development.  The association of KIF26B with HO following THA is novel, however, it 
has previously been associated with ectopic calcification in a rodent knee injury model 
(Rai et al., 2015).  This makes KIF26B of interest in the further study of HO.  
 
Interestingly the two most significant signals associating with HO susceptibility are 
linked through common biological processes.  Both ARHGAP18 and BMP2 are known 
regulators of RhoA.  The Rho GTPases are regulators of osteogenesis through their 
involvement in both canonical and non-canonical WnT signalling (Schlessinger et al, 
2009).  RhoA has been shown to regulate osteogenesis through its effect on both 
osteoblasts and osteoclasts (Yoshida et al 2009) (Chellaiah et al, 2000).  Ohnaka et 
al, studying the effects of pitavastatin on bone, discovered that BMP2 expression was 
regulated by RhoA (Ohnaka et al).  The stimulation of RhoA in MSCs by BMP2 is 
necessary for osteogenesis through its effect on cell spread and shape (Wang et al 
2012).  ARHGAP18 is localised to the leading edge of migrating cells and controls cell 
shape through its regulation of RhoA (Maeda et al 2011). 
The association of BMP2 and ARHGAP18 with RhoA signalling suggests a possible 
common pathway in the development of ectopic bone.  The effects of altered 
regulation of RhoA through transcriptional variation of BMP2 and ARHGAP18 are 
potentially threefold: 1.  Migration of progenitor cells to area of bone formation, 2.  
Actuation of MSCs down an osteogenic lineage through altered regulation of WnT 
signalling, 3.  Enhanced osteogenesis through stimulation of further BMP2 signalling.  
As BMP2 and RhoA signalling have been implicated in a number of biological 
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processes their exact contribution to the pathogenesis of HO remains unclear.  Follow 
on functional studies of ARHGAP18, BMP2 and the RhoGTPases are required to 
explore this further.  
 
This study has limitations.  The sample size was small, and this may have led to fewer 
genome wide significant associations (p<9x10-8), especially for the rarer loci.  We 
attempted to minimise this effect by including only common variants with MAF>0.05.  
A number of the allele effect sizes were quite large and may represent type 1 statistical 
errors, highlighting the importance of a further replication study. Further, we used the 
Brooker classification for HO. This is the accepted standard method, but provides only 
a semi-quantitative measure. An alternative approach using cross-sectional imaging 
would provide volumetric quantitation, but is not used in routine clinical practice.   
 
In conclusion, we have identified several possible signal associations with HO 
susceptibility and severity. However, this data represents only a discovery cohort, and 
replication in independent cohorts is essential before these candidate signals can be 
robustly confirmed.  
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CHAPTER 6 
USING A NATIONAL JOINT REGISTER DATASET AND POSTAL 
METHODOLOGY TO DEVELOP A LARGE DNA ARCHIVE FOR 
MUSCULOSKELETAL DISEASE 
 
6.1 Overview 
 
This chapter outlines the osteolysis replication population recruitment.  Local 
recruitment of sufficient numbers of patients for large scale epidemiological studies is 
difficult and time consuming, especially when studying low incidence phenotypes. 
National joint registries provide large repositories of clinical data and the linking of 
such datasets with patient biological material offers new opportunities to study 
musculoskeletal disease.  We examined the response rates for postal saliva collection 
to build a DNA biobank for patients who had undergone primary and revision total hip 
arthroplasty (THA). The quality and quantity of DNA collected was also examined.   
The DNA and clinical datasets were then linked to examine patient demographic 
factors that associated with DNA yield.  This study highlights the possible extended 
role of arthroplasty registries for large scale recruitment of subjects for the study of 
musculoskeletal disease.  It also demonstrates the feasibility of establishing DNA 
biobanks in conjunction with national registries and the successful linking of datasets. 
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6.2 Introduction 
 
National arthroplasty registers allow the auditing of orthopaedic prosthetic implants 
and their outcomes and were introduced for care quality purposes.  They provide an 
excellent repository of clinical information about the patient experience of joint 
replacement.  The linking of such clinical datasets with patient biological samples can 
extend the role of these registries to answer research questions. The value of linking 
of national arthroplasty datasets with other clinical dataset (Hospital episode statistics, 
HES) has already been realised (Sibanda et al., 2008). Cancer registry data is also 
now being utilised to answer biological questions about disease (Govindaraju et al., 
2008, John et al., 2004).  Many of these registries are now establishing their own 
biobanks of DNA and tissue samples (Goodman, 2009).  To date there have been no 
biobanks established for national arthroplasty registries. 
 
Traditionally, whole blood has been used for obtaining DNA samples, however, this 
method has logistical limitations, especially when applied to the recruitment of large 
cohorts.  Study subjects need to attend a healthcare facility for venepuncture and, due 
to its invasive nature, is disliked by patients.  Additionally, blood samples require 
refrigerated storage and timely processing.  Saliva is a viable alternate source of DNA 
for large genetic epidemiological studies (Ng, 2005, Quinque et al., 2006, Rylander-
Rudqvist et al., 2006, Rogers et al., 2007, Nishista, 2009, Bahlo et al., 2010).  Saliva 
sample return rates have been shown to be higher than those of blood but these rates 
are highly variable between studies (Hansen et al., 2007, Bhutta et al., 2013).  The 
postal collection of saliva is a cost effective, non-invasive, and convenient method of 
obtaining human DNA. 
 
In this study, we aimed to build a repository of DNA from patients after primary and 
revision total hip arthroplasty (THA recruited from a national arthroplasty registry) 
using postal saliva collection.  We evaluated response rates, and assessed whether 
the quality and quantity of DNA collected was adequate for GWAS. 
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6.3 Methods 
 
6.3.1 Recruitment environment 
 
All replication study subjects were recruited from the Norwegian Arthroplasty Register 
(Haukeland University hospital, Bergen, Norway).  This project had the collaborative 
support of the staff and facilities of the register, led by Professor Ove Furnes.   They 
provided access to the necessary number of subjects needed for the stage 2 
recruitment. The register has collected information on primary and revision THA 
procedures performed in Norway since 1987 now has over 200,796 recorded total hip 
prosthesis operations (Norwegian Arthroplasty Annual Report, June 2016, 
http://nrlweb.ihelse.net/Rapporter).   The Norwegian Arthroplasty Register employs 
data entry and management clerks, and statistical epidemiologists that have a large 
experience of conducting follow up postal questionnaire and clinical studies. 
 
6.3.2 Inclusion and exclusion criteria 
 
As in the discovery recruitment outlined in chapter 2, subjects recruited in the 
replication cohort comprised unrelated men and women of North European ancestry 
who had previously undergone primary cemented or hybrid (cemented femur) THA for 
idiopathic osteoarthritis.  Any subject with a fully cementless implant and those who 
had undergone THA for a primary diagnosis other than osteoarthritis, such as 
inflammatory arthropathy or osteoarthritis secondary to another pathology, was 
excluded. 
 
6.3.4 Case and control definition and matching 
 
Cases comprised subjects who have undergone revision surgery for aseptic loosening 
or osteolysis affecting either the acetabular or femoral prosthetic component. 
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Revisions for indications such as dislocation, or infection were excluded; as were 
revisions of fully cementless implants and revisions for liner wear in the absence of 
aseptic loosening or osteolysis.  Although subjects who underwent revision for liner 
wear in the absence of osteolysis could have been considered an interesting group of 
controls, numbers were not sufficient to warrant inclusion.  Controls comprised 
subjects identified to have had primary THA for idiopathic osteoarthritis ≥10 years 
previously, and no recorded revision surgery episodes. 
 
A number of environmental factors affect the development of osteolysis. In the UK 
cohort case-control association study we adjusted for these risk factors using logistic 
regression in order to determine that component of risk for osteolysis which is 
associated with the candidate loci. The Norwegian cohort recruitment strategy was 
planned to minimise differences in known risk factors between the cases and controls 
a-priori. The revision subjects were recruited first and the control group subjects 
individually matched to be of the same age (± 2 years), sex, implant brand, bearing 
couple material and size, implant fixation method, and year of primary surgery (± 2 
years). A total of 9 identified potential controls were matched per revision in order to 
achieve 3 recruited controls per revision, allowing for estimated response rates.  The 
large pool of subjects available for recruitment in the control group (38,000) made this 
approach feasible, and the most robust method for minimising environmental risk 
factor variance between the groups. Two limitations of this approach are that we did 
not have access to wear measurements in the replication cohort, nor radiographic 
evidence of freedom from osteolysis in the control group. In mitigation of the first 
confounder, we adjusted for polyethylene wear as a risk factor in the discovery cohort 
when selecting the signals to progress for replication. To help mitigate against the 
second confounder, we used a screening questionnaire (appendix E) to confirm that 
all control subjects were asymptomatic from the replaced hip at the time of recruitment. 
This will leave a potential group of subjects with silent osteolysis that are misclassified 
in the control group.  
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6.3.6 Subject recruitment 
 
All recruited subjects were provided with an information sheet and signed a study 
specific consent form. Stage 2 recruitment and saliva collection was ethically approved 
in Norway (West Norway Research Ethics Committee, REK reference 2008/100 18-
OYSV, 08.09.08; approval letter in appendix F).  This collection was also reviewed 
and approved for transfer to the UK for DNA extraction and genotyping by the 
Norwegian Biobank authorities (08/8916, 20.10.08).  Recruitment was carried out in a 
number of stages.  
 
6.3.7 Revision Recruitment 
 
Revisions were recruited first in order to adequately match the controls.  Recruitment 
started in April 2009 and subjects registered before this time were identified for 
inclusion, and comprised the first mail outs of invitations.  Following this, at year end 
it was possible to identify and include revisions registered in 2009.  Revisions carried 
out in 2010 formed the third round of invitation mail outs. 
 
6.3.8 Control Recruitment 
 
Control recruitment was undertaken in two batches.  The first group of controls were 
matched against recruited revision subjects up to and including 2009.  Following, 
responses from revision subjects having surgery in the year 2010, further controls 
were matched and invites mailed out in a second recruitment batch in December 2011. 
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6.3.9 Subject Recruitment and saliva collection 
 
Patients enrolled in the Norwegian arthroplasty register who were identified as still 
living in Norway and meeting the inclusion criteria were invited to participate in the 
biobank.   Patients were sent an invitation letter, questionnaire and consent form by 
post.  All subjects who returned a signed consent form agreeing to participate in the 
study received, by post, an Oragene OG-500 DNA Self Collection Kit (DNA Genotek, 
Inc, Ottawa, Canada) with detailed instructions on its use. A prepaid return envelope 
was supplied to return samples.  Non-responders who had been sent a saliva 
collection kit received a further reminder letter by mail (figure 6.1). 
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Figure 6.1.  Schematic diagram outlining the recruitmant strategy 
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6.3.10 Laboratory methods 
 
Saliva samples were stored at room temperature before processing.  A small subset 
was stored at -20oC prior to DNA extraction. Prior to DNA extraction all samples were 
visually inspected to ensure no damaged had occurred on transportation. The volume 
of the saliva was determined by subtracting the 2mls of DNA stabiliser.  The colour of 
the sample was noted as either clear, light brown or dark brown representing 
contaminants. 
 
DNA was extracted manually by precipitation in ethanol using the manufacturer's 
protocol for manual purification of DNA from 4.0mL, PD-PR-015 Issue 2.0. These 
methods are described in detail in chapter 2.2.4. 
 
DNA samples were quantitated using the Qubit dsDNA BR assay kit (Product Code: 
Q32853, Invitrogen) the concentration of DNA was measured using the Qubit 2.0 
fluorimeter (Product Code: Q32866, Invitrogen.) as described in chapter 2.5.5.  DNA 
quality was evaluated in a sample subset, by gel electrophoresis as described in 
section 2.5.4 to measure DNA fragment length, using the TapeStation 2200 (Agilent 
Technologies, CA, US). DNA samples were stored at -20oC immediately following 
extraction and then transferred to -80oC for long-term storage.  Subjects who had 
provided samples with a DNA concentration below that required for genotyping were 
contacted and sent another saliva kit to provide a repeat sample.  
 
6.3.11 Data Linkage 
 
Clinical data was collected from the register database and linked to the subsequent 
DNA collection by a unique identifier.  This data linkage facilitated the examination of 
patient demographic factors that associated with DNA yield. 
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6.4 Results 
 
6.4.1 Subject recruitment and response rates 
 
There were 121,613 primary THAs and 10,255 revision THA cases identified on the 
Norwegian Arthroplasty Registry at the time of study.  8,396 subjects (6,367 primary 
THAs, 2,029 revision THAs, mean age 66.5, 36.5% males) met the inclusion criteria 
and were invited to participate. 3,710 agreed, a response rate of 44%.  3,068 (2,276 
primary THAs, 792 revision THAs, saliva samples were subsequently received from 
agreeing participants (completer rate 36.5%; 83% of responders) (figure 6.2).  
Characteristics of completer subjects can be seen in table 6.1.  The completer rate 
was found to be higher in those subjects who had undergone revision surgery than 
those who had undergone primary surgery (39% vs 35.7% respectively, p=0.001). The 
completer rate was higher in men than women (41.5% vs 33.7% respectively, 
p=0.0001). 
 
 
Figure 6.2. Overview of subjects recruited 
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Characteristic Primary Arthroplasty 
Completers 
Revision 
Arthroplasty 
Completers 
Total 
Mean Age 
(years) 
65.7 (SD 7.1) 64.3 (SD 7.05) 65.3 (SD 7.1) 
Gender 
(male/female) 
937/1339 334/458 1271/1797 
Response Rate 35.7% 39% 36.5% 
 
Table 6.1.  Completing subject’s demographic characteristics 
 
6.4.2 Saliva sample characteristics 
 
3,104 saliva samples were received.  This larger number compared to number of 
completer subjects is due to 36 repeat samples being received from subjects who had 
initially provided low yield DNA samples.  Of these, 31 samples had leaked during 
shipping, 10 samples were contaminated during processing and 7 were lost during 
processing (figure 6.3).  The remaining 3,056 samples were suitable for processing.    
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Figure 6.3.  Overview of sample processing 
 
Received saliva sample volumes ranged from 0.5ml – 4ml.  The mean saliva volume 
was 2.0mL (SD 0.68).  The volume of saliva sample provided was inversely 
proportional to the age of the patient (linear regression, r = -0.09, p = 0.01).  The colour 
of sample was not recorded in 47 samples.  Of the remaining, 67.4% samples were 
clear, 28.2% light brown in colour and 4.4% were dark brown and assumed to be 
heavily contaminated.   
 
6.4.3 DNA Quantitation 
 
The median DNA yield was 52.1µg (IQR 22.65µg – 103.5µg) (figure 6.4).  The median 
stock concentration was 69.05ng/µl (IQR 30.2ng/µl – 136.75ng/µl).  2335 (75.2%) 
samples had extracted DNA concentrations >30ng/µl recommended for high-
throughput genotyping.  80% of extracted DNA had a fragment length of >60 Kilobases 
(Kb) (figure 6.5).  Of the duplicate samples received, the median DNA concentration 
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was 36.2ng/µl with 65% of samples achieving the above required concentration for 
high throughput genotyping.  This was an increase in median concentration in this 
group of subjects by 22.85ng/µl (13.35 - 36.2ng/µl).  There was no difference in DNA 
yield between men and women (p=0.9).  Samples stored at room temperature prior to 
DNA extraction had a greater yield of DNA than those stored at -20oC (84.22 µg vs 
69.6 µg, respectively, p=0.001).  The total yield of DNA had a weak positive correlation 
with the volume of the saliva sample provided (Pearson correlation bivariate two-tailed, 
r = 0.17, p= 0.01) (figure 6.6).  The darker (presumed contaminated) saliva samples 
were found to provide higher yields of DNA (ANOVA, F = 101.39, p = 0.0001). 
 
Figure 6.4.  Histogram outlining the Stock DNA Yield by Qubit 
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Figure 6.5.  Gel Electrophoresis on a D1 agarose gel demonstrating DNA quality.  The 
y axis represents fluorescence intensity of the DNA fragments and the x axis shows 
the length of the DNA fragments.  The peak on the left represents a DNA size standard 
(100bp).  The peak on the right represents the DNA samples tested.  The lack of 
spread in the peak on the right indicates numerous large DNA fragments.     
 
Figure 6 6. Box plot outlining saliva sample volume vs DNA yield 
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6.5 Discussion 
 
In this study, we have demonstrated that postal recruitment of subjects using a 
national arthroplasty registry achieves adequate response rates for large scale 
epidemiological studies.  This supports the current evidence that large scale 
recruitment can be achieved from medical registries (John et al., 2004, Beskow et al., 
2006, Whiffin et al., 2014).  Of all subjects invited to the study, 44% agreed to 
participate and 36.5% returned a saliva sample.  This is consistent with similar studies 
where response rates ranged from 21–72% and sample return rates ranged from 12 
– 41% (Bhutta et al., 2013). 
 
We found that saliva samples were more likely to be returned by patients who had 
undergone revision surgery compared with those having undergone primary 
arthroplasty.  It is unclear whether this is because they had undergone surgery more 
recently or whether they were more likely to participate in view of the increased 
medical contact received. We found that response rates were higher in men than 
women.  This contradicts much of the literature which states that women are usually 
more likely to participate in scientific studies (Galea and Tracy, 2007).  Nishista et al 
found no difference in response rates between men and women in their saliva 
collection for a large genetic study (Nishista, 2009).   
 
We found that postal collection of saliva samples is an effective, non-invasive and 
convenient method of establishing a DNA biobank for an arthroplasty registry. Our 
findings echo those of other studies that DNA yields from saliva are adequate for high 
throughput genotyping (Ng, 2005, Rylander-Rudqvist et al., 2006, Rogers et al., 2007, 
Nishista, 2009).  We found that the DNA yield varies greatly between saliva samples, 
ranging from 0.0µg to 1260µg.  The median yield of 52.1µg from our samples were 
higher than that achieved by other epidemiological studies using the Oragene saliva 
kit (Rylander-Rudqvist et al., 2006, Quinque et al., 2006, Ng, 2005, Hansen et al., 
2007).  Although this DNA yield was comparable to other studies we found it was lower 
than that achieved in our Sheffield postal recruitment subjects.  There are a number 
155 
 
of possible contributors:  1. Extraction for the majority of Norway samples was 
undertaken by another individual; 2. Extraction was undertaken in larger batches in 
the Norway samples and therefore the amount of time scraping excess DNA adherent 
to the inside Falcon tube walls may have been less; 3. The Sheffield samples were 
extracted as soon as they were received whereas the Norway samples were stored 
for a longer period prior to extraction; 4. Some of the Norway samples were stored at 
-20oC prior to DNA extraction whereas all Sheffield samples were stored at room 
temperature.  Twenty-five percent of saliva samples yielded a concentration of less 
than the 30ng/µL required for GWAS genotyping.  This is a comparable percentage to 
that achieved by Rylander–Rudqvist et al (Rylander-Rudqvist et al., 2006). 
 
One of the potential limitations of using saliva as a source of DNA is the bacterial DNA 
content.  Although we did not evaluate the bacterial DNA concentration in our samples 
we found those darker in colour, and therefore assumed contaminated, had higher 
DNA yields.  This may represent a higher contribution by bacterial DNA.   We recently 
measured the bacterial DNA quantity in a separate cohort using the same Oragene 
collection kit.  The median percentage of bacterial DNA was 17% which is comparable 
to other studies using the Oragene kit (Rylander-Rudqvist et al., 2006, Nishista, 2009) 
and within the range of 2 – 29% quoted by the manufacturer (Chartier and Birnboim, 
2005). 
 
We found that saliva volume positively correlated with an increase in DNA yield.  
Nishista et al also found that a larger saliva volumes provided larger DNA yields 
(Nishista, 2009). Patients who had initially provided low DNA yield samples were 
contacted to provide a repeat sample.  We found that the mean DNA yield in these 
duplicate samples was higher with a resultant 65% adequate for high throughput 
genotyping.  This suggests that re-contacting such patients with an explanation is 
worthwhile as they are likely to provide a better quality sample.   
 
DNA Genotek Inc. recommends saliva samples should be stored at room temperature 
prior to extraction.  We found that storage of saliva samples at -20oC was associated 
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with a lower DNA yield. This was similar to findings by Ng et al who also found that 
freezer storage of saliva prior to processing was associated with reduced DNA yield 
(Ng, 2005).  This may be due to DNA degradation as a result of freeze-thawing (Grecz 
et al., 1980).  Following extraction long term storage of DNA was at -80oC.  Isolated 
DNA may be stored at -20oC for several months and -80oC for years (Holland et al., 
2003). An EU workshop for Biobanks has recommended that DNA samples are frozen 
to prevent bacterial growth and reduce risk of sample loss through evaporation 
(EU_Workshop, 2003). The UK Biobank recommends storing samples at -20oC to 
inhibit nucleases (UK Biobank 2004).   A study by Smith et al comparing optimal 
storage conditions found that the highest quantity of DNA remained in the samples 
stored at -80oC (Smith and Morin, 2005).  DNA Genotek advise that Oragene DNA 
samples can be freeze-thawed 3 times without evidence of DNA degradation 
(www.dnagenotek.com). 
  
In conclusion, this study highlights the possible extended role of arthroplasty registries 
for the large-scale recruitment of subjects that may have particular value in diseases 
that are rare, or where very large numbers are needed because of small gene effect 
sizes.  Postal recruitment of subjects identified using a national joint registry achieves 
reasonable response rates.  Self-collection saliva samples received by mail provide 
DNA samples with adequate yield for high throughput genotyping and are therefore 
suitable for the establishment of a registry biobank.  Although the majority of DNA 
extracted from saliva is suitable for whole genome analysis, our study suggests that 
about a quarter of samples will not yield sufficient DNA for genome wide genotyping, 
but may be used for replication analyses using other genotyping technologies, such 
as KASPar.  This should be considered when planning recruitment for epidemiological 
studies using saliva as a source of DNA. 
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CHAPTER 7 
A GENOME-WIDE ASSOCIATION STUDY OF OSTEOLYSIS 
FOLLOWING TOTAL HIP ARTHROPLASTY 
 
7.1 Overview 
 
This chapter describes a GWAS of peri-prosthetic osteolysis susceptibility and time to 
prosthesis failure following THA followed by a replication study and meta-analysis.  
Individuals vary in their susceptibility to osteolysis, and it is thought that genetic 
polymorphism contributes to this variation. To date, our knowledge of this genetic 
contribution has been based on candidate gene studies.  We carried out whole 
genome association analysis in a discovery cohort recruited form the UK.  Osteolysis 
susceptibility case-control analysis and a QTL analysis for time to prosthesis failure 
was undertaken.  Index SNPs from signals with p<9x10-5, were taken forward for 
replication in a separate cohort recruited from the Norwegian Arthroplasty Registry.  
Association analyses were carried out and a meta-analysis of the 2 datasets was 
undertaken.  
 
We identified a several associating signals in both discovery analyses.  The most 
significant signal associated with osteolysis susceptibility lay within CAMK4 (index 
SNP rs306105, p=6.54x10-7) and approached genome wide significance. The most 
significant signal associated with time to prosthesis failure lay within DEFB129 
(rs6105394, p=5.75x10-7) but this signal failed to replicate.  Following meta-analysis, 
the most significant signal in the susceptibility analysis remained that within CAMK4 
(rs306105, p = 3.79x10-4). We have identified some possible risk loci for susceptibility 
to osteolysis with nominal replication in genes that are involved in the regulation of 
immune signalling and bone turnover and forms.  
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7.2 Introduction 
 
Association between genetic variation and susceptibility to periprosthetic osteolysis 
was first identified at the promoter region of the gene encoding tumour necrosis factor 
(TNF) (Wilkinson, 2003).  Subsequently, several investigators have since identified 
associations between SNPs in pro-inflammatory cytokines and bone turnover 
pathways and osteolysis susceptibility (Ambruzova Z, 2006, Gordon A et al., 2008, 
Kolundzic et al., 2006, Gallo, 2009, Malik, 2007, Gordon A et al., 2007, Malik MH et 
al., 2007, Malik MH et al., 2006, MacInnes et al., 2014).  To date, our knowledge of 
the genetics of osteolysis has been based entirely on these candidate gene studies, 
and the only association that has been independently replicated is that found at the 
TNF promoter (Wilkinson, 2003, Gallo and Petrek, 2009).  
 
Candidate gene studies are dependent on a priori knowledge and our limited 
understanding of the pathogenesis of osteolysis has the potential to result in a 
bottleneck in investigation.  Advances in high throughput genotyping together and 
haplotype datasets allows us to now undertake whole genome scanning using a 
hypothesis-free approach.  There have been no systematic studies of the genetic 
architecture of osteolysis at genome-wide level.  We conducted a genome-wide case-
control association study (GWAS) in patients following THA with the aim of identifying 
genetic loci associated with osteolysis susceptibility and time to prosthesis failure. 
Association signals were followed up by replication in independent patient sets.  
 
7.3 Methods 
 
7.3.1 Study Populations 
 
The discovery cohort comprised 894 men and women (317 with osteolysis) as 
described in chapter 3.  Five hundred and fifty-three (217 with osteolysis) were 
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recruited locally between April 2000 and April 2006 as part of a series of case-control 
candidate gene studies, 108 (68 with osteolysis) were recruited locally from Sheffield 
Teaching Hospitals between July 2011 and January 2012,  114 (14 with osteolysis) 
were recruited from the UK between April 2008 and August 2010 as part of the 
arcOGEN study, and 119 (37 with osteolysis) were recruited from the North West of 
England between 2002 and 2004 as part of a separate osteolysis candidate gene 
study (Malik MH et al., 2006).  The replication cohort comprised 2,660 men and women 
(783 with osteolysis) recruited from the Norwegian Arthroplasty Register, as described 
in the previous chapter.  Note that this number is greater than that shown in figure 6.3.  
The reason for this is that the final number of 2,335 stated in the previous chapter 
describes samples suitable for GWAS genotyping.  The 2,660 comprising the 
replication cohort in this study were from the same pool of 3,056 but were suitable for 
sequenom genotyping hence the discrepancy in numbers. 
 
7.3.2 Phenotype Characterisation 
 
Discovery cohort phenotype characterisation is described in section 2.5.  Briefly, all 
subjects in the discovery cohort had undergone either cemented or hybrid THA with a 
metal on polyethylene bearing couple for primary osteoarthritis.  Exclusions are 
outlined in section 3.2.2.  Subjects who were of non-UK European ancestry were also 
excluded.  Cases comprised subjects with radiographic evidence of either femoral or 
acetabular osteolysis, as described previously (Gordon A et al., 2007). The control 
group comprised subjects who had received a primary THA not less than 7 years 
previously, were asymptomatic and had no radiographic evidence of osteolysis at the 
time of recruitment.  Polyethylene wear measurements were made using EBRA 
(University of Innsbruck, Austria) software in patients with available radiographs, as 
described in section 2.7, and used as a covariate in the association analyses. Six 
hundred and five subjects had available radiographs suitable for wear measurements.   
 
Patients in the replication cohort had previously undergone primary cemented or 
hybrid (cemented femur) THA for idiopathic osteoarthritis.  Phenotype characterisation 
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and inclusion criteria have been described in detail in section 6.4 The recruitment 
strategy, described in section 6.4, was planned to minimize confounders between the 
cases and controls.  
 
7.3.3 Genotyping and Association Analyses 
Genomic DNA from subjects in the discovery cohort was extracted from either whole 
blood or saliva and genotyped using the Illumina 610k beadchip (Illumina, San Diego, 
CA).  We undertook quality control checks at sample and SNP level described earlier 
in chapter 2.8.3.  Samples identified by genotype to be from individuals of non-UK 
European ancestry were excluded from association analyses. SNP QC was carried 
out on autosomal SNPs.  SNPs were excluded if they had a minor allele frequency 
(MAF) ≥5% and a call rate <95%, or a MAF <5% and call rate <99%.  SNPs with Hardy 
Weinberg Equilibrium (HWE) p<0.0001 were excluded. Following QC, we imputed the 
GWAS dataset using the European reference panel from the 1000 Genomes Project 
(Dec 2010 phase I interim release) (1000 Genomes consortium et al, 2010), and using 
IMPUTE2 (Marchini et al., 2007).  
 
Osteolysis susceptibility case-control analysis and a quantitative trait locus (QTL) 
association analysis for time to prosthesis failure was undertaken on >10 million 
variants under the additive model using method score implemented in SNPTESTv2.   
Phenotype data was normalised where required and we performed a linear regression 
to adjust for age, gender, fixation method, osteolysis-free survival time and 
polyethylene wear. Residuals were then transformed to z-scores.  Index SNPs from 
signals with p<9x10-5 were prioritised for replication.  Genotype-calling intensity plots 
were examined and SNPs with poorly clustering plots were not taken forward. Only 
associating SNPs with an imputation information score >0.4 and a minor allele 
frequency (MAF) >0.05 were progressed for the replication association analyses. 
 
DNA from subjects in the replication cohort was extracted from saliva and genotyping 
was carried out using the Sequenom MassARRAY iPLEX assay (Agena Bioscience 
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Inc, Hamburg, Germany).  Samples failing gender check or with call rate <80% were 
excluded.  SNPs were removed if their call rate was <80% or with HWE p<10-4. 
Association analyses were undertaken using logistic regression in PLINK v1.07. Z-
standardized residuals were generated on phenotype data requiring normalization and 
regressed on age, gender, implant type, fixation method and osteolysis-free survival 
time.  Summary statistics from both stages were combined and meta-analysed using 
a fixed-effects model implemented in GWAMA v2.1. (Magi and Morris, 2010). 
 
7.3.4 Sensitivity analyses 
 
The effect of including polyethylene wear as an analysis covariate on the findings in 
the discovery analyses was assessed by repeating these analyses for the prioritized 
SNPs and excluding polyethylene wear as an analysis covariate to observe its effect 
on the resultant P-value. Both the case-control susceptibility and time to failure 
analyses were repeated without using polyethylene wear as an analysis covariate, and 
the amount of overlap of SNP selection between the analysis approaches was 
compared. 
7.4 Results 
 
In both the discovery and replication cohorts, subjects in the osteolysis group were 
younger, and a greater proportion were males when compared with the control group, 
although the differences were smaller in the replication cohort because of the covariate 
minimisation strategy.  In the discovery cohort, annual polyethylene wear rate was 
greater in the osteolysis group versus the control group (table 7.1).  These findings 
are consistent with known risk factors associated with osteolysis, and were adjusted 
for in subsequent analyses.  The distribution of fully cemented and hybrid prostheses 
in each cohort is outlined in table 7.2. 
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Table 7.1 Patient characteristics for discovery and replication cohorts 
 
 
Discovery cohort 
  
Characteristics Control Group Osteolysis Group P value 
 
n = 577 n = 317 
 
Age at THA 
(years+SD) 
65.8+8 60.5+8 <0.0001 
Sex (male/female) 228/349 174/143 0.01 
Osteolysis free 
survival (years+SD) 
10.8+6 9.8+5 0.05 
Polyethylene wear 
(mm/year) 
0.08 (0.04 to 0.13) 0.14 (0.08 to 0.24) <0.001 
Replication Cohort 
Characteristics Control Group Osteolysis Group P value 
 
n = 1877 n = 783 
 
Age at THA 
(years+SD) 
65.7+7.1 64.3+6.9 <0.0001 
Sex (male/female) 739/1138 342/441 0.039 
Osteolysis free 
survival (years+SD) 
13.8+5.4 8.6+4.95 <0.0001 
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Discovery Cohort 
 Controls Controls (%) Cases Cases (%) 
Fully cemented THA 466 80.8 291 91.8 
Hybrid THA 111 19.2 26 8.2 
Replication Cohort 
 Controls Controls (%) Cases Cases (%) 
Fully cemented THA 1771 94.4 727 92.8 
Hybrid THA 106 5.6 56 7.2 
 
Table 7.2 Distribution of fully cemented and hybrid prostheses 
 
 
 
7.4.1 Osteolysis Susceptibility 
 
In the discovery analysis we identified 20 independent signals that were associated 
with osteolysis susceptibility (Figure 7.1A and 7.1B, and Table 7.3) at p<9.9x10-5. One 
signal approached genome-wide significance: variant rs306105 lies within intron 1 of 
CAMK4 (effect allele C, EAF 91%, OR 0.4, 95% CI 0.28 to 0.62, p=6.54x10-7, Figure 
7.2. 
 
These 20 independent signals were prioritised for replication through de-novo 
genotyping in the Norwegian cohort. At replication, one variant, within FGL1, showed 
evidence for nominally significant association with the same direction of effect as the 
discovery cohort: rs28603021 (effect allele T, OR 0.86, 95% CI 0.73 to 1.00, p = 0.05). 
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Following meta-analysis no signals approached the genome-wide significance 
threshold of p≤5x10-8 (Table 7.4).  The most significant signal remained that within 
CAMK4 (rs306105, allele C, OR=0.7, 95% CI=0.59 to 0.86, p = 3.75x10-4) and was 
followed by the nominally replicating variant rs28603021 (allele T, OR 0.79, 95% CI 
0.69 to 0.89, p = 3.78x10-4) in FGL1.   
 
 
 
Figure 7.1A. Manhattan Plot for osteolysis susceptibility discovery analysis. The p-
value is denoted on the y-axis and the chromosome position on the x-axis.  Linear 
peaks within each chromosome represent signals consisting of clusters of SNPs.  
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Figure 7.1B. 
QQ plot for osteolysis susceptibility discovery analysis.  The expected p-value is 
indicated by the grey line and the black dots indicate the observed p-values. 
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MARKER EA NEA EAF OR 95% CI P-value 
rs306105* C A 0.911 0.415 0.278 to 0.619 6.54E-07 
rs11119057 A G 0.278 0.541 0.419 to 0.699 2.06E-06 
rs9445504 A C 0.084 2.621 1.738 to 3.951 2.64E-06 
rs28603021* T C 0.704 0.621 0.482 to 0.802 3.35E-06 
rs10145023 T C 0.202 1.869 1.405 to 2.488 5.18E-06 
rs10055976 A G 0.059 2.939 1.767 to 5.035 7.82E-06 
rs7004096 A C 0.080 0.351 0.203 to 0.609 2.25E-05 
rs37476 A G 0.913 0.445 0.297 to 0.666 2.44E-05 
rs12810375 A G 0.137 0.483 0.327 to 0.713 3.22E-05 
rs9435429 G A 0.647 1.597 1.236 to 2.063 3.38E-05 
rs2160505 A C 0.393 0.641 0.500 to 0.822 3.66E-05 
rs3736279 C T 0.146 1.699 1.227 to 2.343 4.34E-05 
rs4143629 G A 0.231 1.731 1.317 to 2.276 6.06E-05 
rs1008727 T G 0.396 1.612 1.267 to 2.051 6.58E-05 
rs9527681 A C 0.472 0.591 0.464 to 0.753 7.25E-05 
rs4775378 G A 0.637 1.513 1.175 to 1.948 7.94E-05 
rs4301763 C T 0.059 0.406 0.220 to 0.750 7.96E-05 
rs7153101 T G 0.705 1.444 1.105 to 1.887 8.64E-05 
rs1891632 A G 0.131 1.813 1.293 to 2.542 8.79E-05 
rs2834401 T G 0.621 0.638 0.500 to 0.814 9.38E-05 
 
Table 7.3.  Results of the osteolysis susceptibility discovery analysis for all 
independent signals with p<9.9x10-5 taken forward for replication.  EA = affect allele, 
NEA = non affect allele; OR = odds ratio, 95% CI = 95% confidence interval, *imputed 
variants, all other variants directly typed. 
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Figure 7. 2.  Regional association plot for rs306105 (that lies within CAMK4) from the 
osteolysis susceptibility discovery analysis.  The index SNP is denoted by the purple 
marker.  The colour reflects the pairwise r2 with index SNP.  The region extends 500kb 
upstream and downstream of the index SNP. 
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Stage  rs_number EA NEA EAF OR 95% CI p-value Direction 
of effects 
Gene 
1 rs306105 C A 0.911 0.414 0.278 to 0.619 6.54E-07 
  
2 rs306105 C A 0.896 0.828 0.668 to 1.025 0.08 
  
MA rs306105 C A 
 
0.710 0.588 to 0.857 3.74E-04 -  - CAMK4  
1 rs28603021 T C 0.704 0.622 0.482 to 0.802 3.35E-06    
 
2 rs28603021 T C 0.693 0.859 0.739 to 1.000 0.05 
  
MA rs28603021 T C 
 
0.790 0.693 to 0.899 3.75E-04 -  - FGL1 
1 rs2834401 T G 0.621 0.638 0.500 to 0.814 9.38E-05 
  
2 rs2834401 T G 0.658 0.874 0.756 to 1.010 0.068 
  
MA rs2834401 T G 
 
0.805 0.711 to 0.912 6.42E-04 -  - LINC00310 
 
Table 7.4.  Results of the osteolysis susceptibility meta-analysis showing signals with 
concordant direction of effect and p<9.9x10-4. EA = affect allele, NEA = non affect 
allele, EAF = effect allele frequency, OR = odds ratio, 95% CI = 95% confidence 
interval, Direction of effects = allele effect direction. 
 
7.4.2 Time to Prosthesis Failure 
 
Genome-wide analysis in the discovery cohort identified 21 independent signals that 
were associated with time to prosthesis failure in the osteolysis cases at p<9x10-5 
(figure 7.3A and 7.3B, Table 7.5). The most significantly associated variant lay 2kb 
downstream from the DEFB129 gene and approached genome wide significance 
(rs6105394, effect allele T, EAF 7%, beta 1.21, SE 0.24, p=5.75x10-7, Figure 7. 4).  
 
Twenty-one independent signals were prioritized for replication through de-novo 
genotyping in the Norwegian cohort. None of these variants showed evidence for 
nominally significant association in the replication cohort.  Following meta-analysis, no 
signals approached the genome-wide significance threshold of p≤5x10-8 and no 
signals showed an increase in nominal significance. 
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Figure 7.3A.  Manhattan Plot for QTL time to prosthesis failure discovery analysis.  
The p-value is denoted on the y-axis and the chromosome position on the x-axis.  
Linear peaks within each chromosome represent signals consisting of clusters of 
SNPs. 
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Figure 7.3B.  QQ plot for QTL time to prosthesis failure discovery analysis.  The 
expected p-value is indicated by the grey line and the black dots indicate the observed 
p-values. 
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MARKER EA NEA EAF BETA SE P-value 
rs6105394* T C 0.072 1.217 0.243 5.75E-07 
rs6754629 C T 0.402 0.494 0.106 2.95E-06 
rs755423* G C 0.909 -0.770 0.176 1.20E-05 
rs702620 T C 0.768 -0.528 0.121 1.27E-05 
rs155109* G A 0.312 0.465 0.107 1.47E-05 
rs1449413 G T 0.356 -0.428 0.099 1.54E-05 
rs4493711 A G 0.153 -0.522 0.122 1.97E-05 
rs9903651 T C 0.773 0.476 0.113 2.61E-05 
rs2029288 A C 0.675 -0.421 0.101 3.07E-05 
rs1499232 C T 0.726 -0.461 0.112 3.67E-05 
rs11904654 G T 0.146 0.554 0.134 3.70E-05 
rs6118046 T C 0.180 0.520 0.126 3.78E-05 
rs10430747 A G 0.701 0.419 0.102 3.80E-05 
rs17099320 G A 0.115 0.657 0.160 3.94E-05 
rs1887063 C A 0.567 0.413 0.102 4.94E-05 
rs6110749* G A 0.080 0.908 0.224 5.41E-05 
rs9929066 A G 0.094 -0.674 0.167 5.52E-05 
rs10924771 A G 0.639 0.417 0.104 6.02E-05 
rs9313886 C T 0.306 0.410 0.104 8.43E-05 
rs2196565* C A 0.176 0.521 0.133 8.66E-05 
rs11686724 A G 0.196 0.471 0.121 9.94E-05 
 
Table 7.5 Results of the QTL time to prosthesis failure discovery analysis.  This table 
includes all SNPs with p<9.9x10-5 taken forward for replication.  EA = affect allele, 
NEA = non affect allele; OR = odds ratio; SE = standard error, *imputed variant, all 
other variants directly typed.  rs6105394 was not taken forward for replication due to 
assay design issues. 
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Figure 7.4.  Regional association plot for rs6105394 from discovery QTL analysis time 
to prosthesis failure.  The index SNP is denoted by the purple marker.  The colour 
reflects the pairwise r2 with index SNP.  The region extends 500kb upstream and 
downstream of the index SNP. 
 
 
7.4.3 Sensitivity analyses 
 
When the case-control osteolysis susceptibility analysis for all signals with p<9.9 x10-
5 was repeated without wear as a covariate, all 20 SNPs showed the same direction 
of effect, albeit with varying ORs, and all showed a p-value that was at least nominally 
significant (Table 7.6). Only 4 signals retained a p-value <9.9 x 10-5. Conversely, when 
the same association analysis was repeated across all discovery SNPs without wear 
as an analysis covariate, 25 independent SNPs with p<9.9 x 10-5 were identified (Table 
7.7), and all showed the same direction of effect and nominal significance when the 
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analysis was conducted using wear as an analysis covariate. Again, only 4 SNPs from 
this set showed significance at P<9.9 x 10-5 for both with and without wear analyses.   
 
When the time to prosthesis failure QTL analysis for all signals with p<9.9 x10-5 was 
repeated without wear as a covariate all 21 SNPs showed the same direction of effect, 
and all except one showed a p-value that was at least nominally significant (Table 7.8). 
Only 2 signals retained a p-value <9.9 x 10-5. Conversely, when the same association 
analysis was repeated across all discovery SNPs without wear as an analysis 
covariate, 20 independent SNPs with p<9.9 x 10-5 were identified (Table 7.9).  All 
showed the same direction of effect and all except one showed nominal significance 
when the analysis was conducted using wear as an analysis covariate. Again, only 2 
SNP from this set showed significance at P<9.9 x 10-5 for both with and without wear 
analyses.   
 
In addition, we undertook replication and meta-analyses for those signals identified 
without wear as a covariate.  We failed to replicate any signals in the case-control 
analysis.  Two variants showed evidence for nominally significant association with the 
same direction of effect as the discovery cohort in the time to prosthesis failure 
analysis: rs12550574 (allele A, beta -0.16, SE 0.07, p = 0.019) which lies 49kbp 
downstream of DOK2; and rs1374879 (allele C, beta 0.175, SE 0.08, p = 0.035) within 
an intronic region of CNTN3. Following meta-analysis no signals approached the 
genome-wide significance threshold of p≤5x10-8.  The strongest signal associated with 
time to failure was the replicating variant rs1374879 (allele C, beta 0.29, SE 0.07, 
p=2.15x10-5) within CNTN3 and was followed by the replicating variant rs12550574 
(allele A, beta - 0.24, SE 0.06, p = 1.29 x10-4) which lies 49kbp downstream of DOK2. 
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 With wear analysis Without wear analysis 
MARKER EA NEA OR 95% CI P-value OR 95% CI P-value 
rs306105 C A 0.415 0.278 to 0.619 6.54E-07 0.510 0.366 to 0.711 3.87E-06 
rs11119057 A G 0.541 0.419 to 0.699 2.06E-06 0.607 0.493 to 0.746 6.44E-07 
rs9445504 A C 2.621 1.738 to 3.952 2.64E-06 2.063 1.492 to 2.852 1.13E-05 
rs28603021 T C 0.622 0.482 to 0.802 3.35E-06 0.650 0.528 to 0.800 4.47E-06 
rs10145023 T C 1.869 1.405 to 2.488 5.18E-06 1.498 1.179 to 1.904 0.0007 
rs10055976 A G 2.939 1.767 to 5.034 7.82E-06 1.843 1.241 to 2.737 0.004 
rs7004096 A C 0.351 0.203 to 0.609 2.25E-05 0.587 0.395 to 0.873 0.002 
rs37476 A G 0.445 0.297 to 0.665 2.44E-05 0.592 0.425 to 0.825 0.01 
rs12810375 A G 0.483 0.327 to 0.713 3.22E-05 0.630 0.467 to 0.852 0.003 
rs9435429 G A 1.597 1.236 to 2.063 3.38E-05 1.351 1.099 to 1.661 0.0006 
rs2160505 A C 0.641 0.500 to 0.822 3.66E-05 0.718 0.588 to 0.876 0.0004 
rs3736279 C T 1.696 1.227 to 2.343 4.34E-05 1.377 1.055 to 1.798 0.002 
rs4143629 G A 1.731 1.317 to 2.276 6.06E-05 1.438 1.151 to 1.798 0.0002 
rs1008727 T G 1.612 1.267 to 2.051 6.58E-05 1.331 1.092 to 1.622 0.005 
rs9527681 A C 0.591 0.464 to 0.753 7.25E-05 0.696 0.572 to 0.846 0.001 
rs4775378 G A 1.513 1.175 to 1.948 7.94E-05 1.306 1.066 to 1.599 0.006 
rs4301763 C T 0.406 0.220 to 0.750 7.96E-05 0.570 0.359 to 0.905 0.002 
rs7153101 T G 1.444 1.105 to 1.887 8.64E-05 1.311 1.055 to 1.629 0.001 
rs1891632 A G 1.813 1.293 to 2.542 8.79E-05 1.613 1.217 to 2.139 0.0005 
rs2834401 T G 0.638 0.500 to 0.814 9.38E-05 0.708 0.579 to 0.865 0.0002 
 
Table 7.6 This table outlines the SNPs identified in the case-control analysis with 
p<9.9x10-5 comparing results when analysis with versus without wear rate as a 
covariate.    EA = affect allele, NEA = non affect allele; OR = odds ratio; 95% CI = 95% 
confidence interval. 
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 Without wear analysis With wear analysis 
MARKER EA NEA OR 95% CI P-value OR 95% CI P-value 
rs11119057 A G 0.607 0.493 to 0.746 6.44E-07 0.541 0.416 to 0.699 2.06E-06 
rs306105 C A 0.510 0.366 to 0.711 3.87E-06 0.415 0.278 to 0.619 6.54E-07 
rs28603021 T C 0.650 0.528 to 0.800 4.47E-06 0.622 0.482 to 0.802 3.35E-06 
rs7973861 C A 1.847 1.414 to 2.413 4.59E-06 1.612 1.170 to 2.222 6.88E-03 
rs4361192 C T 2.119 1.540 to 2.915 5.45E-06 1.892 1.291 to 2.774 0.008 
rs9445504 A C 2.063 1.492 to 2.852 1.13E-05 2.621 1.738 to 3.952 2.64E-06 
rs11600347 A C 0.491 0.327 to 0.736 1.60E-05 0.424 0.256 to 0.700 0.0005 
rs1945691 A G 1.524 1.197 to 1.942 2.43E-05 1.572 1.174 to 2.106 0.0008 
rs6435067 C T 1.584 1.253 to 2.003 2.69E-05 1.507 1.130 to 2.010 0.008 
rs11686261 T C 0.631 0.518 to 0.769 2.87E-05 0.631 0.496 to 0.802 0.002 
rs12640141 G A 1.617 1.256 to 2.080 2.93E-05 1.739 1.278 to 2.366 0.001 
rs10495929 A G 0.592 0.443 to 0.789 3.79E-05 0.610 0.433 to 0.860 0.003 
rs4659764 G A 1.503 1.228 to 1.839 3.92E-05 1.419 1.108 to 1.817 0.003 
rs595298 A G 1.368 1.125 to 1.662 3.99E-05 1.492 1.175 to 1.894 0.0001 
rs2481952 T C 0.698 0.574 to 0.848 4.53E-05 0.611 0.481 to 0.775 0.0002 
rs4680029 T G 0.425 0.271 to 0.666 4.57E-05 0.406 0.240 to 0.687 0.003 
rs822872 A G 0.729 0.592 to 0.897 4.63E-05 0.689 0.535 to 0.888 0.001 
rs10272623 G A 1.729 1.265 to 2.364 4.71E-05 1.616 1.098 to 2.379 0.03 
rs644396 C T 0.668 0.549 to 0.813 6.25E-05 0.699 0.550 to 0.888 0.004 
rs11595566 A G 1.675 1.255 to 2.236 6.71E-05 1.825 1.282 to 2.598 0.001 
rs6065414 G T 0.683 0.552 to 0.844 6.86E-05 0.674 0.518 to 0.875 0.002 
rs10779685 C T 1.521 1.170 to 1.978 7.28E-05 1.589 1.164 to 2.168 0.0006 
rs6441583 G A 0.597 0.454 to 0.783 7.79E-05 0.591 0.426 to 0.820 0.01 
rs11039359 C T 0.426 0.267 to 0.680 8.47E-05 0.445 0.254 to 0.780 0.007 
rs6487867 A G 0.658 0.535 to 0.809 9.14E-05 0.689 0.536 to 0.885 0.002 
 
Table 7.7 This table outlines the SNPs identified (p<9.9x10-5) in the case-control 
analysis without wear as a covariate and compares results with analysis with wear rate 
included as a covariate.    EA = affect allele, NEA = non affect allele; OR = odds ratio; 
95% CI = 95% confidence interval. 
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 With wear analysis Without wear analysis 
MARKER EA NEA BETA SE P-value BETA SE P-value 
rs6105394 T C 1.217 0.243 5.75E-07 0.554 0.179 0.002 
rs6754629 C T 0.494 0.106 2.95E-06 0.275 0.085 0.001 
rs755423 G C -0.770 0.176 1.20E-05 -0.404 0.132 0.002 
rs702620 T C -0.528 0.121 1.27E-05 -0.388 0.101 0.0001 
rs155109 G A 0.465 0.107 1.47E-05 0.193 0.084 0.02 
rs1449413 G T -0.428 0.099 1.54E-05 -0.290 0.083 0.0005 
rs4493711 A G -0.522 0.122 1.97E-05 -0.255 0.100 0.01 
rs9903651 T C 0.476 0.113 2.61E-05 0.302 0.091 0.001 
rs2029288 A C -0.421 0.101 3.07E-05 -0.367 0.085 1.67E-05 
rs1499232 C T -0.461 0.112 3.67E-05 -0.225 0.087 0.01 
rs11904654 G T 0.554 0.134 3.70E-05 0.305 0.112 0.006 
rs6118046 T C 0.520 0.126 3.78E-05 0.456 0.111 4.09E-05 
rs10430747 A G 0.419 0.102 3.80E-05 0.257 0.083 0.002 
rs17099320 G A 0.657 0.160 3.94E-05 0.486 0.131 0.0002 
rs1887063 C A 0.413 0.102 4.94E-05 0.070 0.082 0.4 
rs6110749 G A 0.905 0.224 5.41E-05 0.468 0.162 0.004 
rs9929066 A G -0.674 0.167 5.52E-05 -0.457 0.137 0.0008 
rs10924771 A G 0.417 0.104 6.02E-05 0.258 0.084 0.002 
rs9313886 C T 0.410 0.104 8.43E-05 0.229 0.080 0.004 
rs2196565 C A 0.521 0.133 8.66E-05 0.269 0.109 0.01 
rs11686724 A G 0.471 0.121 9.94E-05 0.219 0.096 0.02 
 
Table 7.8 This table outlines the SNPs identified in the time to failure QTL analysis 
with p<9.9x10-5 and compares results when analysis with versus without wear rate as 
a covariate.    EA = affect allele, NEA = non affect allele; OR = odds ratio; SE = 
standard error. 
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 Without wear analysis With wear analysis 
MARKER EA NEA BETA SE P-value BETA SE P-value 
rs4394754 C T 0.438 0.094 3.08E-06 0.278 0.119 0.02 
rs284486 A G -0.383 0.083 4.28E-06 -0.363 0.103 0.0004 
rs10764837 A G 0.348 0.078 8.41E-06 0.228 0.097 0.02 
rs1374879 C T 0.533 0.120 9.50E-06 0.331 0.144 0.02 
rs6808795 A G -0.351 0.080 1.18E-05 -0.280 0.096 0.003 
rs2029288 A C -0.367 0.085 1.67E-05 -0.421 0.101 3.07E-05 
rs2144456 A G 0.321 0.075 2.03E-05 0.235 0.0907 0.01 
rs2113590 C T 0.773 0.187 3.48E-05 0.595 0.207 0.004 
rs7931608 T C 0.326 0.0791 3.83E-05 0.343 0.098 0.0005 
rs6118046 T C 0.456 0.111 4.09E-05 0.520 0.126 3.78E-05 
rs9783205 C A -0.405 0.099 4.49E-05 -0.338 0.124 0.006 
rs9371581 A G 0.315 0.078 5.90E-05 0.333 0.097 0.0006 
rs304343 C T 0.581 0.145 6.14E-05 0.158 0.179 0.4 
rs11790630 T C -0.373 0.093 6.71E-05 -0.269 0.120 0.03 
rs9870957 C A 0.329 0.083 7.16E-05 0.250 0.102 0.01 
rs749763 G A 0.324 0.082 7.25E-05 0.310 0.099 0.002 
rs7985101 C A 0.341 0.086 7.56E-05 0.329 0.104 0.002 
rs11137472 G A 0.413 0.105 8.90E-05 0.389 0.128 0.002 
rs3766923 G T -0.345 0.088 9.31E-05 -0.336 0.110 0.002 
rs12027243 T C -0.326 0.084 9.67E-05 -0.380 0.101 0.0002 
 
Table 7.9 This table outlines the SNPs identified (p<9.9x10-5) in the time to failure QTL 
analysis without wear as a covariate and compares results with analysis with wear rate 
included as a covariate.    EA = affect allele, NEA = non affect allele; OR = odds ratio; 
SE = standard error. 
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7.5 Discussion 
 
We conducted a genome-wide scan and replication study in an independent 
population in order to identify susceptibility loci for osteolysis after THA, and 
susceptibility loci for time to failure in osteolysis cases. We have identified possible 
associations for osteolysis susceptibility within CAMK4 and FGL1, but no replicating 
evidence for association with time to prosthesis failure. 
  
We undertook a sensitivity analysis to determine the impact of using polyethylene wear 
rates as an analysis covariate. We found that although all initially significant SNPs 
showed the same effect direction and almost all retained nominal significance only 
14% of SNPs retained significance at P<9.9 x 10-5 when wear was excluded as an 
analysis covariate.  When the association analyses were conducted de-novo without 
wear as a covariate we found that the majority of signals at P<9.9 x 10-5 were different 
to those identified when wear was included as a covariate.  There was an overlap of 
only 5 signals in the case control analysis and 2 signals in the time to prosthesis 
analysis at P<9.9 x 10-5.  For the SNPs which showed significance at P<9.9 x 10-5 for 
both with and without wear analyses the p-values were more commonly stronger in 
the with wear analyses.  Interestingly, when we carried out replication analyses in the 
signals identified without using wear as a covariate we found 3 replicating signals.  
Two of these were within or in the flanking region of plausible gene candidates.  From 
these analyses it remains unclear whether adjustment for polyethylene wear, when 
available, is the most effective strategy for genomic discovery.  Polyethylene wear rate 
is an important risk factor for osteolysis as demonstrated by stronger association of 
overlapping discovery signals, however the increase in study numbers achieved by 
not using wear rate as a covariate may be equally important.  Further study will be 
required to clarify this.   
 
CAMK4 resides on chromosome 5, and encodes the calmodulin-dependent protein 
kinase 4 enzyme, which a member of the serine/threonine protein kinase family.  This 
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enzyme has been implicated in transcriptional regulation of mature T cells and 
neutrophils (Lawson et al., 1999, Wang et al., 2001, Kitsos et al., 2005). Calmodulin 
signalling has been strongly implicated in osteoclastogenesis, both as an activator of 
receptor activator of nuclear factor-κb ligand RANK-L through AP-1 transcription 
factors and as a downstream regulator following RANK-L stimulation through nuclear 
factor of activated T cells (NFAT) transcription factors (Seales et al., 2006).  Sato et al 
showed that the CAMK4-CREB pathway was crucial in osteoclastic bone resorption 
through NFAT induction and regulation (Sato et al., 2006).  They also showed that 
CAMK4-/- mice have increased bone density compared to wild types and reduced bone 
erosion when subjected to a lipopolysaccharide (LPS) model of bone destruction. 
 
FGL1 on chromosome 8, encodes fibrinogen-like protein 1 (FGL-1), a hepatocyte 
derived protein member of the fibrinogen family of proteins.  FGL-1 is structurally 
similar to fibrinogen related proteins (FReP) (Yamamoto et al., 1993).  The FRePs are 
upregulated in tissue injury and play a role in innate immunity by activating toll like 
receptor 4 (TLR4) (Zuliani-Alvarez and Midwood, 2015), which has recently been 
shown to play a role in periprosthetic osteolysis (Greenfield et al., 2010, MacInnes et 
al., 2014).  They have also been shown to induce a number of inflammatory cytokines 
including interleukins 4, 6, 10, 17, tumour necrosis factor alpha (TNFα) and vascular 
endothelial growth factor (VEGF) (Zuliani-Alvarez and Midwood, 2015).  
 
The most statistically significant variant in our discovery time to failure analysis, 
rs6105394, lies 2kb downstream of DEFB129. We were unable to replicate in the 
Norwegian population using the Sequenom MassARRAY iPLEX assay as primers for 
this variant could not be constructed. As there were no proxy SNPs we performed the 
replication analysis using the next most significant directly typed SNP, rs6110474 
(beta 0.68, SE 0.17, p=4.97 x 10-5) in the signal using the KASPar assay.  This SNP 
failed to replicate (beta 0.02, SE 0.04, p=0.62). Human β-defensins (hBD) are 
antimicrobial peptides which play an important role in innate immunity, and are thought 
to play a role in inflammatory disorders of bone (Warnke et al., 2006) (Kraus et al., 
2012).   
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We also undertook replication and meta-analyses in the variants identified when not 
using wear as a covariate.  This identified 2 further independent replicating signals 
within or in the flanking region of CNTN3, DOK2 which associated with time to 
prosthesis failure. CNTN3 encodes the protein contactin 3, which mediates cell 
adhesion (Mock et al., 1996).  It’s role in bone turnover is previously undescribed.  
DOK2, which encodes docking protein 2 (Dok2) is involved in the regulation of TLR 2 
and 4 (Shinohara et al., 2005). More recently Dok1 and Dok2 were found to be 
downstream adaptors of TLR-2 inflammatory signalling through regulation of Erk and 
NF-κB signalling (Downer et al., 2013) Kawamata et al demonstrated that Dok1/2 
deficient mice have pre-osteoclast hypersensitivity to macrophage colony stimulating 
factor (M-CSF) and increased numbers of TRAP positive osteoclasts and enhanced 
bone resorption (Kawamata et al., 2011).   
 
Our discovery analysis had ≥80% power to detect variants with a risk allele frequency 
of 0.35 and an allelic OR of 1.65.  The replication analysis had ≥80% power to detect 
variants with a risk allele frequency of 0.45 and an allelic OR of 1.45.  We attempted 
to reduce the impact of modest power by looking only at common variants (MAF ≥0.05) 
but consequently the study was insufficiently powered to detect modest effects 
associated with rarer variants.   
 
In summary, we have carried out the first GWA study for osteolysis and time to 
prosthesis failure.  We have identified some possible risk loci for susceptibility to 
osteolysis with nominal replication in an independent population. However, a larger 
study with substantially more cases and controls is required to better identify genetic 
association signals with osteolysis.  In order to achieve 80% power for our observed 
most significant variants (risk allele frequency 0.1, OR 0.7) we would require 750 
cases and 2000 controls. Table 7.10 shows sample size required to achieve 80% 
power for an osteolysis GWAS for varying allele frequency and effect size. 
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MAF OR Cases (n) Controls (n) 
0.3 1.5 600 1650 
0.3 1.4 1000 1750 
0.2 1.4 1350 2000 
0.1 1.4 2000 5000 
0.05 1.35 5000 10000 
 
Table 7.10 Sample size required for osteolysis GWAS at 80% power 
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CHAPTER 8 
THESIS DISCUSSION 
 
 
8.1 Overview 
 
This chapter provides a summary of the studies presented in this thesis.  A synopsis 
of the findings and significance in keeping with primary and secondary study aims will 
be discussed as well as study strengths, limitations and proposed future work. 
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8.2 Summary 
 
In this work I have explored the genetic contribution to two common conditions 
associated with adverse outcome in total hip arthroplasty: osteolysis and heterotopic 
ossification.  As an investigative team, we have followed a systematic approach 
starting with a candidate gene study using previously recruited subjects and 
progressed to whole genome association studies which required large scale 
prospective recruitment. We have identified several putative novel associated loci 
which have the potential to further our understanding of the complex pathological 
processes involved. Throughout these processes we have demonstrated the feasibility 
of recruitment for large genetic epidemiological studies using a national joint register. 
We have demonstrated that postal collection of saliva provides adequate DNA suitable 
for these studies and can also be stored establishing a biological repository with 
linkage to the registry.  This has significant potential for the study of a number of 
orthopaedic conditions and is especially useful when studying low incidence 
phenotypes where local recruitment is likely to yield insufficient subject numbers to 
achieve adequate power. 
 
In the candidate gene study presented in chapter 4 we identified 4 SNPs within 
TNFRSF11A, (rs4524033, rs9960450, rs7226991, and rs4485469), and one each 
within KREMEN2 (rs4786361), SFRP1 (rs921142), TIRAP (rs8177375), and 
TNFRSF11B (rs11573847) that were associated with osteolysis susceptibility. Our 
finding of possible association of variation in KREMEN2 with osteolysis is novel.  
Kremen2 modulates Wnt signalling, and mice deficient in Kremen2 have increased 
bone formation. (Schulze et al., 2010) The variant rs8177375 lies in the 3' UTR of 
TIRAP associated with osteolysis susceptibility and showed a trend toward association 
with time to prosthesis failure. This variant has previously been associated with risk of 
sepsis-induced lung injury. (Song et al., 2010) Functional studies subsequent to this 
thesis within our group have shown that carriage of the ‘G’ allele may result in mRNA 
degradation and likely inhibition of translation (MacInnes et al., 2014).  
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Despite this being the largest candidate gene study for osteolysis to date, the main 
limitation was that the sample size was still small in genetic association study terms. 
We aimed to mitigate against this in part by using a 2-stage analysis, followed by meta-
analysis.  We also attempted to reduce confounding by studying a single ethnic group 
and using strict exclusion criteria.  Candidate gene selection, however, relied on a-
priori knowledge of osteolysis pathogenesis and this hypothesis-driven approach may 
have led to potentially important genes not being investigated.  This, therefore led to 
the hypothesis-free whole genome association analysis described in chapter 7. 
 
We undertook the first GWAS of HO susceptibility and severity following THA, and 
identified promising novel loci within or in the flanking regions of the ARHGAP18, 
BMP2, LGI1 and KIF26B genes.  GWAS are hypothesis-free studies, which reduces 
the bias afforded by candidate gene selection.  As with the candidate gene study, the 
main limitation of this study was that sample size was very small in GWAS terms, with 
consequent limited power. We aimed to mitigate this to some degree by imposing strict 
phenotyping criteria, ensuring that all controls were free from HO using radiographs 
taken no earlier than 1year post THA, by which time any HO development would have 
occurred.  This created a group of “super-controls” which increased power compared 
to using a background population control group that is commonly used in GWAS. 
Because of the small sample size, we included only common variants with MAF>0.05.  
Although this method increases confidence in identified common variants, it reduces 
the chances of identifying associating rarer variants.  As this was a single stage GWAS 
study some of the associated variants may represent false positives and recruitment 
is currently underway for a replication analysis.  The use of the Brooker grading did 
not provide volumetric quantitation of HO but remains the accepted standard used in 
clinical practice.  Although we did not undertake a repeatability study looking at inter 
and intra-observer reliability in our HO measurements, the Brooker grading has 
previously been shown to have good inter and intra-observer reliability with 77% and 
86% agreement respectively (Wright et al., 1994). 
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The Norwegian Arthroplasty Register cohort study was the first demonstration of the 
possible extended role of national arthroplasty registries for large scale recruitment of 
subjects.  We also showed that postal recruitment of subjects using this approach 
achieves reasonable response rates and postal self-collection saliva samples provide 
adequate DNA yield for high throughput genotyping and are therefore suitable for the 
establishment of a registry biobank. This strategy is scalable and potentially applicable 
across a range of common complex diseases where large-scale epidemiological 
datasets are held.  The savings achieved due to lower personnel costs using saliva as 
a source of DNA compared to whole blood makes large scale postal collection of saliva 
a more cost-effective approach.  Although most saliva samples provided adequate 
DNA concentration for whole genome analysis, we found that about a quarter of 
samples did not. These samples could either be amplified or used for replication 
analyses using other genotyping technologies.  Compliance with providing adequate 
samples should be strongly encouraged in the information provided to patients to 
improve sample quality.  Another limitation of postal collection of saliva was that, 
although unlikely, we were unable to confirm that the sample was provided by the 
study subject. 
 
We conducted the first GWAS of osteolysis susceptibility and time to prosthesis failure 
following THA.  Although a number of candidate genes studies for osteolysis have 
been carried out previously, the lack of a hypothesis-free whole genome scan led to 
the inception of this study with the aim of identifying novel genes not previously 
implicated in the pathogenesis.  We identified possible associating signals within 
CAMK4, FGL1 and DEFB129.  Unfortunately, we failed to identify any signals at 
genome-wide significance and this is likely due to small sample size in the discovery 
cohort.  The genetic architecture of osteolysis is complex and the genetic contribution 
likely consists of variants with modest allele frequency and small effect size.  A larger 
study with substantially more cases and controls is required to robustly identify 
associated signals.  A whole genome analysis of the Norway cohort is planned to 
improve study power. Having repeated the discovery analyses without polyethylene 
wear rate as a covariate we undertook a sensitivity analysis which confirmed wear rate 
as an important covariate in the study of osteolysis following THA.  The advantage of 
the inclusion of wear rate was offset by a loss in number of study subjects.  Wear rate 
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measurements for all study subjects would therefore be the ideal, to prevent this 
reduction in study sample size.  As with the HO GWAS study described earlier, this 
study was strengthened by all subjects sharing ethnicity and the imposition of a strict 
inclusion/exclusion criteria with the aim of reducing confounding.  This population 
matching is evidenced by similar allele frequencies in the discovery and replication 
cohorts.  All subjects had undergone THA for a primary diagnosis of OA and implant 
type was accounted for as a covariate in analyses. By ensuring that controls were 
asymptomatic following THA and with no evidence of osteolysis on radiographs we 
again created a group of “super-controls” increasing power compared to using a 
background population.  We undertook strict pre and post genotyping quality control 
measures as outlined by the WTSI.  We conducted a replication study and meta-
analysis to weed out false positives.  We attempted to reduce the impact of modest 
power by looking only at common variants (MAF ≥0.05).  We did not carry out a 
repeatability study for identification of osteolysis radiologically.  There are no published 
studies exploring the inter and intra-observer reliability of the Harris and McGann and 
Harris and Penenberg classification.  We acknowledge that this may have introduced 
a degree of error into our case and control definition, however, these are the standard 
classifications accepted in clinical practice and most of the cases underwent revision 
surgery where the presence of osteolysis was further confirmed. 
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8.3 Future work 
 
The proof of concept of using a national arthroplasty registry for recruitment and the 
establishment of a linked biorepository has already been implemented in a further 
GWAS in the UK examining the genetic architecture of developmental dysplasia of the 
hip using the National Joint Registry of England, Wales, Northern Ireland and the Isle 
of Man. 
 
The strongest signals identified in the HO GWAS have been taken forward for a 
replication study in a separately recruited population of patients who have undergone 
THA.  The results from this study will be meta-analysed with the study in this thesis to 
examine for replicated association.  The lack of stronger association in the osteolysis 
GWAS meta-analysis has led to a GWAS within the replication cohort.  It is hoped that 
meta-analysis of 2 whole genome datasets will confirm signals with stronger 
association and improved power.   
 
Following the identification of associations in populations of European ancestry these 
variants should then be further examined across other ethnic populations.  Trans-
ethnic replicability of variants further reinforces the robustness of their association and 
reduces the problem of population stratification.  This can also lead to larger trans-
ethnic GWAS providing larger study populations with improved power.    
 
The GWAS described in this thesis have identified a number of associations with 
osteolysis and HO.  Although GWAS demonstrate association they do not explain 
causation.  Functional studies are therefore required to further investigate how the risk 
loci affect gene function thereby influencing the development of these conditions.  
Proven functional associations may then provide the basis for therapeutic target 
development for treatment or prevention.  Further investigation may involve the study 
188 
 
of gene expression within the membrane surrounding loose prostheses.  Common 
studies employed to examine gene function include knockout models and the more 
recently introduced gene silencing approaches.  Unlike gene knockout modes where 
expression is completely repressed, gene silencing methods such as clustered 
regularly interspaced short palindromic repeats (CRISPr) and small interfering RNA 
(siRNA) reduce gene expression without completely eliminating it.  These techniques 
have been used to correct the development of heritable conditions including age 
related macular degeneration (Kaiser et al., 2010) and muscular dystrophy (Long et 
al., 2014). 
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8.4 Conclusion 
 
THA remains an extremely successful orthopaedic procedure.  Periprosthetic 
osteolysis remains the leading cause of THA failure and is the result of an 
accumulation of complex steps which results in prosthetic loosening.  Advances in the 
design and materials used in prostheses including improved wear profiles of bearing 
surfaces have led to substantial amelioration of this problem.  This has resulted in 
reduced incidence of osteolysis and aseptic loosening, however with increasing 
numbers of THAs performed annually and with more active patients now undergoing 
arthroplasty, osteolysis will likely remain a major complication of THA for the 
foreseeable future.    The incidence of other causes of failure of THA, such as infection, 
is increasing and may be a possible avenue for further whole genome study in the 
future.   
 
Furthering our understanding of the biological processes involved in the pathogenesis 
of diseases such as osteolysis and HO is essential for forming prevention strategies 
and treatments.  The studies described in this thesis are novel and comprise the 
largest genetic studies to date investigating osteolysis and HO.  They have followed 
advances in genomic and bioinformatics technology and have provided valuable 
insight into the pathogenesis of these disorders following THA.  The approaches taken 
for these studies are scalable and applicable across a range of common complex 
diseases that have a heritable component.  This has the potential to facilitate the 
development of biological markers for prediction and early detection and the 
development of selective therapeutic agents for treatment and prophylaxis.   
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APPENDIX D 
 
Office use only:  Study ID: _________________  Initials:   
 
Musculoskeletal BioBank Ethnicity Questionnaire (STH15691) 
 
Please note we are not asking about citizenship or nationality but about the ethnic group to which you 
feel you belong. All information received will be used and treated in the strictest confidence. The level 
of care you will be offered at this hospital will not be affected by your decision to complete this form. If 
you have any queries please speak to a staff member. Otherwise please complete the form below by 
ticking the box of the ethnic group you feel you belong to. If you feel you are descended from more than 
one group please tick the one that you feel you belong to, or choose the ‘any other group’ option. 
 
White 
A British  
B Irish  
C Any other white background   
Mixed 
D White and Black Caribbean  
E White and Black African  
F White and Asian  
G Any other mixed background  
Asian or British Asian  
H Indian  
I Pakistani  
J Bangladeshi  
K Any other Asian background   
Black or Black British  
L Caribbean  
M African  
N Any other black background  
Other ethnic groups 
O Chinese  
P Any other ethnic group  
 
Thank you for completing this questionnaire 
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